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Abstract 
Latest epidemiological data suggests that 1.5 billion adults worldwide are 
obese or overweight. Excess weight and adipocyte hypertrophy have long 
been associated with contributing to low-grade systemic inflammation 
through elevated adipokine secretion. These increased endocrine signals 
further augment the metabolic dysfunction related to the presence of obesity. 
A chronic exposure to obesity mediated inflammation is also suggested to be 
responsible for progression of renal pathology and eventual end-stage organ 
failure. In human clinical statistics, these factors indicate a gender disparity, 
as males demonstrate much faster progression rates of obesity-linked renal 
disease than females. Therefore, the aim of this thesis was to investigate the 
role of gender in obesity mediated inflammation in the development of renal 
disease using a large animal model i.e. sheep.  
Post-natal female and male sheep were exposed to a lean or obesogenic 
environment by restricting physical activity from §3 months to §17 months 
of age. Analysis of body composition and adipose tissue physiology, 
morphology and deposition identified the development of moderate obesity 
following chronic exposure to a low physical environment, although no 
differences were observed with gender. With obesity, both genders 
demonstrated metabolic irregularities; males showed hyperinsulinaemia and 
females displayed hypercortisolism. Gene expression analysis identified an 
up-regulation of inflammatory related genes in perirenal adipose tissue (PAT) 
and kidney in obese males, a finding not seen in females, although obese 
females exhibited an up-regulation in glucocorticoid receptor abundance in 
PAT. Furthermore, the males demonstrated adaptations in renal structure and 
function with obesity, modifications not observed in females.  
The main conclusion of my thesis is that after the development of obesity, 
males appear much more sensitive to the metabolic, inflammatory and renal 
adaptations associated with an obese condition. Females displayed a down-
regulation of inflammatory genes with obesity which I propose acts as a 
protective mechanism against the progression of renal disease, perhaps 
mediated by an immunosuppressive glucocorticoid action in adipose tissue. It 
is also possible that sex hormones play a role in obesity inflammatory renal 
disease development, postulated to occur through HPA activation and 
epigenetic alterations.  
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Chapter 1 - Introduction 
 
My thesis reports a study of juvenile onset obesity in sheep and the influence 
of gender on inflammatory responses in the kidney and surrounding perirenal 
adipose tissue. This chapter will discuss and summarise the contemporary 
epidemiological and experimental animal research on obesity in relation to 
gender, the kidney and inflammation, previously published.  
1.1 Obesity and overweight 
Obesity can be defined as the excessive or abnormal accumulation of fat in 
adipose tissue, resulting in increased morbidity and mortality. The World 
Health Organization (WHO) achieves classification of obesity by calculating 
the Body Mass Index (BMI) of an individual shown in Figure 1.1. BMI is a 
simple index calculated by GLYLGLQJDQLQGLYLGXDO¶VZHLJKWNJE\WKHVTXDUH
of their height (m2) and, although an approximate method of determining 
body fat mass, is a widely accepted measurement. As BMI does not 
distinguish between fat and muscular mass, the National Institute for Clinical 
Excellence (NICE) recommend the use of BMI in conjunction with waist 
circumference to estimate adiposity, with measurements of 102cm and 88cm 
in men and women respectively being classed as raised waist circumferences1. 
 
Figure 1.1: Body mass index calculation 
 
Table 1.1 (p2) shows the international classification of adult underweight, 
overweight and obesity according to BMI. For example, an adult who weighed 
90kg and measured 1.81 metres, their BMI would equal 90kg/1.81 m2 = 
27.47, which would indicate a pre obese individual according to BMI 
calculation. Due to the difficulty in estimating fat mass in children aged 5-14, 
no applied standard definition of obesity currently exists, however the WHO 
are developing an international growth reference for school-aged children2. 
  
BMI = Weight (kg) / Height (m2) 
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Classification BMI (kg/m2) 
  Principal cut-off 
points 
Additional cut-off points 
Severe Thinness <16.00 <16.00 
Moderate 
Thinness 
16.00 - 16.99 16.00 - 16.99 
Mild Thinness 17.00 - 18.49 17.00 - 18.49 
Underweight <18.50 <18.50 
Normal Range 18.50 - 24.99 18.50 - 22.99               
23.00 - 24.99 
Overweight   
Pre-obese 25.00 - 29.99 25.00 - 27.49 
27.50 - 29.99 
Obese   
Obese class I 30.00 - 34.99 30.00 - 32.49 
32.49 - 34.99 
Obese class II 35.00 - 39.99 35.00 - 37.49 
37.49 - 39.99 
Obese class III   
Table 1.1: The international classification of adult underweight, overweight and 
obesity according to BMI3. 
Obesity and overweight have reached epidemic global proportions, affecting 
both industrialised and developing countries. Latest statistics from the WHO 
suggest that in 2008 approximately 1.5 billion adults over the age of 20 were 
overweight, of which 200 million men and 300 million women were classed as 
obese. These levels are predicted to rise to 2.3 billion, 300 and 400 million 
respectively by 2015. It is also estimated globally that as many as 43 million 
children under 5 were overweight in 2010. In 2008, the annual Health Survey 
for England (HSE) reported that approximately a quarter of all adults in 
England (24-25%) were obese and 66% of men and 58% of women were 
overweight4. In 2007 31% of boys and 29% girls aged 2-15 were estimated 
to be obese or overweight, however recent figures suggest that childhood 
obesity rates may have stabilised4. Due to this increasing global prevalence, 
obesity and its associated comorbidities are now one of the leading 
preventable causes of mortality worldwide, and it is estimated that obesity 
and its related conditions cost the UK National Health Service around £4.2 
billion a year5. Weight gain and obesity are attributed to an increase in the 
ratio of calorie consumption to calorie expenditure. Research into this 
imbalance has identified a combination of behavioral, environmental and 
genetic factors6; however the current and predicted incidence of obesity in 
the UK implies that behavioral and socio-economic factors, i.e. modern 
sedentary lifestyles and dietary issues, especially in poorer social classes are 
involved to a greater extent than genetic factors4,.  
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It has also been hypothesised that some metabolic adult diseases, for 
example changes in susceptibility to developing obesity may have early life or 
foetal origins7,8. 
Obesity has been linked to exaggerated morbidity and mortality, and 
increased risk factors associated with obesity include development of insulin 
resistance, type 2 diabetes, hypertension, coronary heart disease, stroke, 
cancer, gallbladder disease, osteoarthritis, asthma and sleep apnea9. The 
World Health Organization classify the presence of central obesity, defined by 
BMI and waist to hip ratio, as one of the risk criteria for metabolic syndrome 
alongside diabetes mellitus type II, hyperglycaemia, hypertension, 
dyslipidaemia, microalbuminuria and chronic low-grade inflammation10.  
1.1.1 Gender dimorphism in obesity 
Risk factors associated with obesity depend not only on the amount of 
accumulated fat tissue, but also on its anatomical distribution.  In central 
obesity which is more prevalent in males, fat tissue tends to be accumulated 
in the upper body, i.e. increased intra-abdominal and ectopic visceral fat 
deposits11. Yet in pre-menopausal females, increased subcutaneous fat is 
accumulated in peripheral and lower body areas, i.e. gluteal and femoral 
regions11. This gender dimorphism in fat distribution has been highlighted in 
past research and it is well established that females tend to have a higher 
percentage of total body adiposity to males. However despite this, BMI 
matched males are shown to have nearly twice the amount of visceral 
adipose tissue compared to females11. Research has also identified that fat 
redistribution occurs in females from aging, particularly during and beyond 
menopause, where lower body region adiposity changes to central adiposity12. 
This lower amount of visceral adiposity in pre-menopausal females is believed 
to be linked to the lower prevalence of obesity related metabolic conditions or 
metabolic syndrome, such as hypertension, diabetes, hyperlipidaemia and 
cardiovascular disease (CVD) than seen in BMI matched males13.  
This lower prevalence of obesity related morbidities seen in females does 
however converge with the male population after menopause14, suggesting an 
involvement of female sex hormones in adiposity development and possible 
protection from obesity linked conditions, which will be discussed in 
subsequent chapters.  
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Despite this gender dimorphism in fat storage where pre-menopausal females 
may present a healthier obese metabolic profile than males, obese individuals 
still have an increased risk of morbidity than the general population15.  
1.1.2 Maternal nutrition in the development of obesity 
In 1991+DOHVDQG%DUNHUSXEOLVKHGWKHµ7KULIW\3KHQRW\SH¶K\SRWKHVLVZKLFK
proposed that in a poor nutritional foetal environment, metabolic adaptations 
occur such as an enhanced capacity to store fat through alterations in insulin 
sensitivity and an adaptive response to optimize the growth of key organs at 
a detriment to growth of less important organs, including the development of 
fat8. The hypothesis suggested that these adaptations are strategies for 
survival in similarly poor nutritional post-natal environments, but when 
exposed to over-nutrition, maternal nutritionally restricted offspring become 
more at risk to develop metabolic disorders like obesity and diabetes mellitus 
type II7,8. There is now a considerable amount of scientific evidence to 
support the hypothesis that inappropriate prenatal or early postnatal nutrition 
may predispose individuals to developing obesity and linked metabolic 
conditions  in later life8,16,17,18.  A GLDJUDPPDWLFDOUHSUHVHQWDWLRQRIWKHµ7KULIW\
3KHQRW\SH¶K\SRWKHVLVLVVKRZQLQFigure 1.2, p5. 
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Figure 1.2: Summary of Hales and Barker µ7KULIW\3KHQRW\SH¶K\SRWKHVLV8. 
Early work on the 1944-45 µDutch Famine Birth Cohort¶ study first highlighted 
that 19 year old males exposed in utero to the Dutch famine showed higher 
rates of obesity than those conceived before or after the famine period16. This 
rate of obesity was higher in offspring exposed to intrauterine undernutrition 
in early gestation compared to the mid to late gestation and non-exposed 
males16. A follow up study of the cohort identified that maternal malnutrition 
during early gestation was associated with higher rates of obesity in females 
but not males at 50 years of age17. Additional studies all based on subjects 
exposed to the Dutch famine study indicate that exposure to restricted 
maternal nutrition at any stage of gestation can lead to increased risk of 
disease later in adult life18,19,20. As the Dutch famine study was a unique 
opportunity for such research in humans, animal models are now utilised to 
study suboptimal nutrition at specific stages of gestation in order to elucidate 
the mechanisms responsible for prenatal nutritional programming. Maternal 
undernutrition during early to mid gestation in sheep resulted in increased 
development in adiposity in the offspring at birth21.  
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Studies in rodent models show that exposure to maternal overnutrition and 
maternal obesity during pregnancy and through lactation is associated with 
the development of obesity in the offspring 22, 23.  
An additional rodent study suggested that maternal overnutrition independent 
of maternal obesity and postnatal diet produced an obese phenotype of male 
and female offspring24. In both the animal and human models of gestational 
dietary manipulations, both under and over-nutrition appear to promote the 
development of obesity in the offspring. Furthermore, foetal programming 
studies in adult sheep through pre-natal under-nutrition identified an 
imbalance in glucose-insulin homeostasis in nutritionally restricted animals25. 
These studies indicate that a suboptimal maternal diet during critical periods 
of foetal development, impacts on immediate postnatal and later adult health 
through alterations in adipose tissue development and changes to the 
metabolic milieu. 
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1.2 Adipose tissue 
Adipose tissue is fibrous connective tissue with a highly organised vasculature 
mainly composed of fat cells (adipocytes), but also containing a variety of 
other cells such as endothelial cells, fibroblasts and macrophages26. It serves 
as both an insulating layer and energy store and is found in a range of 
subcutaneous and intra-abdominal organ depots around the body. There are 
two types of adipose tissue; white adipose tissue, and brown adipose tissue. 
The two different types of adipose tissue differ substantially in structure and 
function. Brown adipocytes are polygonal in shape, highly vascularised, 
contain high numbers of mitochondria and contain a number of small lipid 
inclusions (multilocular). In contrast, white adipocytes contain a single, large 
central lipid inclusion (unilocular) which flattens the nucleus and pushes it 
towards the periphery, and have very few mitochondria27, as shown in Figure 
1.3. 
    
Figure 1.3: Microscopic sections of brown adipose tissue (A) and white adipose tissue 
(B). 
Brown adipose tissue produces heat via non-shivering thermogenesis which 
maintains body temperature in neonates and small mammals28. It was initially 
suggested that brown adipose tissue present in the body, predominantly 
located in the internal adipose depots, regresses with age immediately after 
birth where it is completely converted into white adipose tissue by 
adulthood29. Recent research has shown that adult humans retain a small 
amount of brown adipose tissue in the superclavicular region, which was 
determined by glucose uptake using positron emitting topography (PET) 
scans30. It is now also recognised that rather than both adipocyte types being 
derived from the same preadipocyte lineage that BAT maybe derived from 
skeletal muscle precursors31. Although relatively small amounts of brown 
adipose tissue exist in adults ZKLWH DGLSRVH WLVVXH¶V IXQFWLRQ DQG DFWLRQ LV
responsible for the majority of its associated metabolic properties34.  
A B 
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The primary functions of white adipose tissue are passive insulation and 
energy storage which is implemented through the accumulation and 
mobilisation of non-esterified fatty acids (NEFAs). It has also been identified 
as being an important endocrine organ, actively communicating by sending 
and receiving different types of signals, and as a result playing a central role 
in lipid and energy metabolism32.  
1.2.1 Adipocyte alterations with obesity 
Free fatty acids are accumulated in white adipocytes and esterified into 
triglycerides for storage. Once utilisation of triglycerides for energy is required, 
they undergo lipolysis and are hydrolysed to glycerol and NEFAs that are 
transported by the bloodstream to other tissues, mainly muscle and liver33. 
However with obesity, white adipose tissue increases storage of intracellular 
triglyceride stores, causing enlargement of the cell, termed hypertrophy34. 
Initially it was thought that adipocyte cell number was established during 
childhood, but it is now understood that the progression of obesity in adults 
who were not obese during childhood, show hyperplasic adipose tissue 
development34, which is also demonstrated in some animal models35. This 
adipocyte differentiation is believed to be induced by prolonged adipocyte 
hypertrophy during the development of obesity.  
Morphological and functional variation occurs between subcutaneous and 
visceral adipocytes. Subcutaneous adipose tissue is comprised of well 
organised, tightly packed spherical lobules, whereas intra-abdominal adipose 
depots appear highly vascularised with disorganised, irregular shaped 
lobules36. Females have larger subcutaneous adipocytes when compared to 
omental adipocytes, possibly leading to a lower storage capacity in visceral 
depots for triglycerides, leading to more rapid lipid saturation, increased 
lipolysis and possible omental adipocyte cell dysfunction37. In contrast, 
opposite results were found in another study, which again demonstrated that 
subcutaneous adipocytes were larger than omental fat cells in females, but 
subcutaneous adipocytes displayed increased lipolysis compared to omental 
fat. Although less active, the omental adipocytes displayed higher sensitivity 
to lipolytic stimuli through antagonism of the ǃ-adrenergic receptor, 
suggesting omental fatty-acid flux was caused by increased generation of free 
fatty acids rather than greater lipolysis38.  
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Evidence suggests that adipocyte hyperplasia rather than hypertrophy occurs 
in females during fat mass expansion. This observation was reported in 
gluteal but not visceral adipose tissue depots, although adipocyte hypertrophy 
was observable in gluteal fat depots when compared to a lean counterpart39. 
Subcutaneous but not omental fat depots in obese females, also showed a 
positive correlation in size with total fat mass39.  
These results indicate that during subcutaneous adipose tissue expansion in 
females, adipose tissue mass is developing through adipogenesis, lipolysis 
and adipocyte hypertrophy. Theoretically allowing for subcutaneous depots in 
females to store larger amounts lipids, and thus limiting fat accumulation in 
visceral compartments. 
1.2.2 Adipose tissue as an endocrine organ 
Adipose tissue secretes a range of proteins, both hormones and cytokines 
(termed adipokines) that play important functional local and systemic roles in 
metabolism, immune responses, reproduction and the cardiovascular 
system40. In obesity, hypertrophic adipocytes increase production and 
secretion of adipokines in circulation, and that adipokine expression correlates 
to adipocyte size41. In total, over 50 molecular entities have been identified as 
being secreted from adipocytes. The entirety of these secretions along with 
other lipid moieties released by the adipocytes constitutes the secretome42. 
Table 1.2 (p11) shows a summarised table of adipokines secreted by white 
adipose tissue and their respective functions.  
It is thought some of these adipokine secretions signal to induce macrophage 
recruitment and infiltration in adipose tissue, as macrophage numbers are 
significantly higher in expanding adipose tissue depots43. The accumulative 
effect of increased inflammatory adipokine secretion with additional 
macrophage recruitment and activation is one of the mechanisms proposed to 
contribute to the chronic low-grade inflammation, associated with obesity.  
Early research on excess adipose tissue accumulation discovered that 
circulating plasma NEFAs are elevated in obese individuals44. Excess plasma 
NEFA concentrations inhibit insulin action on skeletal muscle glucose uptake 
and suppress hepatic glucose production leading to increased circulating 
insulin (hyperinsulinaemia) and insulin resistance45.  
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Raised circulating insulin plays a pleiotropic role to promote further adipose 
storage and inhibiting lipolysis which promotes preadipocyte differentiation 
and increasing fatty acid synthesis. This results in additional adipose tissue 
expanse and reinforces insulin resistance, leading to development of 
subsequently linked conditions, such as diabetes mellitus type II, 
hypertension and CVD. In humans, macrophage moderated adipose tissue 
inflammation with obesity is a further contributory factor towards the 
development of insulin resistance46. However other studies have shown that 
plasma NEFA concentrations are not significantly increased in obese subjects 
without diabetes mellitus type II. Under these conditions NEFA circulation is 
controlled through increased NEFA turnover and metabolism, yet these 
controls are impaired in the presence of insulin resistance and altered by 
excess dietary fatty acids and during energy consumption47.  
To date the exact developmental mechanisms of both pro-inflammation and 
insulin resistance through adipose tissue and NEFA signaling in obesity are 
not entirely understood, yet appear to be involved in a complex feedback 
system. 
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Adipokine Function/Effect 
Adipocyte lipid binding 
protein 
Regulates systemic glucose and lipid metabolism 
Adipocyte trypsin Immune stress response 
Adiponectin Regulates glucose level and metabolism of lipids in 
energy production 
Angiotensin Blood vessel constriction, release of vasopressin & 
aldesterone which increase blood pressure 
Apelin Regulation of body fluid homeostasis 
C-reactive protein Inflammatory response, insulin resistance 
Cholesteryl ester transfer 
protein 
Mediates the transfer of cholesteryl esters and 
triglycerides between lipoprotein particles 
Hormone sensitive lipase Hydrolysis of triglycerides for NEFA mobilisation 
Insulin-like growth factor Insulin effects & cell growth/development 
Interleukin ǃ (IL-ǃ) Inflammatory response 
Interleukin 6 (IL-6) Immune stress response, insulin resistance 
Interleukin 8 (IL-8) Immune stress response 
Interleukin 10 (IL-10) Anti-inflammatory effect 
Interleukin 18 (IL-18) Inflammatory response 
Leptin Regulates energy uptake/expenditure (appetite and 
metabolism) 
Lipoprotein lipase Mediates lipid uptake 
Macrophage migration 
LQKLELWRU\IDFWRUǃ0,)-ǃ 
Immune stress response 
Metallothionein Immune stress response 
Monobutyrin Vasodilatation of the microvessel 
Monocyte chemotactic 
protein 1 (MCP-1) 
Immune stress response 
Perilipin Regulates lipid metabolism 
Peroxisome proliferator-
activated protein-Ǆ33$5-Ǆ 
Lipid metabolism, vascular homeostasis, inflammation 
Plasminogen activator 
inhibitor-1 (PAI-1) 
Vascular homeostasis 
Resistin Inflammatory response, insulin resistance 
Retinol binding protein  Lipid metabolism 
Steroid hormones Lipid metabolism, insulin resistance 
Transforming growth   
factor-ǃ 
Cell adhesion and migration, growth and 
differentiation 
Tumour necrosis factor-Į
(TNF-Į 
Immune stress response, insulin resistance 
Uncoupling proteins Energy balance and thermoregulation 
Visfatin Insulin resistance 
Zinc-alpha2-glycoprotein Lipid metabolism 
Table 1.2: Adipokines secreted by white adipose tissue and their function and 
effect26,48. 
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1.2.3 Obesity and insulin resistance 
Insulin is a signalling hormone involved in the regulation of carbohydrate and 
lipid metabolism.  Immediately after food consumption, a rapid increase of 
blood glucose occurs which stimulates pancreatic ǃ-cells to synthesize insulin. 
Circulating insulin then facilitates the suppression of hepatic gluconeogenesis 
and modulates the entry and uptake of glucose through the major glucose 
transporter (GLUT4) action in liver, muscle and adipose tissue for conversion 
and storage to glycogen and later utilisation49, as summarised in Figure 1.4, 
p13. In the presence of obesity, the normal insulin sensing mechanism suffers 
dysregulation, this impairment of insulin-responsiveness appears in all insulin 
sensitive tissues thought to arise from a down-regulation of GLUT449. 
Decreased stimulation of insulin mediated glucose transport and subsequent 
impaired glucose storage and metabolism leads to an insulin resistant state at 
a cellular level, resulting in hyperglycaemia and the development of diabetes 
mellitus type II. Obesity has also been demonstrated to contribute to insulin 
resistance through reduced insulin binding to its receptor, modulated by an 
impaired phosphorylation of the receptor and decreased tyrosine kinase 
activity in muscle and adipose tissue49. The obesity mediated mechanisms of 
insulin resistance are complex and not fully elucidated, however it is 
hypothesised that the endocrine function of adipose tissue and the elevated 
secretions in NEFAs, glycerol, cytokines and other signalling molecules from 
adipocytes observed in obesity, all contribute to the development of obesity 
related insulin resistance50.   
Whilst insulin resistance positively correlates to visceral fat mass and BMI, 
epidemiological studies have highlighted that weight loss and reduction in 
central adipose depot size improves insulin sensitivity51. 
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Figure 1.4: Insulin mediated glucose uptake via binding of insulin to insulin receptor 
which initiates signal transduction and glucose transport in to cells through GLUT4 
action52. 
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1.3 Inflammation and the immune response 
The human immune response consists of a number of complex molecular 
pathways and is composed of both the innate (non-specific) and adaptive 
(immunological memory) immune systems53. These protect the host organism 
from infection and also differentiate between host cells and pathogens, 
although if this system fails, auto-immune disease can occur54. When an 
antigen penetrates an external barrier and enters the body, immune 
responses, both cell mediated and humoral, are activated. The antigen may 
be attacked and ingested by phagocytic cells such as monocytes, 
macrophages, neutrophils or dendritic cells53. Certain immune cells can also 
act as antigen presenting cells (APC) to initiate and further develop the 
immune response. Surface major histocompatability complex (MHC) proteins 
bind with invading organism fragments which communicate with helper T-
cells which in turn stimulates B-cells and cytotoxic T-cells; activation of the 
adaptive immune system55.  
In addition to this system, the presence of infection, injury or stress triggers 
cells to secrete chemical signals such as cytokines, chemokines and proteins 
that induce inflammation to protect surrounding tissues. This attracts immune 
cells that are involved in complex biochemical complement cascades activated 
by antibodies to destroy target cells56. The host response to immune system 
agonists includes regulation of the cytokine response, cell-adhesion molecule 
expression, production of oxidative stress factors and cell death57. 
Inflammatory responses can over or under react due to an uncoupling of the 
pro and anti-inflammatory mediator balance which can lead to further tissue 
damage58.  
1.3.1 Obesity induced inflammation 
It is now established conditions such as obesity and hyperinsulinaemia 
stimulate the immune system, specifically activating a chronic low-grade pro-
inflammatory state. Excess adipose tissue mass has been shown to positively 
correlate with expression of the pro-inflammatory gene, tumour necrosis 
factor-Į71)-Į59. It is a gene not only involved in immune cell signaling and 
further cytokine recruitment, but may contribute to insulin resistance by 
decreasing the uptake of glucose in response to insulin by inhibiting tyrosine 
phosphorylation of insulin receptor substrate-1 (IRS-1)59,60. This is further 
evidence of the interlinked and complex nature of obesity, adipose tissue and 
insulin resistance.  
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Other markers of pro-inflammation, such as concentrations of plasma 
cytokines and the acute phase C-reactive protein (CRP), are positively 
correlated with adipose tissue mass42, emphasising the association between 
inflammation and obesity. CRP is also considered to be an independent 
biomarker in the development of CVD42, highlighting the relationship between 
obesity induced inflammation and additional morbidities. 
As described in Table 1.2 (p11), adipose tissue is responsible for the 
synthesis and secretion of numerous molecular signals, but of particular 
interest in an obese pro-inflammatory status are the immune-modulating 
adipokines. In an obese condition it has been demonstrated that 
immunological adipokines from the interleukin family, both pro and anti-
inflammatory molecules interleukin-6 (IL-6) and interleukin-10 (IL-10), show 
up-regulated expression and increased circulating plasma 
concentrations61,62,63. The monocyte/macrophage recruitment molecule, 
monocyte chemoattractant protein-1 (MCP-1) and its receptor chemokine C-C 
motif receptor 2 (CCR2) also show up-regulation in the presence of obesity64. 
These inflammatory molecules are also believed to contribute to the 
development of insulin resistance62,64. 
Numerous mechanisms may be driving adipose tissue induced inflammation, 
including increased adipokine synthesis, circulating NEFAs and triglycerides 
resulting from adipocyte hyperplasia and hypertrophy. Adipocyte hypertrophy 
has also been linked to increased apoptosis and crown-like structure 
development65, which may be responsible for cumulative macrophage 
signalling and recruitment. In addition, immune cell infiltration of adipose 
tissue occurs via elevated adipokine cross-talk, contributing to further 
adipokine synthesis and macrophage accumulation. It is hypothesised that 
the non-fat cell fraction of adipose tissue is responsible for the majority of 
relative adipokine expression66. One of the mechanisms thought to contribute 
to increased non-fat cell development in obesity, is via microcirculatory 
dysfunction and hypoxia caused by adipocyte enlargement67. Hypoxic adipose 
tissue stimulates vascular synthesis and remodelling via up-regulation of the 
vascular endothelial growth factor (VEGF) gene, allowing for endothelial 
growth leading to additional immune cell infiltration and signalling, creating a 
continuous chronic inflammation feedback loop67.  
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Finally, recent research has demonstrated that the metabolic hormones leptin 
and adiponectin, which are known to be direct signallers on the hypothalamus 
in the regulation of appetite and primarily synthesised in adipose tissue, also 
modulate an immune response in obesity linked inflammation, via both direct 
and indirect mechanisms68,69. Figure 1.5, p17 summarises the complex nature 
of obesity induced inflammatory pathways. 
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Figure 1.5: Summary diagram of the mechanisms involved in obesity induced inflammation. 
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1.3.2 Gender and adipose tissue depot differences in inflammation 
Different adipose tissue depots display heterogeneity between genders and 
their metabolic profiles. A study in comparing gender and gluteal and intra-
abdominal visceral adipose depots to their respective inflammatory protein 
markers has shown that visceral adiposity is significantly associated with 
elevated IL-6 and CRP plasma concentrations. The study also demonstrated a 
trend showing increasing subcutaneous thigh adiposity in females resulting in 
lower concentrations of the same inflammatory proteins70. These results 
suggest that visceral adipose tissue is a predictor of inflammatory protein 
concentration and that obese females may show a reduced obesity linked 
inflammatory profile. Adipose tissue from extremely obese females has also 
been identified as synthesising higher levels of inflammatory adipokines 
compared to leaner females, regardless of locale66. Additional studies have 
shown conflicting results in comparison of subcutaneous and omental adipose 
depots. In visceral adipose tissue, MCP-1 and TNF-Į expression is down-
regulated or equal to gene expression in subcutaneous fat66. Yet IL-6, CCR2 
and macrophage migration factor (MIF) gene expression is up-regulated in 
visceral compared to subcutaneous adipose tissue depots71,72, however none 
of these studies examined age or gender differences. Adipose tissue 
inflammatory profiles may show heterogeneity between gender and depot 
location, although the literature presents varied conclusions, summarised in 
Table 1.3. It is possible that any heterogeneity displayed is due to differences 
in the adipose depot components, i.e. relative fraction of non-fat cells and 
adipocyte number and size, although obesity certainly impacts and promotes 
an inflammatory profile in adipose tissue. 
Source Species Gender  Adipose depot Outcome 
Alvehus et al 
(2010) 
Human Both 
Visceral to 
subcutaneous 
CCR2 
expression Ĺ 
0,)H[SUHVVLRQĹ 
Beasley et al 
(2009) 
Human Males to females Visceral 
Plasma IL-6 Ĺ  
Plasma CRP Ĺ 
Beasley et al 
(2009) 
Human Males to Females Subcutaneous 
Plasma IL-6 Ļ 
Plasma CRP Ļ 
Plasma TNF-ĮĻ 
Cinti et al 
(2005) 
Mice Males only Total 
Adipocyte 
deathĹ 
Macrophage 
LQILOWUDWLRQĹ 
Cinti et al 
(2005) 
Humans Both 
Visceral to 
subcutaneous 
MCP-1 
expression Ļ 
TNF-Į
expression Ļ 
Fain et al 
(2004) 
Humans Females only 
Visceral to 
subcutaneous 
Adipokine 
secretion Ĺ 
Table 1.3: Summary of effects in obesity on inflammatory outcomes in relation to 
gender and adipose depots. 
19 | P a g e  
 
The elevated chronic inflammatory status observed in obesity alongside the 
associated obesity comorbidities, is hypothesised to be a mechanism behind a 
more widespread systemic injury, targeting organ systems such as the heart, 
liver and kidneys73. My project investigates the nature of potential obesity 
mediated inflammation and its effects on the kidneys. 
1.4 The kidney structure and function 
In humans and most mammalian species, the kidneys are two highly complex 
reniform shaped organs located in the retroperitoneal space conjoined to an 
adrenal gland and located anteriorly atop each organ. They consist of a 
number of extremely specialised cells, organised in a three dimensional 
pattern, that perform a variety of important biological functions, including 
filtering blood to remove waste metabolites, fluid homeostasis, hormone 
production and regulation of blood pH and pressure74,75,76,77. Kidney 
parenchyma consists mainly of two sections, an outer cortical (cortex) portion 
and an inner medullary (medulla) portion, see Figure 1.6, p20. The kidney 
consists of multilobular, pyramidal elevations called renal papillae which 
project from the cortical medullary junction into the renal sinus, a cavity 
surrounded by the kidney parenchyma and occupied by the renal pelvis, renal 
calyces, nerve fibres and adipose tissue. The renal sinus leads to the renal 
hilum allowing access of the kidney to the renal veins, arteries and 
ureter74,75,76,77. Contained within the pyramidal papillae are the functional 
units of the kidney, called nephrons, see Figure 1.6, p20. There are 
approximately between 800,000 and 1.2 million nephrons in each human 
kidney74. Nephrons consist of the renal corpuscle and renal tubules. The renal 
corpuscle is FRPSULVHG RI WKH%RZPDQ¶V FDSVXOH DGRXEOHZDOOHG VSKHULFDO
case structure which encapsulates a glomerular capillary tuft (the glomerulus 
as shown in Figure 1.7, p21).  
Renal corpuscles are located at the basal pole of the nephron, which are 
almost all exclusively located within the cortical region of the kidney, with 
juxtamedullary renal corpuscles being the exception. The renal tubule 
consists of the convoluted and straight proximal tubule and peritubular 
capillary network, the loop of Henle, the convoluted and straight distal tubule 
and finally the collecting duct. The renal tubule is located at the apex pole of 
the nephron and is located within the medullary region of the kidney74,75,76,77. 
The glomerulus is a three dimensional ball of capillaries, these capillaries 
consist of endothelial cells and a basement membrane, whose exterior is 
coated by renal podocytes and form filtration slits with adjacent podocytes.  
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Each glomerulus contains two vascular poles; located at one of the vascular 
poles is a specialised matrix of connective tissue comprised of mesangial cells 
which fill the void between adjacent capillaries. Located at the same vascular 
pole, are particular epithelial cells connected to the distal tubule termed the 
macula densa. The mesangial matrix and macula densa are called the 
juxtaglomerular apparatus77.  
 
 
Figure 1.6: A ± Cross section of kidney, depicting cortical and medullary regions of 
the organ. Striated regions show pyramidal papillae. B ± A nephron; the basic 
functional filtration unit, which performs majority of organ functions. Renal tubule 
portion of nephron located within medullary region. C ± A detailed image of a nephron. 
The Bowman¶V capsule is a double walled capsule containing the glomerular capillary 
tuft (glomerulus), these two structures constitute the renal corpuscle. The majority 
are located in the cortical region, with juxtamedullary corpsucles being the 
exception74,75,76,77,78. 
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Figure 1.7: A cross section of a renal corpuscle. The vascular poles of the glomerulus 
are located at the openings of the proximal convoluted tubule and the efferent and 
afferent arterioles. The capillary tuft consists of endothelial cells, covering podocytes 
and filtration slits. The juxtaglomerular apparatus comprises of the mesangial matrix 
and macula densa77,79. 
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The kidneys are supplied with blood from the renal arteries which branch into 
smaller interlobular arteries that run along the medullary-cortex border, the 
afferent arterioles which supply the glomeruli, branch off these interlobular 
arteries74,80,81. After entering the glomerulus at a higher pressure than the 
remaining kidney microvasculature, blood is filtered through the glomerular 
capillaries. The volume of fluid filtered through the kidney during a set unit of 
time is a clinical measure of kidney function called the glomerular filtration 
rate (GFR). Filtration occurs via hydrostatic and oncotic µ6WDUOLQJ forces¶ 
through the podocyte fashioned filtration slits, forming urinary filtrate which is 
WKHQ H[FUHWHG LQWR WKH %RZPDQ¶V FDSVXOH DQG WUDQVSRUWHG WR WKH SUR[LPDO
tubule80. Filtered blood from the glomerulus enters the efferent arteriole and 
passes to the interlobular veins. After the urinary filtrate has passed into the 
proximal tubule, ions, molecules and waste metabolites are reabsorbed and 
secreted between the peritubular capillary network and the proximal tubule 
via passive and active transport processes74,80,81. Specialised reabsorption 
transport proteins and ion pumps which transport glucose, amino acids, 
bicarbonate ions (HCO3
-) and sodium chloride ions (Na+ and Cl-) facilitate the 
transfer of these molecules back to circulation. Increased solute concentration 
in the blood subsequently impacts on its osmotic pressure allowing for water 
to also be reabsorbed from the urinary filtrate. These reabsorption and 
secretion mechanisms occur at various degrees throughout the loop of Henle 
depending on solute concentrations until urinary filtrate reaches the distal 
tubule and collecting duct77.  
Whilst still undergoing reabsorption and secretion, the distal tubule reacts to 
the concentration of arginine vasopression (anti-diuretic hormone), to either 
decrease urine volume and water excretion or increase urine dilution and 
urine volume74,80,81. Finally urea and waste metabolites are passed through 
the collecting duct and ureter to be stored in the bladder ready for excretion.  
The kidney is also responsible for the production of various hormones, for 
example the macula densa senses abnormalities in plasma sodium chloride 
concentrations at the afferent arteriole, and in response produces renin74,82, a 
protein involved in the renin-angiotensin-aldosterone system (RAAS). In 
response to hypoxia, fibroblasts in the renal cortex promote transcription of 
erythropoietin (EPO), a hormone that regulates erythrocyte production83. 
These hormones will be discussed in greater detail in subsequent sections.  
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1.4.1 Glomerular filtration rate 
As GFR is accepted to be the best overall measure of kidney function, in 
determination of GFRs, clinical practice regularly measures either endogenous 
or exogenous biomarker clearance from serum by urine excretion. It is 
important that the biomarker used is not reabsorbed by the kidney and freely 
filtered by the glomerulus, examples of exogenous and endogenous 
biomarkers are inulin (a plant polysaccharide) and creatinine (a metabolite of 
muscle synthesised creatine phosphate) respectively84,85. Generally, to avoid 
the administration of an exogenous biomarker, creatinine is used in the 
measure of GFR. To measure GFR, both serum and timed urinary samples are 
collected to determine a creatinine clearance rate, however creatinine 
generation is dependent on muscle mass and is also secreted by the proximal 
tubule, so GFR readings can be over or underestimated using this urinary 
clearance method84,86. Additionally timed urinary collections can also prove 
problematic to achieve accurate results. Therefore standard clinical practice is 
to use an estimated GFR calculation based on serum creatinine measurement. 
There are a variety of estimation formulae available, but routinely, the 
Cockcroft and Gault (in adults, see Figure 1.8) or Schwartz (in children)87 
equations are the standard mathematical estimated GFR formulae. These 
equations take parameters such as age, weight, height and sex into 
consideration to calculate an accurate estimation of GFR84,86. In animal 
studies GFRs are determined by the serum and urinary excretion methods 
using either endogenous or exogenous biomarker clearance rather than 
formulating eGFR equations for multiple animal species85. By using GFR and 
eGFR measurements it is possible to monitor the progression of chronic 
kidney disease. Measurements implying a reduction in GFR, hypofiltration or 
extreme hyperfiltration are often signs of nephropathy and kidney damage84.  
 
Estimated creatinine clearance (eCcr) = (140 ± age) x mass [kg] x 0.85 [if female] 
                                                                               72 x serum creatinine [mg/dl]  
 
Figure 1.8: Cockcroft-Gault creatinine clearance estimation formula used to calculate 
GFR in human adults88. 
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1.4.2 The kidney as a target organ in an obese condition 
The kidneys are sensitive to subtle changes in blood flow volume and oxygen 
delivery, where chronic exposure to such alterations often leads to 
impairment and damage of the nephrons. As previously discussed, obesity 
has consistently been associated with the development of hypertension, 
diabetes mellitus type II and metabolic syndrome, conditions that directly 
impact on kidney function. It is therefore logical to suggest that the presence 
of obesity plays a key role in the development and progression of chronic 
kidney disease. The relationship between an increasing BMI and impairment 
of renal haemodynamics is also evident in subjects without obesity89. 
However, it has been reported that obesity as an independent risk factor 
without the presence of its comorbidities hypertension, diabetes mellitus type 
II and dyslipidaemia, does not significantly increase the risk of cardiovascular 
morbidity and mortality in either gender90. Conversely, once obesity is 
combined with hypertension, the risk of cardiovascular morbidity and 
mortality is dramatically increased, in both genders, albeit with females 
showing a decreased risk compared to males90. Nevertheless, obese subjects 
are at an increased risk of hypertension, but it appears the reverse is also 
true and that hypertensive subjects are predisposed to gain more weight91. 
The evidence from these studies suggests that obesity, hypertension and 
metabolic abnormalities interact and this amplifies their individual 
contribution towards CVD, summarised in Figure 1.9, p25, which is further 
amplified by additional genetic and socio-environmental factors associated 
with obesity development. 
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Figure 1.9: Interactive relationship towards chronic kidney disease by visceral obesity, 
hypertension and metabolic abnormalities92. 
 1.4.3 Pathophysiology of hypertension, metabolic abnormalities and 
obesity tissue in renal disease 
Although the mechanistic knowledge of hypertensive renal damage is fairly 
limited, it is believed that during sustained hypertension, renal microvascular 
endothelial tissue responds by an up-regulation of vasoactive molecules, such 
as endothelin, inter-cellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1)93. These molecules play a role in recruitment 
and activation of immune cells which may be involved in the constriction of 
renal vessels and sclerosis of muscle and endothelial tissue of the renal 
microvasculature seen in hypertension81.  The afferent arterioles which supply 
the nephrons and excretory system with blood, also undergo hyalinisation 
(the deposition of glycoproteins and lipids from plasma), which occurs to a 
greater extent with elevated plasma lipids as seen in obesity. This in turn 
exposes the glomerular capillary apparatus to glomerular hypertension, 
leading to conditions such as focal segmental glomerulosclerosis (FSGS) 
shown in Figure 1.10 (p26) and glomerular injury responsible for continued 
hypertension81. Glomerulosclerosis is the scarring of the glomeruli, whereby 
sustained vascular mechanical injury induces the production and deposition of 
types I, II, III, IV, V and VI collagen in the glomerular basement membrane. 
Immunohistological staining has demonstrated that collagen synthesis and 
deposition in glomerulosclerosis is due solely to podocyte and glomerular 
cells94.  
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The process of glomerulosclerosis development leads to a reduction in 
nephron number, hyperfiltration of remaining glomeruli and an overall 
reduction in filtration efficiency, usually diagnosed by the presence of 
proteinuria and haematuria. It has been established that in obese, proteinuric 
patients with elevated GFRs, a consistent finding in the renal pathology of 
these patients has been glomerular hypertrophy, or glomerulomegaly95. The 
hallmarks of glomerulopathy in obese humans have often been both the 
presence of FSGS and glomerulomegaly, which are clinical signs of kidney 
disease, alongside other clinical observations such as proteinuria, fluctuations 
in GFR and renal vasodilatation96. 
 
 
Figure 1.10: Microscopic histological kidney sections showing glomerular apparatus. 
Image A shows a healthy glomerulus with an open and complete capillary tuft and 
RSHQ%RZPDQ¶VVSDFH. Image B shows a thickening and scarring of the capillary tuft 
DQGDFORVHG%RZPDQ¶VVSDFH, an indication of glomerulosclerosis97.   
The majority of histological based studies researching glomerulopathy in 
obesity have been conducted using animal kidney biopsy experiments. These 
studies have highlighted glomerular alterations such as an enlarged 
%RZPDQ¶V VSDFH FDSLOODU\ PHPEUDQH WKLFNHQLQJ JORPHUXODU K\SHUWURSK\
accompanied by an increased cellular and mesangial matrix proliferation and 
elevated expression of growth and immune molecules96.  
 
A B 
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One of the mechanisms thought to contribute towards visceral obesity and 
increased NEFA derived hypertension and glomerulopathy is through 
activation of the RAAS by stimulating the sympathetic nervous system, 
triggered by hyperleptinaemia and hyperinsulinaemia. Stimulation of renin 
production leads to an up-regulation of angiotension I and II, a pathway 
involved in vasoconstriction and hypertension98. Additionally the presence of 
central obesity is positively correlated to the prevalence of diabetes mellitus 
type II99. Increased circulating insulin from adipose tissue hypertrophy, 
hyperlipidaemia and subsequent elevated inflammatory profile induces insulin 
resistance100 preventing circulating glucose being converted to storable 
glycogen, leading to hyperglycaemia and eventual diabetes mellitus type II.  
Chronic presence of diabetes mellitus type II leads to initial diabetic 
nephropathy, characterised by a thickening of the glomerulus, glomerular 
hypertrophy and mesangial expansion101, affecting GFR and elevating 
proteinuria.  Continued exposure causes further injury to the kidney glomeruli, 
concluding in FSGS, glomerular nephritis, glomerular necrosis and eventual 
end stage renal disease (ESRD)102.  
The WHO reports that 10-20% of diabetes mellitus type II patients suffer 
mortality from diabetes related kidney disease103.  Figure 1.11, p28 
elaborates on the interactive pathways between visceral obesity, hypertension 
and metabolic abnormalities contributing to chronic kidney disease.  
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Figure 1.11: Summary of mechanisms involved in obesity mediated kidney function 
impairment, showing hypertension and metabolic abnormality pathways104. 
1.4.4 The renin-angiotensin-aldosterone system 
The RAAS is a critical regulator of arterial blood pressure through the control 
of extracellular fluid volume, sodium homeostasis and vascular resistance105. 
Production of renin by the granular cells of the juxtaglomerular apparatus is 
stimulated via three primary mechanisms; a decrease in sodium chloride 
concentrations detected by the macula densa, a decrease in arterial blood 
pressure detected by baroreceptor mechanism located within the afferent 
arteriole and sympathetic nervous syVWHPDFWLYDWLRQYLDǃ1 adrenoreceptors106. 
Upon stimulation of the RAAS, circulating plasma renin is increased. Active 
renin (also known as angiotensinogenase) cleaves the substrate 
angiotensinogen which is produced by the liver, to form the inactive peptide 
angiotensin I. Angiotensin converting enzyme (ACE) converts angiotensin I to 
angiotensin II by catalytic cleavage. Angiotensin II action is mediated by two 
receptors, angiotensin receptor-1 (AT1) and angiotensin receptor-2 (AT2). 
Formation of the AT1-angiotensin II complex mediates afferent and efferent 
arteriole vasoconstriction and elevation of sodium ion and fluid 
reabsorption105. Furthermore, angiotensin II is a regulatory factor in the 
synthesis of aldosterone, stimulating production in the adrenal cortex via AT1 
binding.  
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Aldosterone is a mineralocorticoid which binds to glucocorticoid receptor (GR) 
located in the proximal and distal tubules of nephrons. This process regulates 
sodium ion reabsorption and potassium ion secretion via an elevation in ion 
pump and protein transport107. Overall the activation of the RAAS 
(summarised in Figure 1.12) results in systemic vasoconstriction and an 
elevation of systemic arterial blood pressure coupled with reduced blood flow, 
a system which is routinely targeted by pharmacological inhibition to treat 
hypertension and associated cardiovascular conditions105. An over-stimulated 
RAAS is associated with the development of obesity, hypertension and 
metabolic syndrome, a mechanism possibly derived by angiotensin II 
mediated adipocyte growth and differention108.  
 
Figure 1.12: Summary diagram of the renin-angiotension-aldosterone system; a 
decrease in blood pressure is sensed by the juxtaglomerular apparatus resulting in an 
up-regulation of renin. Renin acts on circulating angiotensinogen to form inactive 
angiotensin I, converted to active angiotensin II by angiotensin converting enzyme 
(ACE). Angiotensin II acts to both increase arterial blood pressure and activates 
aldosterone synthesis in the adrenal cortex. Aldosterone increases salt retention in the 
renal tubules resulting in additional arterial blood pressure increase109. 
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1.4.5 Sex differences in obesity mediated renal nephropathy 
As previously discussed, females appear to be at a reduced risk from renal 
nephropathy compared to males. Males also appear to suffer from faster 
progression of a number  of nephropathies110. It is suggested that this gender 
disparity in both humans and animals may be attributable to differences in 
diet, glomerular haemodynamics, glomerular size and the direct actions of 
sex hormones110. A study on both testosterone and oestradiol action on 
mesangial cell proliferation and collagen synthesis demonstrated that whilst 
testosterone had no effect, oestradiol suppressed mesangial cell proliferation 
and collagen synthesis, a potential mechanism behind slower 
glomerulosclerosis progression seen in female subjects111. In regards to the 
sexual dimorphism in cardiovascular parameters, males display higher arterial 
blood pressures and higher plasma renin activity than pre-menopausal 
females or post-menopausal females treated with oestrogen replacement 
therapy112. It is therefore hypothesised that these differences are regulated 
by sex hormone stimulation and suppression of the RAAS. Several 
experimental animal studies have reported that oestrogen both up-regulates 
plasma angiotensinogen, and down regulates renin, ACE and AT1
113, in effect 
suppressing the RAAS. Experimental studies using rats have demonstrated 
that male rats display higher renal angiotensinogen levels than females, 
which are significantly increased during puberty and decreased after 
castration, and renal angiotensinogen mRNA expression is up-regulated in 
females exposed to exogenous testosterone114,115. This evidence suggests 
that sex hormones play an important role in the regulation of blood pressure 
from action through the RAAS, one of the potential mechanisms which may 
account for the gender disparity seen in the progression of renal nephropathy 
and CVD. 
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1.4.6 Perirenal adipose tissue 
Surrounding the fibrous kidney capsule is a variable layer of perinephric or 
perirenal adipose tissue (PAT) used for heat generation in neonates, and for 
protective cushioning and VXSSRUWLQJWKHRUJDQ¶Vretroperitoneal position after 
the neonatal period116.  In animals fed a high-fat diet, obesity development 
and the enlargement of adipose tissue depots is not solely limited to classic 
visceral, subcutaneous and gluteal regions but also to a further extension in 
visceral ectopic adipose depots117. Raised ectopic adipose tissue with obesity 
effects depots around the cardiovascular apparatus, including the kidneys, 
heart and associated vasculature117. In an obese condition perirenal adipose 
tissue enlargement and subsequent adipose infiltration of the renal sinus may 
result in direct physical compression of the renal medullary architecture and 
microvasculature, leading to a restriction of tubule blood flow118. 
Consequently compression of renal nephron apparatus could result in 
impaired fluid and sodium reabsorption, leading to activation of the RAAS and 
contributing to obesity mediated hypertensive renal nephropathy. Perirenal 
adipose tissue thickness has been described as an independent predictor of 
chronic kidney disease and increased renal resistance118. Ectopic renal 
adipogenesis and enlarged ectopic adipose storage has been demonstrated to 
increase lipid deposition in renal cortical tissue of rats119. Excess accumulation 
of intra-renal lipids are also linked to renal lipotoxicity and lipid mediated 
insulin resistance and associated inflammation117,120. 
1.4.7 Hyperlipidaemia and the progression of renal lipotoxicity 
In obesity, the excess lipid accumulation in adipose tissue contributes to 
adipocyte hypertrophy and systemic dyslipidaemia. As previously discussed, 
visceral and ectopic adipocytes appear to have a lower storage capacity for 
triglycerides compared to subcutaneous adipocytes37. With obesity, 
hypertrophy of these specific depot adipocytes is increasingly linked to a 
hyperlipidaemic status121. However obesity is not only associated with 
increased adipocyte lipogenesis and hyperlipidaemia linked adipocyte 
hypertrophy, but may contribute towards lipid accumulation and deposition in 
non-adipose tissue and non-adipocytes. Saturation of lipids in non-adipose 
tissue, a process termed lipotoxicity, impairs and damages tissue via 
metabolic cellular dysfunction and tissue injury pathways122. Adverse 
consequences of excess lipid deposition have been observed in a number of 
different organs and tissues, including skeletal muscle, pancreas, liver, heart 
and kidney123.  
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In skeletal muscle, intracellular accumulated NEFAs activate a 
serine/threonine kinase cascade resulting in reduced phosphorylation of 
insulin receptor substrate-1, a critical pathway of insulin resistance genesis124. 
Such interference in insulin receptor signalling, results in further accumulation 
of intracellular NEFA metabolites, fatty acid coenzyme A and diacylglycerol125.  
In the progression of lipotoxicity induced renal injury, filtered NEFAs carried 
on albumin through the proximal tubule, trigger the inflammatory state 
observed in proteinuria. Accumulating albumin carried NEFAs stimulate 
macrophage infiltration of proximal tubule epithelial cells, demonstrated in 
patients with proteinuria derived nephrotic syndrome by initial monocyte and 
macrophage foam cell precursor infiltration126. Inflammatory cascade 
activation via macrophage infiltration and cytokine recruitment is believed to 
significantly increase tubular cell stress, injury and apoptosis, leading to 
general tubulointerstitial injury and renal nephropathy123. In acute renal 
failure models, excess unmetabolised NEFAs can induce mitochondrial 
dysfunction and activation of nuclear factor kappa light chain enhancer 
activated B cell (NF-ǉ%. These pathways are both mechanisms of excess lipid 
induced cell death127.  Excess NEFAs have also been linked to an increase in 
cellular oxidative stress and further cellular apoptosis, observed by an up-
regulation in nitric oxide production123. 
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1.5 The role of glucocorticoids in obesity and inflammation 
A member of the steroidal hormones family, glucocorticoids are primarily 
synthesised and secreted by the adrenal cortex, although recent data 
suggests that they are also synthesised within local organ and tissue systems 
too128. They regulate a number of metabolic physiological processes and 
maintain immune related homeostasis through interactions with GR, present 
in almost all tissue129. These hormones are responsible for the maintenance 
and increase of blood glucose concentrations via hepatic gluconeogenesis by 
stimulation of lipolysis for glycerol formation from adipocyte stored 
triglycerides and through inhibition of glucose uptake by adipose and muscle 
tissue. Glucocorticoids also have a potent anti-inflammatory and 
immunosuppressive action, and are used pharmacologically in treatment of 
inflammatory and auto-immune disorders130. 
Regulation of glucocorticoid synthesis is controlled by activation of the 
hypothalamic±pituitary-adrenal (HPA) axis, a neuroendocrine negative 
feedback loop, and the RAAS. In response to systemic stress or decreased 
circulating levels of glucocorticoids, adrenocorticotropic hormone (ACTH) is 
produced by the pituitary gland via hypothalamic synthesis and signalling of 
corticotrophin releasing hormone (CRH) and steroidogenic peptide 
proopiomelanocortin (POMC). ACTH stimulates production of glucocorticoids in 
the adrenal gland. Additionally, glucocorticoid synthesis in certain tissues is 
UHJXODWHGE\WKHǃK\GUR[\VWHURLGGHK\GURJHQDVHIDPLO\RIHQ]\PHV131. In 
central obesity both human and rodent models have reported that activity of 
the HPA and RAAS axes are increased98,132, evidence that visceral obesity is a 
form of systemic stress. A link between HPA activity and modification in body 
fat distribution via increased intra-abdominal fat development has also been 
reported133,134.  
Energy balance is controlled via hormonal stimulation from signalling 
molecules including leptin, adiponectin, insulin and cortisol or corticosterone 
(the predominant glucocorticoids in humans and rodents respectively) on the 
HPA axis. Energy hormone concentrations undergo fluxes during pre and 
postprandial periods of appetite regulation135, but with obesity this hormonal 
signalling milieu is dysregulated. For example, patients with &XVKLQJ¶V
syndrome, which is the prolonged exposure of the body to increased levels of 
plasma cortisol (hypercortisolism), central obesity is a prominent feature136.  
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In fact with obesity, cortisol secretions are increased although circulating 
concentrations of cortisol in obese subjects are normal or low suggesting that 
cortisol clearance rate is elevated137, confirmed by raised urinary cortisol 
excretion134.  
Obese human and rodent studies have demonstrated that intracellular tissue 
hypercortisolism exists GXH WR LQFUHDVHG DFWLYLW\ RI ǃ-hydroxysteroid 
GHK\GURJHQDVH W\SH  ǃ+6' an enzyme which converts inactive 
cortisone to active cortisol, reported to be up-regulated in omental but not 
subcutaneous adipose tissue depots134,136,138. Though in human males, central 
REHVLW\KDVEHHQGHVFULEHG WR LQKLELWKHSDWLFǃ+6'DFWLYLW\FRPSDUHGWR
pre-menopausal women134.  
Changes LQ ǃ+6' H[SUHVVLRQ FRQWULEXWH WRZDUGV GHYHORSPHQW RI LQVXOLQ
resistance, hypertension and associated metabolic syndrome139. With respect 
to cortisol action within the kidneyǃ+6'DQHQ]\PHWKDWFRQYHrts active 
cortisol to inactive cortisone is expressed in the tubular nephron architecture 
to prevent inappropriate stimulation of GR and anti-inflammatory action by 
cortisol138. TKHUHVSRQVHRINLGQH\ǃ+6' expression to abdominal obesity 
is so far unknoZQ DOWKRXJK PXWDWLRQV RI WKH ǃ+6' JHQH DUH OLQNHG WR
development of primary hypertension140. 7KH ǃ-hydroxysteroid family of 
enzymes can be regulated by a number of molecular factors, some influenced 
by the presence of central obesity such as insulin, TNF-ĮDQGVH[KRUPRQHV138.   
One of the suggested anti-inflammatory mechanisms of cortisol is inhibition of 
monocyte-macrophage differentiation and function, demonstrated to be 
suppressed in the presence of cortisol. After removal of cortisol, normal 
monocyte-macrophage differentiation and proliferation rates are restored141.  
Furthermore proteins involved in innate immunity up-regulated by the 
presence of lipopolysaccharide (LPS), are down regulated in the presence of 
cortisol142. It also inhibits synthesis of numerous cytokines, immune 
transcription mediators (i.e. NF-ǉ%DQGFHOOVXUIDFHPROHFXOHVLQYROYHGLQWKH
immune response143,144. Although the mechanisms involved in the relationship 
between obesity, gender, glucocorticoids and inflammation are not completely 
understood, imbalance of HPA activity from obesity and cortisol dysfunction 
are potential mediators of adverse clinical outcomes. Figure 1.13, p35 
summarises the pathways of glucocorticoid action in obesity and inflammation. 
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Figure 1.13: Summary of the hypothalamus-pituitary-adrenal (HPA) axis. A stress 
signal activates the hypothalamus which synthesizes corticoptropin releasing factor 
(CRF), in turn stimulating the formation of proopiomelanocortin (POMC) and 
adrenocorticotropic hormone (ACTH). ACTH results in glucocorticoid (cortisol) 
production in the adrenal cortex which inhibits immune cell and downstream cytokine 
synthesis. In obesity, the stress signal is elevated leading to additional immune 
suppression and potential cortisol dysfunction. Adapted from Slominski et al145. 
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1.6 Gene expression 
Gene expression is an important analytical tool to determine the amounts of a 
functional gene product derived from nuclear DNA. In eukaryotes, initially the 
DNA gene sequence is duplicated by RNA polymerase to form a primary 
precursor-messenger RNA (mRNA) transcript; a single complimentary 
molecular strand of genetic information55. Precursor-mRNA is then spliced by 
spliceosome proteins to remove the introns from the sequence leaving only 
an exon comprised mature mRNA sequence.  This functional mRNA sequence 
is then translated to an amino acid sequence via ribosomal transfer RNA 
(tRNA) anti-codon interaction, synthesising one amino acid per three 
nucleotide mRNA bases (codon)55. Translated mRNA products are the initial 
amino acid sequences of the coded protein, which undergo post-translational 
modification into their secondary and tertiary structures for their functional 
purposes55. The gene expression, transcription and translation mechanism is 
summarised in Figure 1.14, p37. Gene expression analysis evaluates the 
levels of mature mRNA within individual cells or a specific amount of whole 
tissue.  
Gene expression is a key factor with regards to regulation of cellular activity, 
and since any alteration in gene expression would reflect changes in cellular 
mechanisms such as proliferation, survival or differentiation146, the ability to 
quantify transcription levels of specific genes is essential to any research into 
gene function. Gene expression profiling is widely used in biological research, 
especially within animal model studies in response to applied experimental 
manipulations or interventions. These studies have identified multiple gene 
function and regulation fluctuations observed in numerous tissues mediated 
by both obesity and renal nephropathy147,148. Gene expression data must be 
supplemented with protein expression analysis to corroborate the successful 
transcription of mature mRNA to expressed protein, which generally show a 
positive correlation149. 
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Figure 1.14: Summary of protein synthesis via gene transcription and translation. 
RNA polymerase converts nuclear DNA strand to precursor mRNA which is then 
converted to mature mRNA by spliceosome proteins. After transport of mRNA to 
cytoplasm, translation via ribosomal tRNA anti-codons occurs forming an amino acid 
chain and eventual protein55,150. 
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1.7 Genes, cytokines and proteins involved in obesity mediated 
inflammation and renal nephropathy 
Numerous cytokines and proteins are involved in the cellular mechanisms and 
pathways of the immune response and inflammation. Although not a 
comprehensive list, this section will discuss the functional roles of certain 
renal hormones, proteins and cytokines involved in inflammation and their 
response in the presence of obesity and how they contribute towards the 
development or prevention of renal nephropathy. 
1.7.1 Glucocorticoids 
1.7.1.1 11ǃ hydroxysteroid dehydrogenase type 1 
The type 1 isoform of the hydroxysteroid dehydrogenase enzyme located in 
the endoplasmic reticulum (ER), is a bidirectional enzyme which principally 
acts as an oxioreductase enzyme to convert inactive cortisone to the active 
glucocorticoid cortisol (corticosterone in rodents), leading to amplified local 
glucocorticoid action151. ǃ+6'DSSHDUVSULPDULO\ LQ WKH OLYHUDQGDGLSRVH
tissue, and acts by reducing inactive cortisone to cortisol by concomitant 
reduction of nicotinamide adenine dinucleotide phosphate (NADPH)152. The 
enzyme has been shown to be expressed by human adipocytes and 
preadipocytes, and expression levels are positively correlated with BMI. Its 
expression is significantly up-regulated in omental adipose tissue in obesity 
compared to peripheral adipose depots and lean control subjects153. Using 
URGHQW PRGHOV RYHU H[SUHVVLRQ RI ǃ+6' LQ YLVFHUDO DGLSRVH WLVVXH LV
linked to the development of hyperglycaemia, dyslipidaemia, insulin 
resistance and hypertension, conditions associated with the metabolic 
V\QGURPH ,Q ǃ+6' NQRFNRXW PLFH KRZHYHU YLVFeral adipose 
accumulation is reduced154. ([SUHVVLRQ RI ǃ+6' KDV EHHQ REVHUYHG LQ
rodent renal architecture, including the distal tubules, aldosterone target cells 
DQGFROOHFWLQJGXFWEXWQRVXEVWDQWLDOOHYHOVRIǃ+6'KDYHEHHQ observed 
in human or sheep kidneys139. 
1.7.1.2 ǃK\GUR[\VWHURLGGHK\GURJHQDVHW\SH 
The type 2 isozyme of the hydroxysteroid dehydrogenase enzyme, ǃ+6'
KDV D FRQYHUVH DFWLRQ WR WKDW RI ǃ+6', and converts active cortisol to 
LQDFWLYHFRUWLVRQHǃ+6'FDWDO\VHVWKHFRQYHUVLRQof cortisol by oxidative 
dehydrogenation to cortisone, a reaction facilitated by the co-factor NAD+152. 
The reaction mechanisms of the heterogeneous ǃ K\GUR[\VWHURLG
dehydrogenase family are shown in Figure 1.15, p39.  
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Figure 1.15: (Q]\PDWLFUHDFWLRQVFDWDO\VHGE\ǃK\GUR[\VWHURLGGHK\GURJHQDVH
W\SHVDQGǃ+6'DQGǃ+6'FRQYHUWVLQDFWLve cortisone to active 
FRUWLVROE\UHGXFWLRQRINHWRQHWRK\GUR[\OJURXSYLD1$'3+FRQYHUVHO\ǃ+6'
catalyses the opposite reaction via NAD+. The human and rodent forms of the 
glucocorticoid molecules are represented by 1-2a and 1-2b respectively152. 
ǃ+6' is present in mineralocorticoid receptor target tissues, including 
kidney, and prevents inappropriate glucocorticoid-mineralocorticoid receptor 
activation through conversion of cortisol to cortisone155. Defects or mutations 
in ǃ+6' expression, thought to arise from elevated sodium reabsorption, 
have been observed to result in cortisol-dependent apparent mineralocorticoid 
excess which clinically manifests itself as severe hypertension, suppressed 
plasma renin activity, hypokalaemia, reduced aldosterone levels, abnormal 
kidney histology and interstitial fibrosis156+LVWRORJLFDO DQDO\VLV RI ǃ+6'
knockout rodent models, have demonstrated distal nephron hypertrophy and 
hyperplasia157. 2EHVLW\DFWLRQRQǃ+6'H[SUHVVLRQLQWKHKXPDQNLGQH\LV
unknown to date, although one recent human VWXG\VXJJHVWVWKDWǃ+6'
activity is elevated in obesity resulting in an intensified supply of cortisone 
from the kidney for extra-UHQDO ǃ+SD1 conversion which may fuel 
development of visceral adiposity and insulin resistance158.  
1.7.1.3 Glucocorticoid Receptor 
As discussed, the GR is a nuclear receptor located in the cellular cytoplasm of 
almost all tissue, intended for the glucocorticoid family of steroid hormones129. 
Glucocorticoid binding to GR primarily initiates transcription of numerous 
genes and factors involved in metabolic homeostasis; additionally 
glucocorticoid binding contributes to an anti-inflammatory status through 
immunosuppressive action on monocyte and macrophage differentiation130,141. 
In humans, two GR isoforms have been identified, GR-Į DQG *5-ǃ ZKLFK
originate from the same gene splicing. GR-ĮKDVEHHQGHVFULEHGDVWKHDFWLYe 
form of GR, demonstrated to be the default expressed GR in human cells and 
GR-ǃ WKH LQDFWLYH IRUP159, which does not bind glucocorticoid ligands or 
initiate gene transcription.  
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Mutations and polymorphisms in the GR sequence have been linked to GR-ǃ
expression, resulting in decreased glucocorticoid responsiveness and 
glucocorticoid resistance160.  
In response to obesity, GR-Į P51$ expression was down-regulated in 
subcutaneous adipose tissue depots of obese patients compared to lean 
subjects, although this alteration was not observed in visceral adipose tissue. 
The authors of the study suggested that the glucocorticoid insensitivity 
displayed by obese patients may have been due to dysregulation in 
expression of GR-Į*5-ǃ UDWLR DOWKRXJK YLVFHUDO DGLSRVH GHSRWV ZHUH VWLOO
responsive to local glucocorticoid synthesis161.  
1.7.2 Appetite regulators 
1.7.2.1 Adiponectin and adiponectin receptors 
Adiponectin is a 244kDa adipose tissue specific protein hormone derived from 
adipocytes and is one of the most abundant gene transcripts in adipose tissue. 
Plasma adiponectin exists as a full-length polypeptide or globular form, which 
can bind and stimulate two cell surface receptors, adiponectin receptor 1 and 
adiponectin receptor 2. Activation of an adiponectin receptor mediates 
pathways involved in cellular energy homeostasis, glucose uptake and fatty 
acid activation162. In contrast to other adipokines in humans and mice, 
adiponectin mRNA expression and plasma levels are decreased with obesity 
and presence of the metabolic syndrome, a trend that is reversed in subjects 
with weight loss163. Obesity is also believed to contribute to a reduction in 
adiponectin sensitivity through decreased adiponectin receptor expression162. 
Mice studies have demonstrated that down-regulation of adiponectin 
expression and decreased plasma adiponectin, correlates with insulin 
resistance. Exogenous doses of adiponectin were observed to decrease insulin 
resistance by reducing triglyceride content in liver and muscle of obese 
mice164. In a study investigating the relationship between adiponectin and 
cardiovascular and renal disease, a 1ǋg/ml increase of plasma adiponectin 
was associated with a decreased risk of CVD. Likewise, patients with chronic 
kidney disease and ischemic heart disease, had lower plasma levels of 
adiponectin compared to patients without, suggesting that 
hypoadiponectinaemia is a predictor of CVD165, indicating that adiponectin 
may additionally possess anti-inflammatory properties. This is supported by 
an observation that plasma adiponectin suppresses macrophage 
differentiation166. 
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1.7.2.2 Leptin and leptin receptor 
Leptin is a 16kDa adipose tissue derived protein hormone which signals 
through binding to the leptin receptor and plays a role in regulation of 
appetite and energy homeostasis through food intake signaling and satiety 
control. The primary target of leptin receptor binding is located in the 
hypothalamus, although recent studies have identified additional peripheral 
targets for leptin action167. Activation of leptin receptor inhibits appetite by 
suppressing synthesis of feeding stimulant molecules, such as neuropeptide 
Y1677KHLQLWLDOGLVFRYHU\RIDQµREHVH¶JHQHLQWKHV ODWHU LGHQWLILHGDV
leptin, demonstrated that a mutation or defect in transcription of the gene led 
to a phenotype of excessive appetite and development of severe obesity in 
mice168. Exogenous introduction of leptin in these animals reversed both 
appetite and adipose tissue mass168. It is now well established that adipose 
tissue mass levels and BMI positively correlate to circulating plasma leptin 
levels, which is observed in both genders albeit with obese females exhibiting 
higher plasma leptin levels than their male counterparts169. The proposed 
mechanism driving the observed sexual leptin dimorphism is via the 
stimulating and suppressive effect of oestrogen and testosterone 
respectively170. 
It is thought that the chronic exposure of higher leptin levels observed in 
obese subjects leads to leptin desensitisation and development of leptin 
resistance; thus a dysregulation of leptin action in appetite regulation and 
energy homeostasis occurs. Hyperleptinaemia has additionally been 
associated with development of insulin resistance, suggesting a role in the 
metabolic syndrome169. More recent research has identified leptin as a 
member of the cytokine family that possesses additional secondary immune 
and inflammatory properties, suggesting a mediator between nutritional 
status and the immune response. Periods of malnutrition or starvation and 
subsequent decreased circulating leptin signal are associated with 
abnormalities and suppression of the immune system171. In experimental 
animal models, using LPS as an inflammatory stimulus is associated with an 
up-regulation of leptin mRNA and circulating plasma leptin. This increase in 
leptin is believed to directly regulate the synthesis of the inflammatory 
cytokines and activate monocyte/macrophage through stimulation of IFN-Ǆ172. 
Leptin has also been identified as an anti-apoptotic and proliferative molecule 
which is reported to mediate the glomerular endothelial proliferation exhibited 
in glomerulosclerosis, a process amplified with an up-regulation of the 
RAAS172. 
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1.7.3 Markers of pro-inflammation 
1.7.3.1 Interferon-Ǆ 
IFN-ǄRULJLQDOO\WHUPHGPDFURSKDJHDFWLYDWLQJIDFWRUDFWLYDWHVPDFURSKDJHV
which stimulate immune cell recruitment and produce inflammatory cytokines 
in an effective innate immune response173. It is produced by various immune 
cells, such as natural killer cells, lymphocytes, APCs, and B and T cells via an 
innate immune system crosstalk, where macrophage pathogen recognition 
mediates cytokine production, additional immune cell recruitment and further 
IFN-ǄV\QWKHVLVDQGPDFURSKDJHDFWLYDWLRQ173. Glucocorticoid action and anti-
inflammatory cytokines have been described as negative regulators of IFN-Ǆ
production173. In cases of glomerulonephritis, macrophage accumulation 
correlates with renal dysfunction, additional activation of these renal 
infiltrated macrophages by IFN-Ǆ LQFUHDVHd proteinuria and glomerular 
proliferation of macrophages174.  
Exposure of macrophages to IFN-Ǆ results in up-regulation and increased 
production of inducible nitric oxide synthase (iNOS) and adhesion molecules, 
suggesting that IFN-Ǆ DFWLYDWLRQ RI Pacrophages augments and modulates 
renal injury174. In support of this finding, IFN-ǄVXSSUHVVLRQE\JOXFRFRUWLFRLGV
reduced proliferation and recruitment of macrophages to inflamed 
glomeruli174. 
1.7.3.2 Interleukin-6 
An important multifunctional cytokine, IL-6 has both pro and anti-
inflammatory properties and is involved in the acute phase and immune 
response. It is produced by a number of tissues and cells including adipose 
tissue, monocytes, fibroblasts, macrophages, endothelial tissue B-cells and T-
cells in the presence of injury, trauma or stress175. This cytokine transmits its 
biological signal through two protein receptors on the cell, a specific binding 
molecule, interleukin 6 receptor and membrane bound glycoprotein 130. IL-6 
forms complexes with these protein receptors, which in turn activates the 
receptor complex initiating a signal transduction cascade, such as the Janus 
kinases and signal transducers and activators of transcription pathway175. This 
cascade simply transforms a signal into a response such as regulation of cell 
proliferation, differentiation and cell apoptosis.  
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It is expressed and produced by numerous tissues including adipose tissue, 
and as previously discussed, obese subjects displayed elevated plasma IL-6 
concentrations which correlated with levels of insulin resistance61. Patients 
diagnosed with ESRD have poorer outcomes in the presence of elevated IL-6 
plasma concentrations176. 
1.7.3.3 Interleukin-18 
Interleukin 18 (IL-18) is structurally homologous to IL-1, but is expressed by 
both immune and non-immune cells and its receptor belongs to the IL1R and 
TLR superfamily177. IL-18 mediates T helper cell immune responses in 
conjunction with interleukin 12 (IL-12) when presented with a microbial agent 
such as LPS, which induces IFN-ǄE\VWLPXODWLQJ7DQGQDWXUDONLOOHUFHOOV,/-
18 also stimulates expression of other cytokines involved in immunity and 
inflammation177. Over production of IL-18 can lead to severe pro-
inflammatory disorders varying from auto-immune diseases to inflammatory 
organ tissue damage. In contrast, mice studies have shown that IL-18 
deficient subjects develop obesity and insulin resistance compared to wild 
type, which may indicate a similar role for IL-18 in energy intake and insulin 
sensitivity homeostasis as seen with IL-6 and TNF-Į178. Urinary IL-18 in 
children was increased in patients with acute kidney injury (AKI) prior to 
urinary creatinine elevation, demonstrating the potential of IL-18 as an 
independent biomarker for kidney damage and inflammatory morbidity179.  
1.7.3.4 Monocyte chemoattractant protein-1 and C-C motif receptor 2 
MCP-1 is a member of the chemokine family, and is produced by a number of 
immune cells. It binds to membrane bound CCR2 proteins which are highly 
expressed on monocyte and activated T cell surfaces. This receptor bound 
MCP1-CCR2 complex primarily is involved in attracting monocytes, T-
lymphocytes and natural killer cells to the site of injury or stress. MCP-1 has 
been shown to up-regulate the synthesis of IL-6 in epithelial cells and in vitro 
models have shown TNF-Į FRQFHQWUDWLRQ EHLQJ DPSOLILHG E\ DQ LQFUHDVH RI
MCP-1 expression. Obesity and increased adipose depot size has been linked 
with elevated mRNA expression of MCP-1 leading to higher MCP-1 plasma 
concentrations64. Obese mice engineered to over express the MCP-1 gene 
exhibited increased macrophage infiltration in adipose tissue, increased 
hepatic triglyceride deposition and insulin resistance, while MCP-1 knockout 
mice demonstrated reduced insulin resistance64.  
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MCP-1/CCR2 complex formation has also been suggested to be a major 
promoter of inflammation, macrophage infiltration, fibrosis and tissue damage 
exhibited in diabetic nephropathy180. 
1.7.3.5 Tumour necrosis factor-Į 
A multifunctional cytokine, TNF-Į is involved in the immune response, 
inflammation, growth promotion and growth inhibition of an organism. Similar 
to all cytokines, TNF-Į LVZLGHO\ VHFUHWHG E\ D QXPEHU RI WLVVXHV DQG FHOOV
including macrophages and monocytes. It binds and communicates with two 
receptors, type 1 (TNF-R1) and type II (TNF-R2) which belong to the TNF 
gene superfamily181. The molecule exists as both a membrane bound protein 
and a soluble form trimer, but is initially produced as a type II membrane 
protein. The membrane bound form is then converted by proteolytic cleavage 
to the soluble form by TNF-ĮFRQYHUWLQJHQ]\PH:KHQD71)-Į trimer binds 
to TNF-R1, silencer of death domain (SODD) proteins are dissociated from the 
TNF-R1 receptor complex and TNF-receptor associated death domain (TRADD) 
proteins are recruited into the receptor complex181. TNF-R1-TRADD complex 
proteins can recruit TNF receptor-associated factor 2 proteins, FAS-associated 
protein with death domain (FADD) proteins and receptor interacting protein 
(RIP) kinase enzymes. This protein recruitment produces TNF-R1 signaling 
complexes involved in the activation of a number of signaling pathways 
including mitogen-activated protein kinase (MAPk), nuclear factor (NF)-ǉ% 
and caspase dependent apoptotic pathways182, see Figure 1.16, p45. These 
pathways play important roles in inflammatory responses, cell growth, 
differentiation, proliferation and pro and anti-apoptotic functions. 
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Figure 1.16: TNF trimer binding to TNF-R1 resulting in recruitment of signaling 
proteins into the receptor complex, which can then lead to either apoptotic or 
proliferative pathways183. 
 
As with other adipokines, TNF-ĮH[SUHVVLRQSRVLWLYHO\FRUUHODWHV WR%0,DQG
adiposity levels, additionally TNF-ĮLVDVVRFLDWHGZLWKGHYHORSPHQWRIREHVLW\
mediated insulin resistance59. TNF-Į KDV EHHQ VKRZQ WR EH D SRWHQW DQG
significant factor in development of glomerulonephritis and renal injury, 
demonstrated by systemic administration of TNF-ĮZKLFKLQGXFHGJORPHUXODU
damage in rabbits184. These findings were supported by TNF-Į GHILFLHQW
glomerulonephritic mice which exhibited reduced proteinuria, decreased 
immune cell infiltration and diminished renal scarring184.   
1.7.4 Markers of anti-inflammation 
1.7.4.1 Interleukin-10 
IL-10 is an important anti-inflammatory and immunosuppressive cytokine 
responsible for the termination of inflammatory responses. It is recognised to 
inhibit the activation and function of T cells, monocytes and macrophages 
alongside regulation of numerous immune cells, by modulating the growth, 
differentiation and cytokine production of B cells, T cells, mast cells and 
natural killer cells185. Similarly to adiponectin which also displays anti-
inflammatory properties, in the presence of visceral obesity, plasma 
concentrations and adipose tissue mRNA expression of IL-10 are decreased186, 
highlighting the pro-inflammatory state observed in subjects with central 
obesity. A dysregulation in cytokine network balance of IL-6, IL-10 and TNF-Į
is associated with the chronic systemic inflammatory condition observed in 
patients with CVD and ESRD187. 
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1.7.4.2 Inducible nitric oxide synthase and nitric oxide 
A member of the nitric oxide synthase family of soluble cytosol enzymes, 
iNOS is involved in the immune and cardiovascular system of mammalian 
species. It is responsible for oxidation of L-arginine in the presence of NADPH 
and molecular oxygen to produce nitric oxide gas (NO), an important 
biological signaling molecule involved in modulation of numerous physiological 
and pathological immune system processes188.  
Present in macrophages, natural killer cells, endothelial and epithelial cells, 
iNOS is activated by stimulation from IFN-Ǆ RU /36-TLR4/CD14 complex 
formation to generate NO. This action drives numerous phenotypic effects, 
but primarily NO possesses a powerful immunoregulatory function. NO 
contributes to both pro and anti-inflammatory effects through the modulation 
of mRNA expression and production of cytokines, chemokines, growth factors 
and inhibition of antibody production and proliferation of B and T cells188. 
Overstimulation of iNOS and NO production can have detrimental effects in a 
biological system. The chemical molecular structure of NO leads to a free 
radical form, which in the presence of a superoxide anion O2
- molecule (a 
natural oxidative occurrence of molecular oxygen) forms a highly reactive 
oxidising peroxynitrite anion (ONOO-) which is classed as a reactive oxygen 
species (ROS)189.  
If the antioxidant counter-response to ROS production is imbalanced or 
decreased, an over production of ROS can result in oxidative cellular toxicity 
triggering programmed cell death and apoptosis. Peroxynitrite damages DNA 
by double-strand breakage and base pair removal, but can also disrupt 
cellular function and increase synthesis of additional ROS through amino acid 
oxidation, inhibition of anti-oxidant enzymes and lipid peroxidation189. Lipid 
peroxidation is the molecular oxidation of unsaturated lipids and fatty acids 
via a free radical molecule, leading to the formation of a lipid radical and 
eventual lipid peroxide molecule, another ROS, further perpetuating the 
oxidative stress cycle189. NO has been observed to be an important 
vasodilatory signaling molecule in the kidney, involved in the regulation of 
sodium reabsorption and renal vasculature blood flow and pressure 
homeostasis190. It is thought to reduce blood pressure in the kidneys via 
inhibition of renin production and increased sodium excretion191. In a rodent 
model of glomerulonephritis, expression of iNOS, eNOS and peroxynitrite 
were demonstrated to contribute to NO free radical induced renal tissue 
injury192.  
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Disruption of iNOS expression and production in obese iNOS knockout mice 
was reported to improve glucose tolerance and normalise insulin sensitivity in 
obese subjects, suggesting that iNOS is also involved in development of 
obesity related insulin resistance193. 
1.7.4.3 Peroxisome proliferating activated receptor-Ǆ 
Peroxisome proliferating activated receptor-Ǆ (PPAR-Ǆ LV DQXFOHDU UHFHSWRU
and ligand-activated transcription factor expressed in practically all tissue, 
and is highly expressed in adipose tissue194. It plays a role in numerous 
pathological metabolic processes such as insulin resistance, diabetes mellitus 
type II and obesity.  Activation of PPAR-Ǆ KDV EHHQ LGHQWLILHG DV a key 
pathway in the regulation of adipogenesis, lipid uptake, lipid metabolism and 
differentiation of pre-adipocytes. This has been demonstrated by over 
expression of PPAR-Ǆ P51$ ZKLFK LQGXFHG OLSLG GURSOHW DFFXPXODWLRQ LQ
differentiated pre-adipocyte and fibroblast cells195. Insulin sensitising agents, 
for example thiazolidinedione (TZD), have been shown to be PPAR-ǄOLJDQGV
TZD binding results in decreased adipocyte lipolysis and a subsequent 
reduction of circulating fatty acids. Additionally PPARǄ-TZD binding regulates 
the expression of insulin modulator proteins and promotes adipose tissue 
remodeling in an attempt to re-direct lipid storage to subcutaneous instead of 
visceral adipose depots196. Additionally PPAR-Ǆ DFWLYDWLRQ KDV GHPRQVWUDWHG
anti-inflammatory properties. PPAR-Ǆ OLJDQGEinding was observed to inhibit 
the release of pro-inflammatory cytokines from monocytes and macrophages, 
modulate the expression of chemokines and endothelin, and reduce synthesis 
of IFN-ǄE\7FHOOVLQLQIODPHGYDVFXODWXUHDVVRFLDWHGZLWKDWKHURVFOHURVLVand 
CVD197.   
1.7.5 Lipid sensing receptors 
1.7.5.1 Cluster of differentiation-14  
Cluster of differentiation-14 (CD14) is a component gene of the innate 
immune system. It is found as a soluble membrane bound glycoprotein which 
is involved in monocyte differentiation and is expressed on the cell surfaces of 
monocytes, macrophages and neutrophils198. CD14 receptor binds the lipid 
component of LPS, which can also be bound by free fatty acids. However it is 
suggested that CD14-LPS binding does not initiate a transmembrane signal 
alone, but rather that CD14 works as a protein anchor for additional signal 
transducers, i.e. toll-like receptors (TLRs), as part of an LPS-activation 
cluster199, shown in Figure 1.17, p49.  
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Activation of this LPS-activation cluster modulates immune cell recruitment 
and synthesis of cytokines. In CD14 knockout mice, obese animals compared 
to wild type displayed lower adiposity, reduced blood pressure, down-
regulated sympathetic activity and improved glucose homeostasis, this 
indicates that CD14 activation may play a role in the development of 
cardiovascular and metabolic conditions associated with obesity200.  Renal 
CD14 expression has also been demonstrated to correlate with the 
impairment of kidney volume and progression of renal disease201. 
1.7.5.2 Toll-like receptor 4 
TLR4 is a gene and member of the toll-like receptor family expressed by most 
tissues in the body and plays an important role in the inflammation and 
immune response pathways. It is a receptor for LPS which is a component of 
the outer membrane of gram-negative bacteria. When stimulated the TLR4 
receptor complex activates inflammatory and immune molecular cascades 
involving the cellular transcription factors myeloid differentiation factor 88 
(MyD88) and NF-ǉ% UHVXOWLQJ LQ DQ XS-regulation of pro-inflammatory 
cytokines, cell mediated immunity and apoptosis202; Figure 1.17 (p49) shows 
the TLR4 activation pathway. Similarly to the TLR protein anchor CD14, TLR4 
can also be stimulated by the lipid component of LPS found in circulating 
NEFAs which are elevated in obese subjects. Adipose tissue has also been 
implicated in the activation of the TLR4 pathway, with enlarged adipose stores 
responsible for the up-regulation of downstream NF-ǉ% WUDQVFULSWLRQ DQG
subsequent pro-inflammatory cytokine generation203. Activation of TLR4 in the 
kidney is linked to the promotion of tubular damage and the progression of 
renal injury. In an experimental model using knockout TLR4 mice, the 
subjects exhibited reduced renal fibrosis by collagen deposition from growth 
factor stimulation204.  
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Figure 1.17: Summary of cellular membrane bound toll-like receptor 4 (TLR4) and 
cluster of differentiation-14 (CD14) lipopolysaccharide (LPS) activation cluster 
pathway. Lipid binding protein (LBP) presents LPS or lipid component of free fatty acid 
to receptor stimulating nuclear transcription factor NF-ǉ%$FWLYDWLRQRI7/5SDWhway 
results in up-regulation of pro-inflammatory cytokines and stimulation of immune 
response205. 
 
1.7.6 Cell adhesion molecules 
1.7.6.1 Intercellular adhesion molecule 1 
ICAM-1 is a cell surface glycoprotein belonging to the immunoglobulin 
superfamily of proteins, that is expressed on vascular endothelial cells and 
non-vascular immune cells206. It plays a role in the inflammation and cytokine 
cascade, acting as a co-stimulatory molecule on APCs to activate T-cells. 
Endothelium bound ICAM-1 molecules function as migratory pathways for 
activated leukocytes to sites of injury, stress and inflammation206.  ICAM-1 is 
induced by numerous cytokines and transcription factors including TNF-Į
IFN-Ǆ DQG 1)ǉ% LQKLELWLRQ RI ,&$0-1 can be regulated by glucocorticoid 
action206. A study on diabetic nephropathy in rodents demonstrated that 
ICAM-1 mediated macrophage and leukocyte infiltration in renal tissue and 
ICAM-1 knockout mice had significantly decreased glomerular hypertrophy, 
proteinuria, mesangial matrix expansion and FSGS associated collagen 
deposition207, suggesting that ICAM-1 facilitates kidney inflammation and 
damage. 
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1.7.6.2 Vascular cell adhesion molecule-1 
Vascular cell adhesion molecule-1 (VCAM-1) is an immunoglobulin-like cell 
adhesion molecule similar to ICAM-1. After stimulation of endothelial cells by 
circulating cytokines, expression of VCAM-1 is up-regulated. VCAM-1 
mediates the adhesion of immune cells, for example, monocytes and 
macrophages to vascular endothelium for migration of adhered immune cells 
or signal transduction at the sites of tissue stress or injury208. Over-
stimulation of VCAM-1 has been attributed to endothelium dysfunction and 
the development of atherosclerotic lesions and subsequent vascular damage. 
Obese subjects with enlarged visceral but not subcutaneous adipose depots 
displayed both elevated plasma concentrations and up-regulated mRNA 
VCAM-1 expression; also these parameters positively correlated with BMI209. 
In healthy human kidney, VCAM-1 is expressed to a small extent, which is 
significantly increased in tubular cells of diseased renal tissue210.  
1.7.7 Cellular proliferation and apoptosis 
1.7.7.1 Caspase-3 
Caspase-3 is a member of the cysteine-aspartic acid protease family of 
enzymes; it has been implicated in key processes involved in effecting an 
apoptotic response by specific cleavage of cytoskeletal cellular proteins, a 
process initiated via apoptotic stimuli and cascaded by activation of the 
initiator and effector caspases resulting in degradation of DNA211. Apoptosis 
and programmed cell death are morphologically distinctive from necrotic cell 
death, and are believed to be responsible for regulation of cellular turnover 
and cellular homeostasis. Dysregulation of apoptosis is thought to contribute 
to the development of many pathological conditions; decreased apoptosis is 
linked to cancer,  cellular hyperproliferation, auto-immune development and 
other chronic inflammatory disorders, whereas increased apoptosis may 
contribute to neuronal damage and neurodegenerative disease212. In rodent 
studies using an immune model of glomerulonephritis, up-regulation of 
apoptosis in renal cells was caspase-3 dependent, demonstrated by increases 
of caspase-3 activity, mRNA and protein expression. Increased renal cell 
apoptosis has been linked with renal scarring, FSGS, interstitial tubular 
fibrosis and tubular atrophy213. 
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1.7.7.2 Proliferating cell nuclear antigen 
Proliferating cell nuclear antigen (PCNA) is a protein involved in DNA 
replication and repair, which is a component of the cell cycle control 
apparatus. It is a homotrimeric protein which acts as a clamp and can slide 
along the double stranded helical molecule of DNA enabling localisation of 
proteins to specific areas of DNA214. This PCNA clamp protein localisation 
mechanism allows for DNA polymerase enzymes to access the DNA strands 
for replication and for nucleotide excision or repair in response to damaged or 
mutated DNA 214. A balance of proliferative and apoptotic cellular processes 
control the natural cellular turnover, however a proliferative imbalance or 
over-expression of PCNA is associated with the renal nephropathies 
mesangioproliferative glomerulonephritis and glomerulosclerosis215.  
1.7.8 Renal molecules 
1.7.8.1 Erythropoietin receptor 
Erythropoietin receptor (EPOR) is the specific cell surface receptor for 
erythropoietin (EPO), the cytokine red cell progenitor and growth factor 
involved in erythropoiesis.  The EPO and EPOR regulatory system is controlled 
via a feedback loop mechanism (shown in Figure 1.18, p52), where during 
periods of abnormal oxygen tension i.e. hypoxia or anaemia, it stimulates 
generation of EPO by endothelial cells of the kidney peritubular vasculature. 
This leads to increased circulating EPO and eventual correction in oxygen 
tension from EPO-EPOR binding and erythropoiesis216. 
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Figure 1.18: Regulation of erythropoiesis by negative feedback loop mechanism. 
Erythropoietin (EPO) is produced by the kidney resulting in increased circulating EPO 
in response to detection of abnormal oxygen tension216. 
It has been demonstrated that EPO-EPOR up-regulation reduces apoptotic 
processes and decreased caspase activity in renal tissue, and EPO injection 
protects against renal dysfunction and reduced morphological damage217. 
Conversely, a severe elevation in EPOR gene expression has been linked to 
the progression of chronic renal disease218. This heightened up-regulation 
may be a compensatory response to EPO-EPOR resistance which is attributed 
to cytokine derived inflammation, seen in patients with chronic kidney disease 
and heart failure219.  
1.7.8.2 Renin 
Renin is a 37kDa enzyme produced by the granular cells of the renal 
juxtaglomerular apparatus in response to certain stimuli for activation of the 
RAAS. Mice lacking the renin gene displayed a lean and insulin sensitive 
phenotype; in addition these mice were resistant to diet induced obesity 
regardless of changes to dietary intake and physical activity, a result 
explained by the authors as an increase in metabolic rate220. This is further 
evidence to suggest that the RAAS plays an important role in obesity 
development, highlighting the potential of renin blockade as a potential 
therapeutic target in obesity treatment.  
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1.7.9 Gene, cytokine and protein summary 
Obesity and related metabolic comorbidites are associated with a stimulation 
and up-regulation of pro-inflammatory and immune cytokines, proteins and 
other cellular communicators. Cytokines, proteins and signaling molecules 
involved in immune responses are not stored in intracellular compartments 
but newly synthesised by expression and transcription of mRNA in specific 
cells and released as a direct response to inflammatory stimuli221. Hence 
these signaling molecules and cytokines are widely used as biomarkers to 
analyse the inflammatory and immune status of certain tissues or organisms 
under various interventions or conditions222. However with regards to using 
cytokines as biomarkers, cytokines are pleiotropic molecules, meaning they 
are not limited to one speFLILFIXQFWLRQDQGWKXVFODVVHGDVµUHGXQGDQW¶VLQFH
a number of cytokines can perform the same biological function221. Cytokines 
also induce other cytokines through complex inter-linked cascades and 
network pathways, sometimes referred to as cytokine crosstalk223.  
Evidence in the literature suggests that the kidneys are especially sensitive to 
obesity, and an over-stimulated immune response in kidney tissue mediates 
renal injury and impaired renal function. Figure 1.19 (p54) is a summary of 
the relationships and pathways involved in the inflammation cascade network, 
alterations in renal function, increased adiposity and presence of metabolic 
comorbidities. In regards to inflammatory profiles and gender, there is a 
definite paucity of information in relation to sexual dimorphism and to date, 
any potential difference is unknown.  
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Figure 1.19: Summary of mechanism pathways involved in obesity activated inflammation and subsequent renal nephropathy113-204. 
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1.8 The sheep as an experimental model for obesity 
Due to ethical reasons, it is not possible to manipulate humans using highly 
invasive physiological or experimental procedures. Large human 
epidemiological studies are widely used in some aspects of obesity research, 
for example a 2010 national UK study investigating childhood obesity 
recruited over one million subjects throughout UK schools224. However, there 
is a need to validate these data and elucidate the molecular biological 
mechanisms behind obesity and its associated comorbidities. Therefore it is 
important to use animals as translational tools, which display and have 
comparable characteristics when manipulated with specific key challenges or 
interventions, in this instance, an animal model of obesity. Sheep are 
important animals in biomedical research and possess comparable 
physiological features to humans, which is significant for the investigation of 
cardiovascular, respiratory, endocrine, renal and reproductive physiological 
systems. Sheep offspring are comparable in number, i.e. single, twin or triplet 
offspring, rather than large litter sizes. Newborn sheep are comparable in 
birth weight to human newborns (§4.5kg); and are also born with fully 
developed organ systems and a mature HPA axis225. The metanephros 
(mature ovine kidney) develops over the early-mid gestation period, from 
gestation day 27 to gestation day 110, and at birth newborn sheep possess a 
fully mature renal system226. Sheep studies investigating the exposure of 
restricted maternal nutrition during periods of early gestation encompassing 
the period of nephrogenesis have identified a sensitivity of ovine kidney 
development to changes in maternal diet. These effects include the 
development of hypertension, elevated renal mRNA expression of GR and 
reduced nephron number226.  
However, sheep are ruminants and as such possess a more complex digestive 
system resulting in different dietary requirements and glucose utilization 
compared to humans. Yet despite this, credible models of ovine obesity have 
been developed using programs of manipulation in maternal diet, post-natal 
feeding and post-weaning activity. This developmental pathway of obesity, i.e. 
a number of factors rather than solely over-consumption, is comparable to 
the one observed in human society. Secondly, these models also lead to 
development of obesity-related metabolic complications observed in humans 
such as hypertension, hyperleptinaemia, impaired inflammatory renal profile 
and insulin sensitivity226,227,228.  
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The development of obesity observed in these models shows central visceral 
and ectopic perirenal and pericardial adipose tissue enlargement, which is 
believed to contribute to the development of a low grade chronic 
inflammatory state and obesity mediated metabolic comorbidities229. In 2005 
a British Heart Foundation funded obesity study was performed by the 
Academic Child Health group at Nottingham University. This study 
investigated sheep exposed to restricted maternal nutrition during early 
gestation, post natal overfeeding and limited physical activity (17 sheep per 
50m2) to promote obesity, which generated three experimental groups; lean 
control (C), obese (O) and nutrient restricted obese (NR)227,230. At 1 year of 
age the O and NR sheep ZHUH §% heavier than the control sheep 
(C=58.58±2.46kg; O=88.71±2.67kg; NR=85.83±4.57kg), and in more 
detailed analysis NLGQH\ PDVV ZDV §0% (C=117.27±9.20g; 
O=155.70±6.68g; NR=164.86±7.16g) and PAT mass was §00% 
(C=553.88±93.48g; O=2692.14±294.33g; NR=2783.23±197.92g) larger in 
the two obese groups compared to the lean animals230. In addition mean 
blood pressures were increased in the obese groups227,230 (C=91.5±1.75; 
O=102.3±2.65; NR=102.5±2.6mmHg). Also in determination of the 
inflammatory response and macrophage signaling in obesity, mRNA analysis 
showed an elevation in CCR2 (2-fold) expression in PAT and a reduction in 
renal MCP-1 and CCR2 (2.5-fold) mRNA expression in comparison of obese 
and lean sheep227. These findings supported the hypothesis that obesity 
modulates physiological changes in the kidney, possibly through adaptations 
in PAT and haemodynamic parameters, although gender was not investigated 
during this previous study. 
Finally, sheep being larger animals than rats or mice allows for insertion of 
sampling or monitoring devices, manipulation of foetal development and 
higher yields in terms of amount of body fluids and organ tissues harvested 
after euthanasia etc. Although the husbandry time and expense of larger 
animals is increased compared to smaller rodent experiments231. 
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1.9 Main hypothesis and aims 
The introduction chapter has discussed the ideas behind obesity and how 
increased adiposity mediates a chronic inflammatory status and the 
mechanisms contributing to impaired renal function. Alongside gender, these 
aspects have so far been discussed as independent variables. Although the 
scientific literature suffers from a dearth of gender specific investigations in 
relation to obesity or inflammation and renal disease, clinical evidence 
suggests a sexual dimorphism exists which could have real implications in the 
treatment of obesity modulated morbidity.  
The primary hypothesis behind this study was that the development and 
presence of onset obesity in an ovine model, promotes an amplified 
inflammatory state, mediated by physiological adaptations in ectopic adipose 
tissue depots. This heightened inflammatory milieu then contributes to 
structural renal impairment, dysfunction and damage. It was also possible 
that in agreement with epidemiological data, that gender may display 
dimorphic responses to the presence of obesity and related inflammation and 
the potential progression in kidney disease. 
The following chapters were designed to answer the above hypothesis; 
 
1. Description of gender differences observed in morphometric 
measurements and alterations in adipose tissue physiology and 
systemic metabolism induced by exposure to a postnatal 
obesogenic environment. 
2. Determination of obesogenic PAT alterations on subsequent PAT 
inflammatory and metabolic genotype.  
3. Identification of the renal morphology and physiology of each 
gender and their respective gene regulation and renal 
inflammatory genotype induced by exposure to a postnatal 
obesogenic environment. 
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Chapter 2  - Materials and methods 
 
Chapter 2 will explain the basic scientific theory and implementation of the 
study models and experimental procedures used throughout this study.  
 
2.1 Procedural & legislative declaration 
All animal experimentation carried out in this study (2.2.1-2.2.5, p59-63) was 
conducted in accordance with the UK Home Office and the UK Animals 
(Scientific Procedures) Act (1986) by Professor M.E Symonds and Dr D. 
Gardner and performed by Dr S. Sebert. Additionally, all experimental 
procedures were completed under licence and with ethical approval from the 
University of Nottingham.  All chemicals, reagents and laboratory procedures 
were assessed and implemented in compliance with the UK Health and Safety 
([HFXWLYH¶V&RQWURORI6XEVWDQFHV+D]DUGRXVWR+HDOWK&26++, SI No. 1657, 
1988) and Risk Assessment guidelines.  
 
All laboratory-based techniques & protocols were conducted within the 
Academic Child Health department, School of Clinical Sciences, Division of 
Human Development, University of Nottingham4XHHQ¶V0HGLFDO&HQWUH and 
the School of Veterinary Medicine and Science, Sutton Bonington Campus, 
University of Nottingham. The methodological procedures used in the study 
were either as recommended by the manufacturers and suppliers, or 
optimised within the Academic Child Health department by myself, Dr S. 
Sebert, Dr L. Chan, Dr M. Hyatt and Mr M. Pope.  
 
All materials were purchased from Sigma-Aldrich (Poole, Dorset, UK) unless 
otherwise specified.  
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2.2 Study design  
This study was conducted using sheep from the 2007 Early Nutrition 
Programming Project (EARNEST, FP6, #FOOD-CT-2005-007036232), which 
aimed to investigate the effects of maternal nutrition in utero and post-natal 
activity in the development of obesity and metabolic related disease  later in 
adult life.  
Experimental treatments in animals occurred at two critical stages of 
development. These were: 
x Prenatal ± Mothers were fed a low- or high-calorie intake during the 
last third of gestation (110 days to term) - as detailed below.  
x Post Weaning ± 3 month old offspring were placed in high or low 
physical activity environments until 17 months of age to encourage the 
development of lean and obese animals, respectively228.  
 
2.2.1 Animals, diets and environments 
Twenty Bluefaced Leicester cross Swaledale ewes of similar body weights and 
ages were selected and bred DW WKH8QLYHUVLW\RI1RWWLQJKDP¶V -RLQW$QLPDO
Breeding Unit, Sutton Bonington Campus. Twin bearing was confirmed by 
ultrasound scanning at 75 dGA. Ten pregnant ewes were randomly assigned 
into a nutritional restricted group (N) and received 60% of normal daily 
energy requirement (0.46 MJ/kg0.75 body weight at 110 dGA and 0.72 
MJ/kg0.75  body weight at 140 dGA) for pregnant sheep during the last third of 
pregnancy. Ten were allocated in fed to appetite group (A) and consumed 150% 
of energy requirements (1.15 MJ/kg0.75 body weight at 110 dGA and 1.80 
MJ/kg0.75 body weight at 140 dGA). 100% of nutrition and energy 
requirements for pregnant ewes was based on recommendations from the 
$)5&PDQXDORIµ(QHUJ\DQG3URWHLQ5HTXLUHPHQWVRI5XPLQDQWV233, and 
the amount and composition of nutrition, metabolisable energy and protein 
supplied to each sheep was calculated using maternal body weight, 
gestational age and expected energy utilisation for maintenance. After birth, 
the offspring for both groups (N: n=20 and A: n=20) were raised and fed by 
their mothers as twins for the 3 month lactation period. The mothers were fed 
to requirements during this stage. At weaning, twins were then separated into 
two experimental groups to determine the effect of physical activity on the 
development of obesity. Twins were either allocated into a restricted activity 
area (barn), an obesogenic environment (O) with a stocking rate of 6 sheep 
per 19m2, or an unrestrained activity area (field), lean environment (L) with a 
stocking rate of 6 sheep per 1125 m2.  
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During this phase, all sheep were fed the same diet, a mixture of hay (8.9 
MJ/kg) and high concentrate pellets (12.6 MJ/kg) (Manor Farm Feeds, 
Oakham, UK) containing 100% recommended of energy requirements. For 
each animal, daily energy intake was assessed through weighed intake and 
food refusal. Diets were also supplemented with vitamins and minerals and all 
sheep had unlimited access to water.  
Physical activity was measured using uniaxial accelerometers (Actiwatch, 
Linton Instrumentation, Diss, UK) of the two groups in periods of 30 seconds 
over a 24 hour period whilst in their respective manipulated activity 
environments. Accelerometry probes were placed on collars around the necks 
of the animals for a 24 hour period, with activity measurements recorded 32 
times per second. The resulting readings were then subsequently uploaded to 
specialist software (Actigraph, FL, USA) for formatting and analysis. 
Accelerometry identified a two to three-fold increase in activity between the 
µREHVH¶DQGµOHDQ¶VWRFNHGHQYLURQPHQWV. 
Throughout the study, specific physiological measurements were gathered 
from all animals; this involved moving the sheep to different holding pens for 
varying lengths of time before being returned to the original designated 
environment. Two weeks prior to completion of the study, all sheep were 
moved into individual indoor holding pens to conduct pre-mortem 
physiological measurements and plasma sampling.   
During the experimental procedure, there were a small number of animal 
losses during the lactation and post-natal weaning stages. Figures 2.1-2.2 
(p60), summarise the experimental animal models used, and the final group 
definitions and sample numbers. The final grouping of the experimental 
subjects for statistical analysis is discussed in 2.10, p101. 
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Figure 2.1: Initial experimental animal groups: N = nutrient restricted (60% of 
normal energy requirements), A = fed to appetite (150% of normal energy 
requirements), L = lean environment, O = obesogenic environment, and breakdown of 
groups into gender. Four animals between the NL and NO groups expired during the 
experimental procedure.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Final experimental animal groups: LF = lean females, OF = obese females, 
LM = lean males and OM = obese males. Four female animals expired during the 
experimental procedure. 
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2.2.2 Physiological measurements 
Body weight measurements were determined every 3 days, including 
immediately at birth, during the first month and then once every week up 
until 3 months of age. Body weights were measured at specific time points 
until the completion of the study. All body weight measurements were 
determined by standard weighing scales. Both diastolic and systolic blood 
pressure measurements were determined at 16 months with a standard blood 
pressure measuring device during sedation. 
2.2.3 Dual x-ray absorptiometry 
Alongside these measurements, bone densities, fat mass and free fat mass 
were determined by dual x-ray absorptiometry234 (DXA) at 8 and 16 months 
of age. Overnight fasted sheep were sedated with an intramuscular injection 
of ketamine and xylazine and scanned for 15 minutes using a Lunar DPX-L 
bone densitometer (Lunar, Florida, USA). After scanning, animals were 
allowed to recover from sedation and were returned to the holding pens. To 
validate the DXA scan method, whole carcass chemical analysis was 
performed. Fourteen half carcasses were scanned by DXA before being 
macerated and dried. Nitrogen content and fat percentage analysis were 
determined on 250g of dried homogenised tissue using a FlashEA1112 
nitrogen analyser (Thermo Scientific, Massachusetts, USA) and Gerhardt 
Soxtherm fat analyser (Wolflabs, York, UK). 
2.2.4 Plasma sampling 
At 6 and 16 months of age, overnight fasted sheep (§0800h) were locally 
anaesthetised with lidocaine, and temporary jugular vein catheters were 
surgically implanted. Twenty four hours after surgery, sheep were subjected 
to intravenous glucose tolerance tests (GTT) by injecting a bolus. 5ml blood 
samples were withdrawn into ethylenediaminetetraacetic acid (EDTA) tubes at 
-10, -5, 10, 20, 30, 60, 90 and 120 minutes following 0.5g kg-1 glucose 
perfusion. A normal feeding regime was restored after the glucose tolerance 
test had been performed. After 48 hours, 5ml blood samples were withdrawn 
from overnight fasted animals into lithium heparin tubes for use in 
determination of circulatory leptin and cortisol levels at 0, 2, 4, 8 and 24 hour 
time points after being fed to requirement. 
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Following blood collection, both heparin and EDTA samples were rapidly 
centrifuged at 2500g for 10 minutes at 4°C to obtain plasma samples that 
were then stored at -80°C until analysis. Plasma leptin (Diasorin, Slough, UK) 
and cortisol (Diagnostic Products Corporation coat-a-count, Siemens, 
Camberley, UK) were determined by radioimmunoassay. Plasma insulin was 
measured by sheep insulin enzyme linked immunosorbent assay (ELISA) kit 
(Mercodia, Diagenics Ltd, Milton Keynes, UK). 
2.2.5 Post mortem analysis 
All animals were humanely euthanised between 0900h and 1100h by 
electrical stunning and exsanguination. All major tissues, glands, adipose 
depots and organs were weighed. Selected tissues sampled were partially 
dissected for histological analysis and fixed in 10% formalin. All remaining 
WLVVXHVZHUHµVQDS¶IUR]HQLQOLTXLGQLWURJHQDQGVWRUHGDW-80°C.  
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2.3 Tissue analysis 
Prior to all tissue and analytical molecular work, benches and instruments 
were cleaned with RNAse Zap® (Ambion, California, USA), or 1% Virkon 
disinfectant (Antec International, Suffolk, UK) and 70% denatured ethanol 
(Ecolabs, Surrey, UK). Additionally, all experimental work was performed on 
ice, using autoclaved and sterile equipment including filter pipette tips, whilst 
wearing gloves. This was to eliminate possible contamination and ensure and 
preserve the integrity of all samples throughout the performed experimental 
procedures. The selected tissues were removed from -80°C storage and 
transferred to dry ice for sampling. The desired amount of renal cortical tissue 
or PAT was dissected for use in the relative assay and placed in labelled 
containers for later use.  All samples were returned to -80°C storage until 
needed.  
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2.4 Ribonucleic acid extraction 
Total Ribonucleic acid (RNA) extraction from tissue can be achieved using an 
adapted version of the single step acidified phenol-chloroform homogenisation 
method235 alongside an RNA extraction kit. By lysing the desired samples and 
homogenising in a phenol and guanidine thiocyanate mono-phase solution, 
this causes the denaturing and dissolution of all proteins and inhibition of any 
RNase activity236. Addition of chloroform leads to the formation of three phase 
layers, with proteins dissolved in the organic bottom phase, DNA dissolved in 
the interphase and RNA dissolved exclusively in the top aqueous phase235,236. 
After separation, the aqueous RNA solution should be treated with ethanol to 
provide appropriate binding conditions to the RNA centrifuge column where 
WRWDO51$JELQGVWR WKHPHPEUDQH$VHULHVRIZDVKLQJVWHSVwith 
ethanol and guanidium salt-based buffers to remove any contaminants is 
performed before the final elution of RNA using nuclease-free water. 
Extracted RNA yields are unknown and can contain proteinaceous impurities, 
it is therefore necessary to determine the concentration and purity of 
extracted samples. One method by which this is achieved is through 
spectrophotometry. Nucleic acids absorb UV light at a wavelength of 260nm 
and thus RNA concentration can be estimated through relative wavelength 
absorption. As protein absorbs UV light at 280nm, protein contamination of 
the sample can also be measured through a ratio of absorption between 
wavelengths 260nm:280nm237; the recommended absorbance ratio for RNA is 
between 1.8 and 2.0238. 
 
2.4.1 RNA extraction procedure 
Cortical §JRU3$7§J tissue samples were individually added to 
1ml of TRI® Reagent. The samples were homogenised at 3000rpm using a 
Dispomix homogeniser (Medic Tools, Zurich, Switzerland) and then 
centrifuged for 1 minute at 550g. PAT samples were incubated for 2 minutes 
in a water bath at 37°C to break down the lipid content. Following this, the 
supernatant was transferred to a sterile 1.5ml eppendorf tube. ǋO RI
analytical-grade chloroform (Fisher Scientific, Leicestershire, UK) was added, 
vortexed and left at room temperature for 10 minutes to allow for phase 
separation.  
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Following incubation, the samples were centrifuged at 12000g for 15 minutes 
DW & DIWHU ZKLFK WKH WRS DTXHRXV OD\HU §O ZDV SLSHWWHG LQWR a 
genomic deoxyribonucleic acid (gDNA) column and centrifuged at 8000g for 
30 seconds at room temperature, to remove any remaining gDNA 
contamination. The remaining RNA was transferred into a sterile 2ml 
eppendorf tube and 700µl of ethanol was added to the solution.   
 
RNA was extracted from each individual sample using the RNeasy Plus Mini 
extraction kit (Qiagen, West Sussex, UK) by transferring the solution to a 
RNeasy minispin column and centrifuging at 8000g for 15 seconds at room 
temperature, discarding any flow-through, with all RNA being retained in the 
column. 700µl of RW1 buffer was added to the column and centrifuged at 
8000g for 15 seconds at room temperature, discarding the flow-through. 
500µl of RPE buffer was then added and centrifuged at 8000g for 2 minutes 
at room temperature, discarding the flow-through. The minispin column was 
then transferred to a sterile 2ml collection tube and centrifuged at 8000g for 
1 minute to eliminate any chance of RPE buffer carry-over, which could 
interfere with future RNA applications. The minispin column was then 
transferred to a sterile 1.5ml collection tube; 30µl of RNAse-free water was 
added and centrifuged at 8000g for 1 minute. This final step was repeated to 
obtain higher concentrations of RNA. RNA concentration and purity 
measurements were determined using a Nanodrop®ND-1000 (Nanodrop 
Technologies, Wilmington, USA) spectrophotometer. To avoid freeze-thawing 
stock RNA which is attributed to RNA degradation238, ǋO DOLTXots of each 
extracted 51$VWRFNZHUHWKHQGLOXWHGWRǋJǋOWRQRUPDOLVHVDPSOHVUHDG\
for quantitative RT-PCR. All extracted RNA samples were stored at -80°C until 
further use.  
 
2.4.2 Polymerase chain reaction  
The concept and development of hot-start polymerase chain reaction (PCR) 
was a huge breakthrough in DNA analysis, and allowed the isolation and 
amplification of a specific region of a small known quantity of DNA sequence 
using a pair of complimentary oligonucleotide forward and reverse primers in 
an enzymatic reaction239. This reaction contains the target DNA, primers, 
deoxyribonucleoside triphosphates (dNTPs), thermostable enzyme (Taq 
Polymerase), and suitable pH and ion buffer.  
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Amplification of the target sequence occurs by repeated cycles of heat 
denaturation of the double stranded DNA, annealing primers to the 
complimentary sequence and extension of the annealed primers by enzymatic 
reaction. After each full cycle, the product of DNA is doubled, leading to an 
exponential increase of target DNA, approximately 2n, where n is the number 
of cycles240. Figure 2.3 shows the basic PCR process and the exponential 
amplification of the target DNA sequence. 
 
 
Figure 2.3: Basic theory of polymerase chain reaction. Template DNA is amplified 
exponentially in an enzymatic reaction of temperature controlled cycles by 
complimentary oligonucleotide primers. 
Primer design is probably the most important aspect when working with PCR 
analysis, as elongation and amplification will only occur on the DNA sequence 
to which the complimentary primers have annealed. Poorly designed primers 
can lead to a decreased product yield, through interaction between each other 
to form primer dimers and hairpins or through dissimilar annealing and 
melting temperatures, which is affected by primer length and sequence 
content239. Table 2.1 (p68) shows the general parameter guidelines for 
optimal PCR primer design. 
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Parameter Optimal Values 
Primer Length 18-30 bases 
Melting Temperature (Tm) 55-72°C 
Percentage guanine/cytosine (GC) content 40-60% 
No self-complimentarity (hairpin structures) FRQWLQXRXVEDVHV 
No-complimentarity to other primer (primer dimers) FRQWLQXRXVEDVHV 
Distance between two primers on target sequence <2000 bases apart 
Tm difference between forward and reverse primer set & 
No long runs with the same base < 4 continuous bases 
Table 2.1: General parameter guidelines for optimal polymerase chain reaction primer 
design239. 
 
2.4.3 Reverse transcription PCR  
PCR has the ability to amplify low-abundance messenger ribonucleic acid 
(mRNA) obtained from nucleated tissue samples, which can then be 
quantified by agarose gel electrophoresis and chemiluminescence, or 
spectrophotometry241. As the principle of PCR is based on amplifying a double 
stranded molecule such as DNA, for single stranded RNA to work within the 
reaction, it must first be transcribed into double stranded complimentary DNA 
(cDNA) using a DNA primer and a reverse transcriptase enzyme; a process 
known as reverse transcriptase PCR (RT-PCR).  
 
Using template mRNA, a DNA primer sequence anneals to its complimentary 
sequence of mRNA where elongation and transcription occurs by enzymatic 
reaction, thus creating a cDNA molecule ready for standard PCR to convert to 
a double stranded molecule and further amplification. Figure 2.4 (p69) shows 
a diagram of the basic principles of RT-PCR. 
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Figure 2.4: Diagram of reverse transcription polymerase chain reaction. A random 
primer binds to single stranded mRNA and sequence is elongated by a transcriptase 
enzyme to create cDNA. Template of double stranded cDNA is then amplified by classic 
PCR. 
2.4.4 Quantitative PCR 
Through advancements in PCR technology, nucleic acid analysis can now be 
achieved in real-time, i.e. detection and quantification of a sequence of DNA 
or mRNA can occur at the same time in vitro without additional steps of 
analysis such as gel electrophoresis or northern blotting, thus reducing time 
taken, expenditure and the probability of contamination242. Quantitative PCR 
(Q-PCR) also removes the need to use hazardous fluorescent nucleic acid 
reagent dyes, such as ethidium bromide. Q-PCR detects and quantifies a PCR 
product by measuring a signal of fluorescence which is emitted by a 
fluorogenic chemical reagent when bound to DNA or cDNA. The intensity of 
fluorescent signal correlates to the amount of DNA bound to the fluorogenic 
tag, i.e. the greater the intensity of signal, the higher the concentration of 
DNA present. As these dyes emit a basal level of fluorescence, the detector 
unit within the Q-PCR instrument will only detect the fluorescent signal after a 
certain level of background fluorescent has been crossed, also referred to as 
the cycle threshold (ct)
 or crossing point (cp). The cycle threshold is the 
parameter used for quantification and correlates to the initial amount of 
target template.243  
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As the amplification of the targeted sequence within the PCR reaction is 
exponential, the instrument graphically represents this increase in fluorescent 
signal as a sigmoidal curve, from which the linear section of the curve can be 
compared to signals from other samples run within the same experiment, see 
Figure 2.5. 
 
 
Figure 2.5: 7\SLFDOµVLJPRLGDO¶FXUYHVLQ4-PCR. Fluorescent signal crosses threshold 
and increases exponentially until plateau from expenditure of reagents or cycle 
number. Red lines represent external standards, green are unknown samples and blue 
represent negative controls.  
 
This method of analysis allows quantitation of cDNA concentration by 
standard curve method, where serial dilutions of a known concentration of 
target cDNA are amplified using the target sequence primers and then used 
to interpolate the concentration of an unknown from a standard curve. By 
plotting the log concentration of standards against cycle number when cycle 
threshold is reached on a graph, and thus calculating a straight line equation, 
shown in Figure 2.6 (p71), the efficiency of the reaction (E) and correlation 
coefficient (R2) can be determined. This additionally acts as a positive control 
and verification of the experiment. Efficiency is calculated by the following 
formula, Efficiency of PCR reaction = 10(-1/gradient)-1244; which is a derived 
from the basic equation describing PCR amplification245. 
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Figure 2.6: Standard curve from Q-PCR. Cycle number at cycle threshold is plotted 
against logarithm of known dilution series to produce linearised graph of exponential 
PCR reaction. Correlation coefficient (R2) and reaction efficiency (E) are then 
calculated. 
 
To quantify gene expression, it is vital to normalise samples for any variation 
in starting RNA abundance. By analysing the expression of a gene which is 
expressed at relatively constant high levels across all cells in many or all 
known conditions, usually a gene needed for cell function, it is possible to 
normalise mRNA expression levels for a target tissue. Comparison of the 
H[SUHVVLRQRIWKHµreference JHQH¶ against the gene of interest from the same 
sample makes it possible to quantify expression of the target gene. Using a 
mathematical model of a ratio of change in cycle threshold of reference 
control against the change in cycle threshold of target gene, relative gene 
expression can be calculated. Using the 2^-delta ct (2
-¨ct) method presented 
by PE Applied Biosystems246, ZKHUH ¨ct = [average ct of target gene ± 
average ct of reference gene (of the same sample)], this method assumes 
that the efficiency of the PCR reaction is 100%, i.e. the cDNA strands 
replicate entirely within each cycle, hence 2^. This assumption of efficiency is 
verified by the standard curve, whereby general accepted efficiency limits 
range from 90-105%244. 
 
As with standard PCR, primer design is a key component to specific region 
amplification of a sequence. However, fluorescent dyes such as SYBR green 
do not only fluoresce when bound to the desired double stranded DNA 
molecule, but also to non-specific bound dye-DNA complexes, for example, 
primer dimers. Thus, it is important to analyse the PCR product qualitatively 
to ensure the PCR product is the sequence targeted.  
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This is verified by performing a melt-curve, which records the temperature at 
which the PCR product(s) denature by measuring decrease in fluorescent 
signal. Melting temperatures are influenced by length and sequence base 
composition, and an expected melt curve for a specific product should 
produce one peak, see Figure 2.7. Further qualitative analysis can be 
performed by DNA sequencing after the product has been extracted by gel 
electrophoresis.  
 
Figure 2.7: Typical melt curve from Q-PCR. The single peak indicates specificity of 
product amplified. 
2.4.4.1 Reference genes in Q-PCR 
The use of reference genes as internal controls and for RNA quantification is a 
common method, but it is vital that the selected reference gene(s) are 
validated when used in a particular tissue or with a specific experimental 
model247. A good reference gene by definition should have very little variation 
in expression throughout sample sets and be expressed relatively higher than 
any genes of interest248. Existing proposals in gene normalisation suggest that 
to accurately measure mRNA expression levels, the geometric mean of 
multiple reference genes should be utilised247,249, however it is still important 
that any reference genes used match the criteria necessary to be a good 
reference gene. In an attempt to validate various reference genes, the genes 
ribosomal 18s (r18s), beta-actin (ACTB) & Tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein (YWHAZ), 
which have all been validated as reference genes in previous studies249,250,251, 
were analysed to quantify expression in the specific tissue and animal model 
used in this project. Of the three genes analysed, only r18s yielded 
acceptable levels of expression and variation between samples to be a 
suitable candidate reference gene, see Figure 2.8, p73, a finding supported 
by other RT-PCR studies252,253. 
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Figure 2.8: Comparison of three genes r18s, YWHAZ and ACTB. Crossing threshold of 
each gene was determined against 32 samples to validate use as mRNA reference 
gene. 
 
As YWHAZ and ACTB displayed high variation and low expression, using them 
as controls in a multiple reference gene normalisation would reduce the 
effectiveness of such calculations and therefore only a single reference gene, 
i.e. r18s was used for normalisation in the QPCR analyses of renal tissue. 
Due to intergroup variation of r18s mRNA expression in PAT samples, QPCR 
analysis performed on PAT was normalised using multiple reference genes, 
shown in Table 2.2, p75. Each reference gene was run against the study 
samples, and crossing threshold values for each reference gene were 
processed through geNorm software v3.5 (Primer Design Ltd, Southampton, 
UK). The geNorm software uses an algorithm of the geometric mean and 
pairwise variation of each gene compared to all other genes analysed, to 
calculate a stability value (M) for each gene and selects the two most stable 
genes, i.e. the two genes with the lowest M value for normalisation247,249. The 
geNorm software then calculates a normalisation factor for each sample. 
Relative target gene values are divided by the normalisation factor to 
determine the gene of interest¶V expression. Figure 2.9, p74 shows the 
geNorm output from the four reference genes used in PAT mRNA analysis; a 
lower M values confirms higher stability. 
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Figure 2.9: Graphical output from geNorm software in analysis of four reference 
genes. A lower M value represents a higher stability. A combination of RPL19 and RPO 
were determined to have the highest stability of the reference genes analysed, and 
were used to calculate PAT sample gene expression. 
 
2.4.5 Development of oligonucleotide primers for Q-PCR 
Primers were designed using Beacon Designer 4.0 software (Premier Biosoft, 
Palo Alto, USA) using the sheep genome sequence from the National Centre 
for Biotechnology Information (NCBI) online database. The primer design 
software ensures amplification with greater specificity to the gene of interest 
by designing primers that flank exon boundaries in the intron sequence, and 
creates primers with similar optimum annealing temperatures, guanine-
cytosine base pair content and length to achieve the most favourable reaction 
conditions. All designed primers were checked against the sequence and 
genome of interest using the NCBI nucleotide BLAST database to ensure 
amplification of the correct sequence. Primers were developed by and 
acquired from Sigma Aldrich or previously optimised by Dr S Sebert, Dr M 
Hyatt and Dr D Sharkey within the Academic Child Health Laboratory, 
4XHHQ¶V0HGLFDO&HQWUH1RWWLQgham, UK and stored in nuclease free water at 
a stock concentration of 100ǋmol/l. Tables 2.2, 2.3 and 2.4 (p75-77) detail all 
primer sequences used in mRNA quantification.  
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Reference Gene Publication or 
NCBI seq. 
Oligonucleotide Sequence (5'-
3') 
18s ribosomal RNA (r18s) Williams P.J, et 
al (2007) 
For - GATGCGGCGGCGTTATTCC 
Rev - CTCCTGGTGGTGCCCTCC 
L19 ribosomal protein (RPL19) Garcia-Crespo 
D, et al (2006) 
For - CCGGGAATGGACAGTCACA 
Rev - CAACTCCCGCCAGCAGAT 
Large ribosomal protein (RPO) Robinson T.L, et 
al (2007) 
For - CAACCCTGAAGTGCTTGACAT 
Rev - AGGCAGATGGATCAGCCA 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation 
protein (YWHAZ) 
Garcia-Crespo 
D, et al (2006) 
For - TGTAGGAGCCCGTAGGTCATCT 
Rev - TTCTCTGTATTCTCGAGCCATCT 
Table 2.2: Reference gene primer sequences for mRNA quantification. 
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Target Gene Publication or 
NCBI seq. 
Oligonucleotide Sequence (5'-
3') 
ǃK\GUR[\VWHURLG
dehydrogenase 1 ǃ+6' 
NM_001009395.1  For - GGCCAGATCCCTGTCTGAT 
Rev - AGCGGGATACCACCTTCTTT 
ǃK\GUR[\VWHURLG
dehydrogenase 2 ǃ+6' 
 Dodic M,  et al 
(2002) 
For - AGCAGGAGACATGCCGTTC 
Rev - GCAATGCCAAGGCTGCTT 
Adiponectin (ADI) NC_007299.4 For ± ATCAAACTCTGGAACCTCCTATCTAC 
Rev - TTGCATTGCAGGCTCAAG 
Adiponectin receptor 2 
(ADIPOR2) 
NC_007303.4 For ± GGCAAGTGTGACATCTGGTTTC 
Rev - GAAACGGAACTCCTGGAGGTT 
Chemokine (C-C motif) receptor 
2 (CCR2) 
Sharkey D, et al 
(2009) 
For - TGTCCATGCTGTGTTTGCTT 
Rev - CCCCAAGATGCTCCTCATAA 
Cluster of differentiation-14 
(CD14) 
NM_001077209.1 For - TCAAGGCTCTGCGCGTTCGG 
Rev - GCAGGCCCAGTGGCTTCCAG 
Glucocorticoid receptor (GR) Williams P.J, et al 
(2007) 
For - ACTGCCCCAAGTGAAAACAGA 
Rev - ATGAACAGAAATGGCAGACATT 
Intercellular adhesion 
molecule-1  
(ICAM-1) 
NM_001009731.1 For - ATGGACTACTGTGACCGTGGAATG 
Rev - GGCAGCAGAGCAGGAGAAGTTG 
Interferon-Ǆ,)1-Ǆ NM_001009803.1 For - TGCAGATCCAGCGCAAAGCCA 
Rev - TGCTCTCCGGCCTCGAAAGAGA 
Interleukin-6 (IL-6) Sharkey D, et al 
(2009) 
For ± ACCACTCCAGCCACACAC 
Rev ± GCCGCAGCTACTTCATCC 
Interleukin-10 (IL-10) NM_001009327.1 For ± GTGCTCTGTTGCCTGGTCTTC 
Rev ± GCTGTTCAGTTGGTCCTTCATTTG 
Interleukin-18 (IL-18) Sharkey D, et al 
(2009) 
For ± AACGACCAAGTTCTCTTCATTA 
Rev ± GAACAGTCAGAATCAGGCATA 
Inducible nitric oxide synthase 
(iNOS) 
AF223942.1 For ± TTGAGCGAGTGGTGGATGGC 
Rev ± TGAGTGAGCAAGGTGGCAGTC 
Leptin (Ob) NM_173928.2  For ± GGGTCACTGGTTTGGACTTCA 
Rev - ACTGGCGAGGATCTGTTGGTA 
Leptin receptor (Ob-R) NM_001009763.1  For - TGAAACCACTGCCTCCATCC 
Rev - TCCACTTAAACCATAGCGAATC 
Monocyte chemoattractant 
protein-1 (MCP1) 
Dunphy J, et al 
(2001) 
For ± GCTGTGATTTTCAAGACCATCC 
Rev ± GGCGTCCTGGACCCATTT 
Toll-like receptor 4 (TLR4) Sharkey D, et al 
(2009) 
For ± TGCTGGCTGCAAAAAGTCTG 
Rev- CCCTGTAGTGAAGGCAGAGC 
Tumour necrosis factor-Į
71)Į 
NM_001024860.1 For ± CCGAGTCTGGGCAGGTCTAC 
Rev ± GGGATGAGGAGGGTCTGAAGG 
Vascular cell adhesion 
molecule-1  
(VCAM-1) 
NM_174484.1 For ± TGCTGCTCAGGTTGGCGACTC 
Rev ± AGCCCTCACTCCTCACATTCCC 
Table 2.3: Inflammatory gene primer sequences for mRNA quantification. 
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Reference Gene Publication or 
NCBI seq. 
Oligonucleotide Sequence (5'-
3') 
Erythropoietin receptor (EPOR) AY029232.1 For - CCAGGGAGGCCGAAAATG 
Rev - GGACAGTGATATTCTCACTGAAGCT 
Peroxisome proliferator 
activated receptor gamma 
33$5Ǆ 
 
NM_001100921.1 For - CGCATGCCACAGGCCGAGAA 
Rev - CCCGTCAAGATCGCCCTCGC 
Renin NM_001009299.1 For ± GCAGACACCGCCGCCTTCAG 
Rev - GTCCACGCCTCGCTCCTTCAG 
Table 2.4: Additional gene primer sequences for mRNA quantification. 
2.4.6 RT-PCR procedure 
Two sterile 0.2ml eppendorf tubes were labeled for each sample, one for the 
reverse transcription and one for a no-reverse transcription enzyme control to 
ensure transcription efficiency. A negative RNA template control, replaced 
with nuclease-free water, was also prepared. The reaction mix for each tube 
was as follows: 
 
x 1.5µl of 1µg/µl of sample RNA 
x 1µl of random primer  Pd(N)6 (Roche, Basel Switzerland) 
x 7.5µl nuclease-free water (Ambion) 
 
Samples were then centrifuged for 1 minute at 5000g and incubated for 10 
minutes at 65°C in the Techne Touchgene Gradient thermal cycler (Techne 
Incorporated, New Jersey, USA) for primer hybridization and elongation.  
During the above incubation, reverse transcriptase and control master mixes 
were prepared, using the method from Superscript II Reverse Transcriptase 
kit (Invitrogen Life Technologies, Paisley, UK) per sample tube as follows: 
 
x 4µl 5x reaction buffer  
x 2µl dithiothreitol (DTT) 
x 1µl dNTPs 
x 2.5µl nuclease-free water (3µl in no RT controls) 
x 0.5µl Superscript® II enzyme (omitted from no RT controls) 
 
10µl of either RT or no RT master mix was then added to the corresponding 
sample tube and centrifuged for 1 minute at 10000g. Samples were returned 
to the thermal cycler and run on the reverse transcription program for 45 
minutes at 42°C. After reverse transcription the cDNA samples were stored in 
a freezer at -20°C. 
 
78 | P a g e  
 
2.4.7 Hot start PCR procedure 
For primer optimization and the creation of cDNA Q-PCR standards, 
conventional PCR was performed. 0.2ml eppendorf tubes were labeled on ice 
and reaction mixture added per tube as follows: 
 
x 2µl random cDNA template 
x 10µl Thermo start PCR master mix (Abgene, Epsom, UK) 
x 1µl 1:10 dilution of forward primer 
x 1µl 1:10 dilution of reverse primer 
x 6µl nuclease-free water 
 
Negative controls containing no template cDNA and no primers were run 
concurrently to ensure the integrity of the prior RT-PCR reaction, and as 
quality controls against genomic DNA contamination. Tubes were centrifuged 
for 1 minute at 10000g then loaded into the Techne thermal cycler and ran on 
a 60°C hot start PCR program, the PCR program steps are shown in Table 2.5.  
Process Temperature 
(°C) 
Duration (mins) 
Initiation 105 4 
Enzyme activation 96 15 
   
Denaturing cDNA strands 94 0.5 
Primer annealing 60 0.5 
Primer Extension 72 1 
   
Final Extension 72 7 
Hold 4  
Table 2.5: Hot start PCR program conditions. Second phase of program repeats for 35 
cycles. 
 
2.4.8 Agarose gel electrophoresis & DNA extraction 
PCR products can be analysed and resolved using a matrix such as agarose or 
polyacrylamide gel by electrophoresis. DNA molecules are negatively charged 
due to their phosphate ion backbones and can be separated according to the 
size of the DNA fragment by applying an electric field to the fragments; 
smaller fragments migrating further and quicker towards the positive 
electrode254. To visualise the DNA fragments, it is necessary to add an 
intercalating DNA dye to the separating medium, usually ethidium bromide, 
which fluoresces when exposed to ultra-violet light, consequently showing the 
presence of any DNA fragments as an intense band within the matrix.  
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By comparison of these unknown fragments with a positive control DNA 
IUDJPHQW³ODGGHU´LWLVSRVVLEOHWRLGHQWLI\WKHVL]HRIWKHXQNQRZQEDQGVTo 
remove the DNA from the agarose gel medium, it is necessary to extract the 
fragments which can be achieved using commercially available kits. The 
QIAquick® Spin extraction kit utilises high DNA affinity silica membrane 
columns and buffer washing steps to eliminate any possible contamination or 
agarose carry-over. The purified suspended DNA can then be eluted using 
either nuclease-free water or elution buffer.  
2.4.8.1 Agarose gel electrophoresis & DNA extraction procedure 
2% w/v of agarose electrophoresis grade (Invitrogen Life Technologies) was 
dissolved in 50ml of 1x TAE buffer, from a 50x stock solution of 
tris(hydroxymethyl)aminomethane base (tris), glacial acetic acid (Fisher 
Scientific), EDTA buffer, heated and mixed with 5µl of 10mg/ml ethidium 
bromide for visualization, and cooled to form a gel. PCR products were dyed 
with glycerol blue dye and passed through the gel alongside a DNA marker 
ladder (100bp Blue eXtendec, Bioron, Ludwigshafen, Germany) at 100v for 50 
minutes. Gels and PCR products were visualised under a UV trans-illuminator 
CCD camera (Fuji film luminescent image analyser LAS-1000 v1.01). 
Fluorescent gel bands were cut out of the gel and extraction and purification 
of the PCR products was achieved using the QIAquick® gel extraction kit 
(Qiagen).  
Dissected gel bands were weighed and re-dissolved in 1.5ml eppendorf tubes 
LQǋO GQ buffer SHUǋJRIJHOat 50°C for 10 minutes. Once dissolved, 
ǋO LVRSURSDQRO (Fisher Scientific) SHU ǋJ RI JHO ZDV DGGHG and the 
solution vortexed to aid DNA precipitation. This agarose-buffer mixture was 
then pipetted into a QIAquick spin column and centrifuged at 10000g for 1 
PLQXWHZLWK DQ\*4EXIIHU DQG LVRSURSDQRO ILOWUDWHGLVFDUGHG ǋO RI *4
buffer was added to the spin column and centrifuged at 10000g for 1 minute 
to remove any remaining trace of agarose; again all filtrate was discarded. 
ǋORIPE buffer containing ethanol was added to the spin column, allowed 
to stand for 5 minutes and centrifuged at 10000g for 1 minute, with the 
filtrate discarded. The spin column was transferred to a fresh 2ml tube and 
centrifuged at 10000g for 1 minute to ensure removal of all residual PE buffer. 
The spin column was then transferred to a 1.5ml eppendorf tube and DNA 
was eluted by piSHWWLQJ ǋO RI HOXWLRQ EXIIHU (% EXIIHU directly onto the 
column membrane and centrifuging at 10000g for 1 minute.  
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Concentration and integrity measurements of the final DNA product were 
analysed using the nanodrop spectrophotometer. Samples from newly 
designed primer products were sent for DNA sequencing within the University 
RI1RWWLQJKDP¶V&HQWUHIRU*HQHWLFVDQG*HQRPLFV4XHHQ¶VMedical Centre, 
Nottingham UK) and cross-referenced against the NCBI online database. All 
extracted and purified DN$ VDPSOHV ZHUH GLOXWHG WR QJǋO DOLTXRWV DQG
stored at -20°C until needed.  
2.4.9 Q-PCR procedure 
For each gene analysed, serial dilutions up to and including 1 x 10-9 from the 
QJǋO WHPSODWH F'1$ JHQH VWDQGDUG ZHUH FUHDWHG DQG UXQ LQ WKH 4-PCR 
experiment with the unknown samples to verify the efficiency of the 
experiment. For gene expression analysis, all unknown samples were 
measured with housekeeping gene r18s to normalise all unknown cDNA 
samples.  
Samples and standards were loaded into a 96 well PCR plate (AbgeneLQǋO
aliquots from a Q-PCR master mix, protocol for each individual well as follows: 
x ǋOQXFOHDVH-free water dilution of sample or standard 
x ǋO RI SYBR® green (Thermo Scientific) containing Taq DNA 
polymerase, magnesium chloride, dNTP mix in optimised buffer 
x ǋOGLOXWLRQRIIRUZDUGSULPHU 
x ǋOGLOXWLRQRIUHYHUVHSULPHU 
 
Samples and standards were run in duplicate to calculate the coefficient of 
variation within each experiment. Negative controls for no template cDNA and 
no primers were also run for each gene analysed. 
Once prepared, PCR plates were heat sealed using an Abgene plate sealer and 
thermal seals (Alpha Laboratories, Hampshire, UK) and placed in the 
Quantica® Q-PCR instrument (Techne) or the StepOne Plus Real Time PCR 
System (Applied Biosystems).  Q-PCR program steps are shown in Table 2.6, 
p81. 
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Process Temperature Duration 
Initial denaturing of cDNA 
strand 
95°C 15 minutes 
  
Denaturing cDNA strand 95°C 15 seconds 
Annealing of primers* 58-62°C 30 seconds 
For 45 cycles 
Melt curve analysis 65 to 95°C in 1°C 
increments 
15 minutes 
For 31 cycles 
Hold 95°C 10 minutes 
Table 2.6: QPCR program conditions. * denotes range of optimal temperatures for 
genes analysed. 
 
Q-PCR analysis was measured using the Quansoft® (Techne) or the 
6WHS2QHY$SSOLHG%LRV\VWHPVVRIWZDUHSDFNDJHVDQGJHQHH[SUHVVLRQ
data converted to and analysed using the 2-¨ct method for kidney or gene of 
interest expression against a genorm normalization factor for PAT. 
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2.5 Histology 
Histology is the anatomical microscopic study of sectioned tissues enabling 
visualisation of the structure and cellular composition, which can be enhanced 
by various histological stains. It is necessary to chemically fix all tissue prior 
to histology to preserve it from degradation; this is achieved by fixing the 
tissue in formaldehyde which irreversibly cross-links proteins contained in the 
tissue to preserve the sample255. It is also essential to encase the tissue in a 
holding matrix to maintain the structural and cellular composition of the 
sample and allow sectioning for microscopic analysis. A suitable matrix must 
be able to flood and permeate throughout the sample without disturbing or 
damaging its structure which can then solidify to suspend the tissue. A widely 
used matrix in light microscopy is paraffin wax. As paraffin wax is immiscible 
in water, a dehydration step must be performed on any tissue before 
embedding in the wax, usually by treatment with a dehydrating agent and a 
hydrophobic clearing chemical, usually by immersing the samples in ethanol & 
xylene. Once embedded, tissue sections can be sliced using a microtome. 
2.5.1 Histological tissue processing 
Renal and PAT from each animal were treated with 10% formalin (10% v/v 
formaldehyde in 0.9% w/v sodium chloride/distilled water (Fisher Scientific) 
saline solution) for two hours. Segments of each sample were loaded into a 
Histosette II (Simport, Quebec, Canada) 30mm x 27mm x 5mm cassette and 
processed through six stages of ethanol dehydration followed by three stages 
of xylene (Fisher Scientific) for ethanol-clearing. Samples were then 
immersed in three stages of paraffin wax using the 6KDQGRQ([FHOVLRUWLVVXH
wax processor (Thermo Scientific) at 60°C, and allowed to solidify overnight.  
Once the tissue samples had been paraffin blocked, they were sectioned for 
10 slides per sample at ǋP, using a sledge microtome (Anglia Scientific, 
Cambridge, UK), rinsed in 70% ethanol and floated in 45°C water to stretch 
out WKH VOLFHV E\ VXUIDFH WHQVLRQ6HFWLRQVZHUH WUDQVIHUUHG WR6XSHUIURVW 
Plus slides (Menzel-Gläser Inc, Braunchweig, Germany), dried on a heat rack 
for 15 minutes and stored in a drying oven at 37°C for 24 hours. 
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2.5.2 Haematoxylin and eosin staining 
+DUULV¶KDHPDWR[\OLQLVD basic aluminium salt dye used for nuclear staining in 
tissue. Haematoxylin is oxidised to haematein by the chemical oxidising agent 
mercuric oxide and binds to acidic structures, i.e. nucleic acids, with the 
addition of an aluminium salt mordant. It is used as a regressive dye and is 
reduced in intensity and ³EOXHG´RIIE\ZDVKLQJZLWKDZHDNDONDOL256,257. Eosin 
Yellowish is used as a contrasting dye to haematoxylin for visualising the 
tissue architecture surrounding the nuclei. Eosin is an acidic dye which binds 
to basic structures, termed eosinophilic, staining proteinaceous material such 
as cytosol, muscle fibres, collagen and erythrocytes256. Differentiation of the 
eosinophilic formations occurs through washing with water.  
Haematoxylin and eosin (H&E) staining is widely used in kidney histology to 
examine the renal structure and architecture of samples. The development or 
presence of disease and injury, in particular renal tubule and glomerular 
abnormalities258,259, can be assessed by observational study and through 
quantitative analysis.  
2.5.2.1 H&E staining procedure 
One slide from each sample was blinded by assignation of a random identifier 
and placed in a slide rack. Slides were dewaxed by immersion in two 
consecutive xylene troughs for 3 minutes and rehydrated through two stages 
of 100% ethanol immersion and one stage of 70% ethanol/distilled water 
immersion, before a final wash with distilled water. The sections were 
nuclear-stained in a trough of +DUULV¶KDHPDWR[\OLQ(VWR Ltd, Lutterworth, UK) 
for 5 minutes and then rinsed in tap water for 5 minutes to remove all excess 
dye. The haematoxylin stain was regressed by immersion in an acid-alcohol 
(1% conc. hydrochloric acid in 70% ethanol) solution for 5 seconds, rinsed in 
WDS ZDWHU DQG ³EOXHG´ RII LQ DONDOLQH 6FRWW¶V WDS ZDWHU D  VRGLXP
bicarbonate and 20% magnesium sulphate distilled water solution) for 1 
minute. Slides were washed in tap water, transferred to a 1% Eosin Yellowish 
(VWR Ltd) counter stain for 3 minutes, and washed in tap water afterwards to 
remove any excess and to differentiate any eosinophilic staining. Sections 
were then dehydrated in two stages of 100% ethanol immersion for 2 
minutes and ethanol cleared in two 3 minute immersions of xylene. Sections 
were mounted with coverslips (VWR) using DPX mounting medium (Fisher 
Scientific), and left to dry overnight.  
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2.5.2.2 Glomerular H&E analysis 
H&E-stained slides were visualised through a Leica DRM microscope (Leica 
Microsystems, Wetzlar, Germany) at 10x magnification and photographed for 
analysis using a Hamamatsu digital camera (Hamamatsu, Hertfordshire, UK). 
Renal sections were generally observed and quantified for changes in 
glomerular cross-sectional area H[FOXGLQJ%RZPDQ¶VVSDFHand glomerular 
cell count. Blinded samples were assessed by a manually optimised and 
validated technique using Volocity© v5.2.0 image software (Perkin Elmer, 
Massachusetts, USA) in forty randomly- selected glomeruli per sample, based 
on an adapted glomerular area method as described by Henegar et al260. 
2.5.2.3 Perirenal adipocyte H&E analysis 
Stained slides were visualised as described in 2.5.2.2 on all complete 
adipocytes in the field of vision using one slide per lean animal and two slides 
SHUREHVHDQLPDODW[PDJQLILFDWLRQ,QGLYLGXDODGLSRF\WHSHULPHWHUVǋP
DQGDUHDVǋP2) were determined using Volocity image software.  
2.5.3 0DVVRQ¶VWrichrome staining 
Trichrome staining is the general staining technique to differentiate between 
various connective tissues such as cytoplasm, muscle, collagenous tissue, 
fibrin and erythrocytes. The three-colour stain works by two acidic dyes with 
different molecular sizes penetrating and staining proteinaceous material 
depending on porosity, with the permeating larger molecular dye replacing 
any initial smaller molecular dye256. Treating the samples with 
phosphomolybdic acid (PMA) between the small and large molecular dyes, 
allows the PMA to compete with the small molecular dye removing any excess, 
behaving as a mediator for and prior to exposure of the larger molecular dye. 
The larger molecular dye then replaces the PMA256. A third basic nuclear dye 
is also used within WKLV WHFKQLTXHVLPLODUO\ WR WKH+	(PHWKRG ,Q0DVVRQ¶V
trichrome, the smaller molecular dye is Acid Fuchsin (red/pink), the larger 
molecular dye is Light Green SF Yellowish (green/blue) and the nuclear stain 
LV +DUULV¶ +DHPDWR[\OLQ SXUSOH 7KHVH WKUHH VWDLQV GHPRQVWUDWH WKH
presence of cytoplasm and keratin, collagen and the nuclei respectively.  
0DVVRQ¶VWULFKrome is another histological technique used for kidney analysis. 
Collagen formation and thickening in renal architecture has been researched 
as a determinant of renal disease and repair in a number of studies261, 262. 
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2.5.30DVVRQ¶VWrichrome staining procedure 
Similarly to the H&E staining method (p20), one slide per animal was 
randomly assigned a blind identifier, dewaxed and rehydrated in xylene, 
ethanol and distilled water baths. Slides were nuclear-VWDLQHG LQ +DUULV¶
haematoxylin for 5 minutes, regressed and blued off as per the H&E method.  
Sections were next immersed in a 0.5% Acid Fuchsin (Nustain, University of 
Nottingham, UK) in 0.5% acetic acid solution for 1 minute and rinsed in tap 
water before being transferred to 1% PMA (Raymond Lamb, London, UK) 
solution for 5 minutes.  
Slides were then stained in a 2% Light Green Yellowish SF in 2% acetic acid 
solution for 1 minute, washed in tap water and immersed in a 1% acetic acid 
solution to remove any excess green dye. Slides were lastly treated in ethanol 
and xylene troughs to dehydrate the tissue sections, mounted with coverslips 
using DPX mounting medium and dried overnight.  
Masson trichrome stained renal samples were visualised and photographed at 
four random areas using 5x magnification and blindly assessed by three 
reviewers for collagen development using an adapted semi-quantitative 
grading method263. The grading scale used ranked the amount of positive 
green/blue staining present in each image i.e. rank 0 = 0%, rank 1 = 
UDQN -49.9%, rank 3 = 50-74.9%, rank 4 = 75-100%. 
2.5.4 Immunohistochemistry 
Immunohistochemistry (IHC) is a method of detecting and localising a specific 
antigen, i.e. a protein of interest, in histological sections through binding of 
labeled antibodies, which produces a signal upon formation with the target. 
Antibodies can be conjugated with a variety of signaling markers, including 
fluorescent dyes and enzymes and used in a direct or indirect method of 
staining, shown in Figure 2.10, p86. Direct staining involves a primary 
antibody conjugate that binds with the target antigen to produce a signal; 
indirect staining uses primary and secondary antibody conjugate complexes, 
which has the advantage of increased specificity264.  
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Figure 2.10: Antibody action in direct and indirect immunostaining method. Direct 
IHC uses a specific primary antibody conjugate to bind to target antigen, producing a 
signal for measurement, e.g. colour development. Indirect IHC uses a secondary 
antibody conjugate to bind to the primary antibody to form an antigen-primary-
secondary antibody complex to produce the signal, an increased specificity method for 
antigen detection264. 
 
A common method for indirect IHC is the use of a horseradish peroxidase 
(HRP) enzyme labeled secondary antibody, which develops a brown 
precipitate in the presence of 3,3 diaminobenzidine (DAB), a chromogenic 
substance, through catalytic conversion265. Prior to antibody exposure, it is 
important that all sections are dewaxed and rehydrated, similarly to 
histological staining, to allow all reagents access to the tissue. Furthermore 
the initial formalin fixation of the tissue results in the cross-linking of proteins, 
which in effect masks many antigenic sites. To break these protein cross-links, 
samples are treated to a heat-induced epitope retrieval (HIER) step266, 
usually heating with citrate buffer to unmask all hidden antigenic sites. 
2.5.4.1 IHC procedure 
One slide per animal and a negative control were labeled with a random 
identifierSODFHGLQDVOLGHUDFNDQGORDGHGLQWRD/HLFD%RQG0D[,+& slide 
processor (Leica Microsystems), and run on an automated software program 
(Vision Biosystems Bond version 3.4A) using Bond polymer refine detection 
reagents (Leica).  
Direct IHC 
Indirect IHC 
 
Cell 
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Samples were first treated with 1 minute xylene and 1 minute ethanol washes, 
before incubation at 95°C with epitope retrieval solution. Samples were then 
treated with Peroxide Block for 5 minutes at room temperature. All samples 
except the negative control were then exposed to 150ǋl of pre-optimised 
primary polyclonal anti-rabbit antibody (Abcam, Cambridge, UK) dilution 
(PCNA 1:4000, Abcam 18192; Caspase-3 1:50, Abcam 4051) for 30 minutes, 
and then exposed to 150ǋl of HRP conjugated secondary anti-mouse and 
rabbit antibody polymer for 8 minutes. Sections were subsequently exposed 
to 3,3 DAB for 10 minutes until brown precipitate had developed, and then 
nuclear VWDLQHGZLWK+DUULV¶KDHPDWR[\OLQIRUPLQXWHV for orientation. After 
each stage on the automated BondMax, slides were washed with Bondwash 
buffer and distilled water. Tissue sections were mounted with coverslips using 
DPX mounting medium and dried overnight.    
Blinded sections were visualised at 10x magnification and photographed for 
analysis at ten random areas. Positive stained cell percentage, normalised 
against total cell number, was estimated using a manually validated 
technique on Volocity imaging software. 
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2.6 Plasma metabolite analysis 
To help develop a metabolic profile for each of the animals used in the study, 
collected plasma from overnight fasted animals was analysed for circulating 
levels of glucose, NEFAs and triglycerides. The following sections describe the 
reaction principles of the target metabolites measured.  
2.6.1 Glucose analysis 
The glucose analysis measurement is based on an enzymatic colourimetric 
reaction adapted from  Barham and Trinder267. Glucose, in the presence of 
oxygen and water, is oxidised by glucose oxidase to form hydrogen peroxide 
and gluconic acid. The hydrogen peroxide formed then undergoes catalysis by 
peroxidase to form a violet coloured complex with phenol and 4-
aminophenazone, with absorbance measured at 500nm268 (Figure 2.11). 
                                                                        Glucose oxidase 
Glucose +O2 + H2O                gluconic acid + H2O2 
 
                         Peroxidase 
2H2O2 + 4-aminophenazone + phenol               quinoneimine + 4H2O 
Figure 2.11: Principle enzymatic reaction involved in glucose analysis reaction267,268. 
2.6.2 Non-esterified fatty acids analysis 
NEFAs can be measured by reaction with acyl-coenzyme-A synthetase which, 
when added to plasma in the presence of adenosine triphosphate (ATP), 
forms complex thiol esters of coenzyme-A and hydrogen peroxide269. 
Oxidation of the formed hydrogen peroxide by peroxidase with N-ethyl-
N(2hydroxy-3-sulphopropyl)m-toluidine (TOOS) and 4-aminoantipyrine (4-
AAP) forms a purple adduct which can be measured at 550nm, shown in 
Figure 2.12270. 
                                                               Acyl CoA synthetase 
NEFA + ATP + CoA                Acyl CoA + AMP + PPi 
 
            Acyl CoA Oxidase 
Acyl CoA + O2                2,3,--trans-Enoyl-CoA + H2O2 
 
                  Peroxidase 
2H2O2 + TOOS + 4-AAP                purple adduct + 4H2O 
Figure 2.12: Principle enzymatic reaction involved in NEFA analysis reaction269,270. 
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2.6.3 Triglyceride analysis 
Triglyceride concentrations can be determined by enzymatic hydrolysis with 
lipases to break down the triglycerides in the presence of water to glycerol 
and fatty acids. Catalysis of glycerol by glycerol kinase in the presence of ATP 
results in the formation of glycerol-3-phosphate, which can be oxidised by 
glycerol phosphate oxidase to create dihydroxyacetone phosphate and 
hydrogen peroxide. A final peroxidase catalysis step of hydrogen peroxide 
with 4-aminophenazone and 4-chlorophenol forms quinoneimine, a pink 
chromagen, and absorbance measured at 500nm, see Figure 2.13271. 
 
                 Lipases 
Triglycerides + H2O                glycerol + fatty acids 
 
           Glycerol kinase 
Glycerol + ATP               glycerol-3-phosphate + ADP 
 
                                       Glycerol phosphate oxidase 
Glycerol-3-phosphate + O2               dihydroxyacetone + phosphate + H2O2  
 
                                         Peroxidase 
2H2O2 + 4-aminophenazone + 4-chlorophenol               quinoneimine + HCl 
+ 4H2O 
Figure 2.13: Principle enzymatic chemical reaction involved in triglyceride analysis 
reaction271. 
2.6.4 Plasma metabolite analysis procedure 
Plasma samples were thawed gently on ice and bubbles removed from the 
sample surface before being loaded into a Randox RX Imola auto-analyser 
(Randox Laboratories, County Antrim, UK). The auto-analyser completed a 
calibration curve for each metabolite measured, before analysing each sample 
in duplicate. All specific metabolite reagent kits were supplied by Randox and 
plasma samples were analysed once and at the same time to limit freeze-
thaw cycles; analyses were repeated for samples that showed a variance 
coefficient of higher than 5%. 
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2.6.5 Plasma creatinine analysis 
Creatinine concentrations in biological fluids can be determined by an 
enzymatic colourimetric reaction. Creatinine can be converted to creatine by 
creatininase and creatine converted to sarcosine by creatinase. Sarcosine is 
then oxidised by sarcosine oxidase to form a product which reacts with a 
probe to form a purple product272, see Figure 2.14, with absorbance at 570nm.   
                     Creatininase                     Creatinase                          
Creatinine               Creatine                Sarcosine 
 
                                                               Oxidation 
Sarcosine                  3UREH3XUSOHSURGXFWǊmax = 570nm) 
Figure 2.14: Enzymatic reaction involved in plasma creatinine analysis272                                     
2.6.5.1 Plasma creatinine analysis procedure 
Plasma creatinine analysis was performed using a creatinine assay kit (Abcam, 
ab65340) on overnight fasted plasma samples. Plasma samples were gently 
WKDZHGRQLFHDQGǋORIHDFKVDPSOH or negative control was pipetted into a 
96-well microplate ensuring no bubbles had formed. To create a standard 
FXUYHVWDQGDUGVRIDQGǋOZHUHSLSHWWHGLQWRWKHVDPHSODWH
DQGPDGHXSWRǋOZLWKDVVD\EXIIHUǋORIUHDFWLRQPL[FRQWDLning assay 
buffer, creatininase, creatinase, enzyme mix and probe was added to each 
well and the microplate was incubated at 37°C for 1 hour for colour 
development. Creatinine concentrations ZHUH WKHQ PHDVXUHG RQ D ǋ4XDQW
plate reader (BIO-TEK Instruments Inc. Vermont, USA) at 570nm using KC 
Junior analysis software (Biotek Ltd, Vermont, USA) and expressed as nmol 
SHUǋO$OOVDPSOHVDQGVWDQGDUGVZHUHDQDO\VHGLQGXSOLFDWHDQGVKRZHGD 
variance coefficient RI  
2.6.6 Plasma cytokine analysis 
Through performance of ELISA or immunoassays, it is possible to detect the 
presence and quantity of specific target antigens in plasma samples. ELISAs 
are based on a similar methodological premise as shown in Figure 2.10 (p86). 
Formation of a labelled-antibody antigen complex produces a fluorescent or 
electrochemical signal which can be measured. It is necessary to first coat the 
surface of each well in the detection microplate with a capture antibody, i.e. 
an antibody which binds to the target antigen.  The second step involves 
incubating the plate with a blocking agent to block any non-specific binding 
sites, followed by introduction of the sample containing the target antigen.  
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Application of the antigen-specific primary antibody and secondary antibody 
enzyme-conjugate completes the full protein complex which when exposed to 
a chemical converter, produces a signal, shown in Figure 2.15. Gentle 
washing with buffered saline solution occurs after each stage to remove all 
excess reagents. 
 
 
 
 
 
 
 
 
Figure 2.15: Stages of sandwich ELISA. A: Microplate is coated with capture antibody, 
and non-specific binding sites blocked with blocking agent. B: Sample containing 
target antigen introduced to well. C: Primary antibody applied to bind to target antigen. 
D: Secondary antibody with enzyme conjugate applied to primary antibody complex. 
Protein complex emits fluorescent signal after addition of chemical reagent. 
 
2.6.6.1 Plasma cytokine analysis procedure 
A 96 well microplate was coated with 100µl of capture antibody; 2µg/ml 71)Į
CC327 mouse monocolonal to cow antibody (Abcam 25797) diluted in sodium 
carbonate/sodium bicarbonate coating buffer or 8µg/ml IL-6 CC310 mouse 
monocolonal to cow antibody (GTX82951, Genetex, California, USA) diluted in 
distilled water, and incubated overnight at room temperature. After 
incubation, plate wells were washed five times with 500µl PBS and 0.05% 
Tween® 20 washing buffer and blocked for a minimum of 1 hour at room 
temperature with 300µl of 1% sodium casein/PBS blocking reagent. Plate 
wells were again washed five times with 500µl washing buffer, before loading 
with 100µl/well of samples or standards diluted in blocking buffer and 
incubated for 1 hour at room temperature.  
 
 
A: Coated and 
blocked microplate 
B: Target antigen C: Detection of 
primary antibody 
D: Secondary 
antibody enzyme 
conjugate and colour 
development 
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After a repeated washing step, 100µl/well of secondary antibody was pipetted 
LQWR WKH PLFURSODWH JPO 71)Į && PRXVH PRQRFORQDO WR FRZ
biotinylated antibody (Abcam 35284) or 1µl/ml anti-ovine IL-6 polyclonal 
rabbit serum diluted in blocking buffer, and incubated for 1 hour at room 
temperature. After another repeated washing step, the IL-6 ELISA method 
contained an additional step, whereby IL-6 plate wells were coated with 
100µl/well of 1µl/3ml sheep anti rabbit IgG biotin (Abcam 97093) and 
incubated for 1 hour at room temperature. Plate wells were then washed five 
times in washing buffer, and coated with 100µl/well of 2µl/ml Streptavidin-
HRP (GE Healthcare UK Ltd, Buckinghamshire, UK) diluted in blocking buffer/ 
0.05% Tween and incubated for 45 minutes at room temperature. After a 
repeat washing step, plate wells were developed with 100µl/well of TMB 
substrate (10mg TMB in 1ml dimethylsulphoxide (DMSO) in 99ml sodium 
acetate/citric acid (BDH) pH6 solution, activated with 1.5µl hydrogen peroxide) 
and incubated for 30 minutes at room temperature. Plate development was 
stopped using 50µl of 1M sulphuric acid, and microplates read at 450nm using 
a spectrophotometer.  
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2.7 Triglyceride analysis 
In 1957 Folch, Lees and Stanley published a method of lipid isolation and 
extraction from tissue273, which has been used to extract triglycerides from 
frozen kidney tissue in recent studies274. This method utilises interactions 
between a chloroform-methanol-saline (8:4:3) homogenisation solvent, which 
separates the solution into its lipid and non-lipid components by dissolution, 
centrifugation and filtration. The pure lipid components released upon 
homogenisation of the tissue are dissolved in the chloroform phase of the 
solvent, applying gravity filtration, and washing this mixture with saline 
removes any contaminants or solid tissue from the chloroform fraction.  
Removal of the filtrated solvent mix occurs under nitrogen steam, leaving the 
evaporated pure lipid component which can be stored or re-suspended in 
solvent, and the triglyceride concentration measured using a number of 
commercially available assay kits. The Randox triglyceride analysis kit uses a 
colourimetric reaction to determine triglyceride concentration by 
spectrophotometric absorbance at a specific wavelength. The kit contains 
enzymatic reagents which react with triglycerides to form quinoneimine as 
previously described in Figure 2.13 (p89), a coloured product measured at 
500nm absorbance. Triglyceride concentrations for unknown samples are 
determined by interpolation of measured values from an internal control 
standard curve. 
2.7.1 Triglyceride analysis procedure 
500mg of renal cortical or longissimus dorsi (LD) muscle tissue from each 
animal was homogenised in a 50ml dispomix tube in 2ml of chloroform-
methanol mixture (2:1 ratio) and gently centrifuged at 150g for 1 minute to 
ensure all homogenised tissue was exposed to the solvent. Samples were 
then agitated in an orbital shaker for 20 minutes at room temperature, before 
being passed through a funnel and 150mm Whatman filter paper (Scientific 
Laboratory Supplies, Nottinghamshire, UK) into a 15ml tube under gravity to 
recover the liquid phase. Tubes and filtration equipment were washed with 
8ml of chloroform-methanol solvent, ensuring all available lipids were 
collected. Filtrated samples were next washed with 2ml 0.9% saline, vortexed 
for 5 seconds and centrifuged at 800g for 1 minute to separate the organic 
and aqueous phases of solution. The aqueous phase (top layer) of solution 
was discarded using a Pasteur pipette and 2ml of the remaining organic phase 
transferred to a 2ml eppendorf tube and evaporated under nitrogen steam 
using a Driblock DB-3 (Techne).  
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Evaporated lipid samples were then re-GLVVROYHG LQ ǋO WHUW-butanol (BDH) 
DQGǋO Triton X-100, and stored in a spark-free fridge until further analysis. 
Analysis of triglycerides was performed with the Randox triglyceride assay kit 
XVLQJ DQ DGDSWHGPHWKRG IURP WKHPDQXIDFWXUHU¶V LQVWUXFWLRQV 2ǋO RI HDFK
sample, negative control or standard, DQGǋl of supplied enzyme reagent 
were pipetted into a 96 well microplate (Grenier Bio-one, Gloucestershire, UK), 
ensuring no bubbles were formed and incubated at 37°C for 5 minutes for 
colour development. Triglyceride concentrations were then measured on a 
ǋ4Xant plate reader at 500nm and expressed as a ratio of triglyceride in 
micrograms (mg) per gram (g) of kidney tissue (mg/g). Each sample 
extraction and analysis was performed in duplicate, with a 5% coefficient of 
variance accepted between duplicate samples; analyses were repeated for 
samples outside this CV% value.  
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2.8 Thiobarbituric acid reactive substances analysis 
Lipid peroxidation is the oxidative degradation of lipids and is a mechanism of 
cellular damage within plant and animal tissue. ROS, particularly free radicals, 
initiate a reaction with unsaturated lipids which ultimately form lipid 
peroxides275. Lipid peroxides are unstable molecules that decompose to form 
other compounds such as malondialdehyde (MDA), reported as a DNA 
mutagen and carcinogen276, and 4-hydroxynonenal (4-HNE). A number of 
commercially available Thiobarbituric acid reactive substances (TBARS) assay 
kits determine the end products of lipid peroxidation by measuring the 
colourimetric byproduct between thiobarbituric acid (TBA) and MDA, see 
Figure 2.16.  
 
 
Figure 2.16: Malondialdehyde-thiobarbituric acid adduct formation275. 
7KH2[LVHOHFW TBARS Assay kit (Cell Biolabs Inc, CA, USA) determines lipid 
peroxidation through the formation of MDA-TBA adducts under acidic 
conditions at approximately 95°C. This reaction produces a pink chromagen 
which can be measured colourimetrically at 532nm. However, the specificity 
of the reaction has been questioned, as TBA and MDA can both react with 
additional compounds such as aldehydes, DNA and amino acids to form 
similar colourimetric products275,277,278, and hence it is suggested the reaction 
measures TBARS rather than MDA concentration. Despite this, the method is 
still the most widely used analysis to determine lipid peroxidation275,278 and 
has recently been published within a renal oxidative-stress study279.  
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2.8.1 TBARS procedure 
§100mg of renal cortical tissue from each sample was resuspended and 
homogenised in 1ml of 1 x butylated hydrotoluene kit reagent (BHT) and 
phosphate buffered saline (PBS). Samples were initially centrifuged for 1 
minute at 2000g at room temperature with the supernatant transferred to 
1.5ml labeled eppendorf tubes. Centrifugation was repeated at 10000g for 5 
minutes at 4°C and the supernatant transferred to clean 1.5ml tubes to 
ensure removal of any remaining cell debris. Samples were then stored at -
20°C until use in the TBARS assay, or for total protein concentration analysis. 
$QDO\VLVRI7%$56ZDVSHUIRUPHGXVLQJ WKH2[LVHOHFW7%$56DVVD\NLW DV
SHU WKHPDQXIDFWXUHU¶V LQVWUXFWLRQV; analysis of both standards and samples 
were performed in duplicate.  
Ten MDA standards (500µl) were created ranging from 0mg/dl-195mg/dl 
using the MDA reagent supplied and distilled water. 100µl of standard, 
negative control or unknown sample was added to a fresh 1.5ml eppendorf 
tube; 100µl of sodium dodecyl sulphate (SDS) lysis solution was added to 
each tube and incubated at room temperature for 5 minutes. 250µl of TBA 
reagent was next added and tubes were incubated in a water bath at 95°C for 
60 minutes, after which samples were removed and cooled on ice for a 
further 5 minutes.  Samples were then centrifuged at 1200g for 15 minutes, 
with 300µl of supernatant transferred to a fresh eppendorf tube. 300µl of n-
butanol was next added to the samples to prevent interference of 
haemoglobin and its derivatives. Samples were vortexed for 1-2 minutes and 
centrifuged for 5 minutes at 10000g at room temperature to allow for phase 
separation. The n-butanol layer, i.e. the top layer of the solution, was then 
decanted into another eppendorf tube for spectrophotometric analysis. 200µl 
of each sample and standard was then pipetted into a 96 well microplate and 
absorbance measured at 532nm. Unknown sample concentrations of 
MDA/TBARS were determined against the standard curve, and normalised 
against total protein concentration using the bicinchoninic acid (BCA) method 
(2.8.2.1, p97), results were expressed as TBARS µM / total protein 
concentration (µg/µl). 
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2.8.2 Bicinchoninic acid total protein determination 
Total protein concentrations were determined using the BCA assay method. 
This assay relies on a colourimetric reaction between proteins, BCA and 
copper sulphate280,281. Peptide bonds in proteins reduce Cu2+ to Cu1+ ions 
when incubated at temperature; BCA reagent then chelates to Cu1+ ions 
which forms a purple coloured compound280.  
The colour development (from green to purple) is in proportion to the amount 
of protein present in the sample and absorbance can be measured at 562nm. 
Unknown concentrations can then be referenced against a standard curve.  
2.8.2.1 BCA assay procedure 
50ml of BCA reagent (reagent A) containing 1% bicinchoninic acid, 2% 
sodium carbonate, 0.16% sodium tartrate and 0.4% sodium hydroxide was 
made up to volume with distilled water and made to pH 11.25 with 10% 
sodium bicarbonate. 50ml of 4% copper sulphate solution (reagent B), was 
made up to volume with distilled water. Reagent C was then made by mixing 
reagent A and reagent B in a ratio of 100ml: 2ml and stored at 4°C until 
needed. To create the standards, eight concentrations of bovine serum 
albumin (BSA) ranging from 1.0-0.00 mg/ml were made up in 0.9% saline. 
2.5µl of each unknown protein sample was diluted by 1:20 in 0.9% saline 
solution to make a final volume of 50µl.  
10µl of each standard, negative control or unknown was pipetted into a 96-
well microplate. 200µl of reagent C was then added to each well and 
incubated in an orbital shaker at 37°C for 30 minutes for colour development, 
after which absorbance was measured at 562nm. Each analysis was 
performed in duplicate, with a 5% coefficient of variance accepted between 
duplicate samples; analyses were repeated for samples outside this CV% 
value. A 20x multiplication factor was applied to all recorded absorbance 
results to account for the initial 1:20 dilution factor.   
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2.9 Western blotting 
Western blotting or protein immunoblotting is a method to analyse protein 
size and expression in biological cell lysate samples282. Tissue samples are 
homogenised and lysed to release the proteins into the sample and protein 
concentration measured. To denature, ionise and align the proteins, samples 
are heated with an ionic detergent, usually SDS and 2-mercaptoethanol to 
prevent additional protein disulphide bond cross-linking. Protein samples 
along with a protein marker ladder (Biorad Precision Plus Protein Standards, 
Biorad, California, USA) are then loaded onto a 2-D polyacrylamide gel and 
undergo electrophoresis. Proteins are separated along the polyacrylamide 
matrix towards the positive electrode according to their size and molecular 
charge. Once separated the proteins can be transferred from the gel matrix to 
an electrostatic membrane, either nitrocellulose or polyvinylidene fluoride 
(PVDF), using a semi dry electroblotting method. Membrane cut to the same 
size of the gel is laid directly onto the gel surface, which is then sandwiched 
between buffer soaked filter paper and placed into a semi-dry blotter. A small 
electric FKDUJH LV WKHQ SDVVHG WKURXJK WKH µJHO VDQGZLFK¶, drawing the 
proteins from the gel and onto the membrane, by a combination of capillary 
action and electrostatic attraction283. After blotting, the membrane is stained 
using a reversible protein dye to ensure completion of protein transfer. As 
described in the IHC (2.5.4, p86) and ELISA methods (2.6.6, p90), detection 
of protein in Western Blotting occurs by a similar mechanism. The membrane 
is first incubated in a blocking reagent to block any non-specific binding sites, 
before the target antigen-antibody protein complex is built through incubation 
in optimised primary and secondary antibody dilutions. Detection of the 
secondary antibody enzyme conjugate occurs by incubation in a 
chemiluminescent reagent, which emits a signal in proportion to the 
abundance of target antigen present. Chemiluminescent signal can be 
detected by exposure with a CCD camera and quantitation determined 
through analysis of protein band density using densitometry software.  
2.9.1 Western blot protein extraction procedure 
For each sample §J cortical tissue was weighed into a dispomix tube and 
homogenised in 4ml CelLytic MT lysis reagent and 0.04ml protease inhibitor 
cocktail P8340 at 3000 rpm for 30 seconds. The homogenate was then 
transferred to a 2ml eppendorf tube and centrifuged for 10 minutes at 
12000g to pellet all cell debris.  
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Protein supernatant was then transferred to a fresh 2ml eppendorf tube and 
protein concentration of each sample determined by BCA method. Samples 
were then stored at -20°C for further analysis.  
2.9.2 Western blot polyacrylamide gel electrophoresis procedure 
Extracted protein samples were diluted to 4.2mg/ml using CelLytic MT diluent 
EHIRUHDGGLWLRQRIǋl protein association buffer (containing 50mM Tris, 10% 
glycerol, 2% SDS, 5% beta-mercaptoethanol and distilled water pH 6.8). 
6DPSOHV ZHUH PDGH XS WR ǋO ZLWK JO\FHURO-bromophenol dye (containing 
0.01g bromophenol blue, 14.9g sodium hydroxide and 23.5ml distilled water) 
and incubated for 10 minutes at 100°C in a water bath.   
A 12% polyacrylamide-resolving gel (containing 12ml 30% polyacrylamide 
(Severn Biotech, Worcestershire, UK), 9.9ml distilled water, 7.5ml 1.5M Tris 
pH 6.8, 0.3ml      10% SDS, 0.3ml 10% ammonium persulphate (APS) and 
0.012ml 111¶1¶-tetramethylethylenediamine (TEMED) (Acros Organics, 
New Jersey, USA)) was cast in a 18cm b 16cm Hoefer SE600 gel chamber 
(Hoefer Inc, Massachusetts, USA), by syringe injection, allowing a 3-4cm 
space for stacking gel and loading comb. Water-saturated butanol was poured 
onto the gel to level the resolving gel surface and prevent the gel from drying 
out, and allowed to polymerise for 1 hour at room temperature. The butanol 
was poured off and the set gel washed with distilled water. A 3% stacking gel 
(containing 1.7ml polyacrylamide, 6.8ml distilled water, 1.25ml 1.0M Tris pH 
6.8, 0.1ml 10% SDS, 0.1ml 10% APS and 0.01ml TEMED) was injected in the 
gel chamber on top of the resolving gel. A loading comb was inserted in the 
stacking gel and allowed to polymerise for 1 hour at room temperature. After 
removal of the loading comb, gel wells were washed with distilled water and 
filled with 1x running buffer (containing 5mM tris, 50mM glycine (Fisher 
Scientific), 2% SDS and distilled water). 20ǋl of each sample, a non-immune 
mouse serum negative control and a protein marker ladder were randomly 
loaded in duplicate onto the gel, loading any empty wells with 20ǋl glycerol-
bromophenol dye to ensure even running during electrophoresis. The gel 
chamber was attached to the upper and lower electrophoresis chambers, 
which were filled with 1x running buffer, and electrophoresis was run at 150v 
(40mA) for 2 hours.  
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2.9.3 Western blot semi-dry blotting procedure 
A nitrocellulose membrane (Hybond-C Super, GE Healthcare) and six sheets 
of 1mm filter paper were cut to approximately the same size as the 
polyacrylamide gel. Filter paper was soaked in Towbin buffer (containing 
25nM Tris, 192mM glycine, 20% v/v methanol, and distilled water, p.H 8.3). 
After electrophoresis the gel tank was disassembled and the gel carefully 
unloaded. The stacking gel was removed and the resolving gel was placed 
directly onto the nitrocellulose membrane, placing three sheets of filter paper 
either side of the gel and membrane to form a sandwich. Any air bubbles 
were carefully rolled out of the gel sandwich, which was then placed into a 
Hoefer semi-dry transfer unit TE77x and proteins transferred at 0.8mA per 
cm2 at a maximum of 30v for 2 hours.  
2.9.4 Western blot protein detection procedure 
After protein transfer, the nitrocellulose membrane was washed in 100ml tris 
buffered saline with Tween® 20 (TTBS), and then soaked in 100ml 1:10 
Ponceau S red stain dilution (containing 0.2g ponceau S, 3g trichloroacetic 
acid (Fisher Scientific), 3g sulphosalicylic acid (Acros Organics) and distilled 
water), to visualise protein band location. The protein marker ladder was 
highlighted with a rabbit primary antigen/antibody pen (Alpha Diagnostic, 
Texas, USA), before removing Ponceau S stain from the membrane with 
distilled water and TTBS. The membrane was then blocked overnight at 4°C 
in 100ml 10% Marvel dried milk powder ensuring complete dissolution, to 
prevent any speckling on the membrane. The membrane was blocked for an 
additional 30 minutes at room temperature before being rinsed twice in 
100ml TTBS. Next, the membrane was agitated in 10ml 1:50 TTBS/3% 
Marvel dilution of mouse monoclonal to TLR4 primary antibody (Abcam 22048) 
for 1 hour at room temperature, after which the membrane was washed in 
100ml TTBS for 3 x 10 minutes. The membrane was agitated in 10ml 1:2000 
TTBS/ 3% Marvel dilution of rabbit polyclonal to mouse IgG HRP conjugate 
secondary antibody (Abcam 6728) or 1:2000 protein G HRP conjugate 
secondary antibody (Biorad) for 1 hour at room temperature, followed by four 
15 minutes washes in 100ml TTBS and a further two 30 minute washes in 
TBS. Additionally, a negative control using a primary binding solution of 
1:1000 non-immune mouse serum was conjugated with 1:2000 rabbit 
polyclonal to mouse secondary antibody. 
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For chemiluminescent visualisation, 3ml of hydrogen peroxide and 3ml 
luminol (Immobilon Western Chemiluminescent HRP Substrate, Millipore, 
Massachusetts, USA) were applied directly onto the membrane and agitated 
for 5 minutes, before being drained and covered in cling wrap. Protein bands 
were visualised using a CCD digital camera, exposing the membrane for 5 
minutes under visible light (EPI) and chemiluminescence.  
Protein band densities were analysed using Aida Densitometry v2.0 software 
(Raytek Scientific Ltd, Sheffield). Efficiency of protein transfer from 
polyacrylamide gel to nitrocellulose membrane was assessed by washing the 
polyacrylamide gel in Coomassie Brilliant Blue dye for 1 hour, to visualise any 
remaining protein bands.  
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2.10 Statistical analysis 
Prior to any statistical analysis, coefficient of variance between each duplicate 
individual sample was calculated for the assays and experiments performed 
using Microsoft Office Excel 2007 software spreadsheet package (Microsoft 
Corporation, Berkshire, UK) $ FRHIILFLHQW RI YDULDQFH   FRQILUPHG ORZ 
variance, thus supporting the reproducibility of the respective assay. Data 
points that fulfilled this criterion were included in further statistical analyses. 
Statistical analysis of data was performed using SPSS v18.0 statistical 
software for Windows package. All data were subjected to the Kolmogorov-
Smirnov normality test for parametric or non-parametric distribution, where p 
 GHWHUPLQHGQRUPDOLW\ &RPSDUDEOH JURXSV (i.e. groups with at least 
one of the same variable) were assessed using either analysis of variance 
(ANOVA) for parametric data or Kruskal-Wallis one-way analysis of variance 
for non-parametric data, with multiple group post hoc %RQIHUURQL RU'XQQ¶V
correction tests applied respectively. All statistical graphs were produced 
using software package GraphPad Prism v5.00 (GraphPad Software, California, 
USA), and for consistency, data presented as mean average ± standard error 
of the mean (SEM). Details of any additional statistical tests used are 
provided in the relevant results chapters. 
 
In analysis of all 8 groups, i.e. groupings by maternal nutrition, obesity and 
gender (NLf, ALf, NLm, ALm, NOf, AOf, NOm and AOm, see Figure 2.1, p105), 
there were no statistical differences between the maternal nutrition 
intervention groups; this applied to all the experiments performed as 
described in this chapter. These results did however indicate that gender and 
post-natal obesity displayed an overriding influence within the study groups. 
To examine the effect of gender and post-natal obesity throughout this study, 
the maternal nutrition groups were combined, thus the groups analysed were 
lean females (LF, n=7), lean males (LM, n=11), obese females (OF, n=9) and 
obese males (OM, n=9), shown in Figure 2.2, p105. 
To reduce the probability of performing a type I or type II statistical error, i.e. 
by erroneously rejecting or accepting the null hypothesis respectively, power 
calculations were performed using Minitab v16 statistical software (Minitab 
Ltd, Warwickshire, UK). Minitab power calculations determine the 
recommended sample sizes per group depending on an expected difference 
and standard deviation between each group. Sample size was calculated at 80% 
power, a value generally accepted in the literature as standard.  
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The recommended sample size to detect a 20% difference between groups 
with a 10% standard deviation was 6 samples per group with a statistical 
SRZHURI to yield a significant result of p<0.05. However, to detect a 
smaller difference with similar standard deviations at the same power and 
significance, as may have been present between the maternal nutrition 
groups, it is recommended that sample sizes are increased to §100 per group.  
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Chapter 3 ± The effect of gender and 
obesity on systemic metabolism and 
adipose tissue physiology 
 
3.1 Introduction and aims 
Surveying the scientific literature has identified the association of obesity 
development leading to an alteration in adipose tissue expansion and 
enlargement, and also a change in adipose tissue location, which may be 
influenced by gender37,38. This responsiveness between adaptations in adipose 
tissue profile is postulated to play a role in mediating a chronic low grade 
inflammatory phenotype, to which the kidneys are particularly sensitive 
resulting in structural and functional renal impairment. This chapter therefore 
aimed to investigate whether the exposure to an obesogenic environment of 
restricted physical activity encourages the development of central obesity by 
switching the deposition location from peripheral to intra-abdominal adipose 
tissue. These adaptations could result in an elevated inflammatory systemic 
profile, via increased circulatory hormones, cytokines and metabolic 
molecules. Promotion of an inflammatory phenotype can then contribute to an 
increased risk in CVD and related end organ damage69. 
Therefore, this chapter details the effect of a reduced activity obesogenic 
environment and how this environment encourages the development of 
adipose tissue size and its locale, and the subsequent impact on systemic and 
PAT physiological alterations in sheep, with additional gender analysis.  
3.1.1 Hypothesis 
The hypothesis for Chapter 3 was that sheep exposed to a restricted area of 
physical activity develop increased deposits of adipose tissue and impaired 
metabolic status. Additionally, development of intra-abdominal and 
subcutaneous fat depots may depend on gender.  
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3.2 Materials and methods 
A complete description of all the methods used in this chapter can be located 
in Chapter 2. The experimental model used in my study which is referenced in 
the subsequent results chapters is reviewed in Figure 3.1. All reported animal 
experimentations, i.e. DXA measurements, tissue weights, plasma 
measurements and dissections were performed and supervised by Dr 
S.Sebert and Dr L.Chan. Leptin and cortisol plasma analyses were performed 
by Miss N.Dellschaft and Dr S.Sebert. Where appropriate, any sample or 
analytical omissions are explained in the relevant results section. In addition, 
description of statistical tests utilised are provided in this results chapter or 
are detailed in Chapter 2.  
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Review of experimental animal model used throughout my thesis: LF = 
lean female, OF = obese female, LM = lean male and OM = obese male sheep. Four 
female animals expired during the experimental procedure. 
110 Days - Term 0 ± 3 Months 3 ± 17 Months 
 
Female Offspring (F)  
n = 20 
Male Offspring (M)   
n = 20 
Lean Females (LF)        
n = 7 
Obese females (OF)      
n = 9 
Lean Males (LM)           
n = 11 
Obese Males (OM)        
n = 9 
Gestation 
110 days - Term 
Post-Weaning Lactation 
0 ± 3 Months 3 ± 17 Months 
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3.3 The ovine model of obesity and maternal nutrition 
Previous work from the University of Nottingham Academic Child Health 
Department on models of ovine obesity, have utilised models derived from a 
combination of maternal nutrition restriction and postnatal activity 
manipulation228. The nutritional intervention has targeted the in utero period 
of ovine embryo- and organogensis, i.e. the early to mid-gestation period 
(dGA 30-80)227. In analysis of physiological renal and adipose tissue 
adaptations, this study identified that restriction of maternal nutrition during 
this period alters inflammatory and metabolic gene-protein responses in renal 
and perirenal adipose tissue in comparison of lean, obese and nutrition 
restricted obese subjects227,284. Additionally the nutrient restricted obese 
group displayed advanced signs of metabolic dysfunction characterised by 
increased renal oxidative stress, apoptosis and proliferation in addition to 
elevated renal lipid and collagen depositions230.  
However, my study utilised a restricted maternal nutrition period targeting a 
late gestation in utero window (i.e. dGA 110-130). As previously mentioned, 
this development period is after nephrogenesis226, meaning that the renal and 
urinary systems are fully matured prior to the applied nutritional intervention, 
thus resulting in no discernible effect in these systems. This is the probable 
explanation why no significant differences were observed between the 
maternal nutrition intervention groups for both phenotype and genotype, and 
as discussed in Chapter 2, comparisons of gender and obesity were the 
overriding influences in all analyses.  
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3.4 Results 
3.4.1 The effects of an obesogenic environment and gender and their 
contribution to body weight and adipose tissue deposition 
During the post-weaning period (§3 months) to the time of euthanasia (§17 
months), both lean and obesogenic environment animals were allowed access 
to the same amount of food and water. Obese males showed significantly 
higher energy intake than the lean males, a response not observed in the 
females. Obese males additionally displayed greater energy intake than the 
obese females. However, analysis of energy intake per kg of body weight 
showed no significant differences between either obesity or gender groups, 
see Table 3.1. 
Group LF (n=7) OF (n=9) LM (n=11) OM (n=9) Gender Obesity 
Energy intake 
(MJ/24h) 
17.02±1.16 22.91±1.16
a
 16.27±1.42** 30.35±1.79
b
**  S S 
Relative 
Energy intake 
(MJ/kg/24h) 
0.35±0.02 0.38±0.02 0.29±0.02 0.36±0.02 NS NS 
Table 3.1: Energy intake (MJ/kg/24 hours) throughout post-natal environment 
intervention of lean female (LF), obese female (OF), lean male (LM) and obese male 
(OM) sheep. Values are means ± SEM. NS = no significant differences, S = 
significance where only one of two comparable groups display significance; statistical 
difference is denoted by ab,** = p<0.005 (ANOVA). 
Conversely, activity measurements for the animals highlighted a significant 
difference in increased activity between the lean and obesogenic environment 
males, a trend also displayed by the females, shown in Figure 3.2, p108. In 
the lean males and both female groups, no activity data was recorded for one 
animal, most likely due to a fault with the accelerometer. These omissions 
may have reduced the power of the applied statistical test (ANOVA), thus 
providing a possible explanation as to the lack of statistical significance in 
comparison of the two experimental female groups. 
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Figure 3.2: Area under curve (AUC) of mean activity per 24 hour period of lean 
female (LF; n=6), obese female (OF; n=8), lean male (LM; n=10) and obese male 
(OM; n=9) sheep. Values are mean ± SEM. Statistical difference is denoted by *** = 
p<0.001 (ANOVA). 
From the individual values of energy uptake and mean physical activity, it 
was possible to determine relative values for food intake percentage and 
physical activity percentage. These values were then used to calculate an 
energy uptake to physical activity ratio using the lean group as a reference. 
This energy balance ratio was determined by ((food intake %/physical 
activity %)/(food intakeref %/physical activityref %)) -1, where the average 
relative ratio for lean animals was considered to be 0. A positive value for 
energy balance represents a net gain of energy, and a negative value 
represents a net loss of energy, see Figure 3.3, p109.  
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Figure 3.3: Ratio of energy intake to physical activity of lean female (LF; n=6), obese 
female (OF; n=8), lean male (LM; n=10) and obese male (OM; n=9) sheep. Values 
are mean ± SEM. Statistical difference is denoted by *** = p<0.001 (ANOVA). 
Obese males exhibited a significant increase in the ratio of energy intake to 
physical activity in comparison to lean males, a trend also displayed between 
obese females and obese males (p=0.078). No significant differences were 
observed in comparison of the female groups, but similarly to the mean 
activity results, obese females appeared to display a trend towards increased 
energy intake and physical activity ratio, and any statistically significant result 
was potentially dampened through a reduction in sample number as 
previously discussed. 
 
The obesogenic environment intervention of reduced activity and subsequent 
change in energy balance contributed towards the development of larger 
sheep. As BMI is a weight formula specifically for humans, body weight 
measurements were used to determine an overweight or obese condition. 
Body weights (kg) showed a statistical significant increase in comparison of 
lean to obese animals in both genders, with an approximate increase of 25-50% 
in body weight. Additionally obese males exhibited higher body weight 
compared to obese females, a result not seen in the lean animals, see Table 
3.2, p110. An estimation of total fat mass by DXA scan further allowed a 
comparison of lean and obese animals which identified a significant rise in 
total fat mass (kg) shown in Table 3.2 (p110). In addition relative fat mass 
percentage was calculated (total estimated fat mass/ body weight). Relative 
fat mass percentage showed a significant, two-fold increase between lean and 
obese animals for both genders.  
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Females exhibited slightly higher relative fat mass percentage in both lean 
and obese groups compared to their male counterparts, however these 
results were not statistically significant, Table 3.2. Total fat mass was 
increased with obesity, as were body weights corrected for total fat mass (kg). 
These results showed that obese males were significantly larger when 
compared to lean males and obese females, a result not observed between 
female groups, Table 3.2. To ascertain as to whether the increased corrected 
body weight observed in obese males was due to amplified lean mass 
development, analysis of lean mass (kg) identified a significant difference 
with gender but not obesity, and although not statistically significant, lean 
males exhibited a 25% increase in lean mass compared to lean females. 
Finally analysis of lean to total fat mass ratio showed a decrease in lean mass 
ratio in the presence of obesity but not with gender, Table 3.2. 
 
Group LF (n=7) OF (n=9) LM (n=11) OM (n=9) Gender Obesity 
Body 
weight 
(kg) 
49.50±1.04 61.56±2.07
a
 56.38±2.59 83.84±1.82
b
 S ** 
Total fat 
mass (kg) 
3.85±0.48 8.11±0.74 3.61±0.44 9.67±0.88 NS ** 
Relative fat 
mass (%) 
8.42±1.12 14.31±1.26 6.77±0.66 12.93±1.06 NS ** 
Body 
weight 
corrected 
for fat 
mass (kg) 
45.30±0.75 52.20±1.84
a
 52.50±2.13** 73.00±1.81
b
** S S 
Lean mass 
(kg) 
39.72±0.87 44.03±1.22
a
 49.09±1.89 62.41±1.30
b
 S NS 
Lean mass: 
total fat 
mass ratio 
(kg) 
11.40±1.59 5.83±0.57 15.31±1.62 6.93±0.67 NS * 
Table 3.2: Body weight parameter measurements of lean female (LF), obese female 
(OF), lean male (LM) and obese male (OM) sheep. Values are mean ± SEM. NS = no 
significant difference, S = significance where only one of two comparable groups 
display significance; statistical differences are denoted by * = p<0.05; ab,** = 
p<0.005; *** = p<0.001, (ANOVA). Body weight corrected for fat mass, Lean mass 
and Lean mass:total fat mass ratio analyses treated with Kruskal-Wallis statistical test. 
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As expected, exposure in an obesogenic environment promoted total fat mass. 
To determine how an obesogenic environment impacted on adipose tissue 
development and deposition, fat mass was further analysed with regard to its 
different depots and relative composition of total fat mass, calculated in Table 
3.3. 
 
Group LF (n=7) OF (n=9) LM (n=11) OM (n=9) Gender Obesity 
Subcutaneous 
(kg) 
3.12±0.38 5.33±0.48 3.06±0.36*** 7.07±0.70*** NS * 
Omental 
(kg) 
0.33±0.06 1.62±0.17 0.26±0.05*** 1.54±0.16*** NS * 
Perirenal  
(PAT) (kg) 
0.31±0.04 1.06±0.13 0.22±0.02 0.96±0.11 NS *** 
Relative 
subcutaneous 
(%) 
81.45±1.15 65.97±1.31 85.17±0.76 72.98±1.46 NS ** 
Relative 
omental (%) 
8.11±0.93 19.73±0.88
a
 6.63±0.64 16.03±0.96
b
 S *** 
Relative 
PAT (%) 
8.05±0.44 12.90±0.64
a
 6.83±0.26 9.90±0.67
b
 S *** 
Table 3.3: Adipose tissue depot measurements of lean female (LF), obese female 
(OF), lean male (LM) and obese male (OM) sheep. Values are mean ± SEM. NS = no 
significant difference, S = significance where only one of two comparable groups 
display significance; statistical differences are denoted by ab,* = p<0.05; ** = 
p<0.005; *** = p<0.001 (ANOVA). Omental (kg) and relative subcutaneous analyses 
treated with Kruskal-Wallis statistical test. 
 
In response to obesity, all adipose tissue depots showed a significant increase 
in size. Obese males showed a greater development of subcutaneous and 
omental adipose tissue deposition compared to lean males (p<0.001), in 
comparison to the presence of obesity in the female groups (p<0.05). No 
further gender effects were observed. Relative adipose tissue deposition (%) 
showed a similar effect to the presence of obesity, expressed by an increased 
relative percentage in both obese groups compared to lean. Additionally, 
obese females also exhibited increased relative PAT and omental adipose 
tissue depots compared to obese males. 
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3.4.1.1 The effect of an obesogenic environment and gender on 
perirenal adipose tissue and adipocyte development 
As PAT depot size was increased in both genders from exposure to an 
obesogenic environment, histological analysis of PAT adipocytes was 
performed, as described in 2.5.2, p83. Figure 3.4 shows representative 
microscopic slides of lean and obese samples for both genders.  
 
 
Figure 3.4: Representative microscopic slides of haematoxylin and eosin stained 
perirenal adipose tissue (PAT) of lean female (A), obese female (B), lean male (C) and 
obese male (D) sheep. Adipocyte membranes (pink stained boundaries marked by 
arrow E) in obese groups are enlarged and more polygonal in shape, thus contain 
more lipid area (white non-stained region; arrow F). Blue stained nuclei in obese 
samples appear pushed to periphery of adipocyte membrane (arrow G). Slides are 
displayed at 20x magnification. 
PAT adipocytes appeared larger in the obese samples, as demonstrated by an 
enlarged white coloured lipid area and expanded adipocyte membrane, with 
no apparent effect of gender. None of the microscopic samples from lean or 
obese animals displayed an increased infiltration of nucleated cellular 
structures or any development of crown-like structures. Therefore, any 
quantification of this measurement was impossible to perform. Visual 
software analysis of microscopic slides identified a significant increase of 
adipocyte perimeter (ǋm) and adipocyte area (ǋm2) between lean and obese 
for both genders (p<0.001), as shown in Figure 3.5 and 3.6, p113.  
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One obese female and one lean male PAT sample had not been loaded into a 
paraffin histology cassette at time of dissection, and thus were omitted from 
the PAT histology analysis.  
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Figure 3.5: Adipocyte perimeter (ǋm) of perirenal adipocytes of lean female (LF; 
n=7), obese female (OF; n=8), lean male (LM; n=10) and obese male (OM; n=9) 
sheep. Values are mean ± SEM. Statistical difference is denoted by *** = p<0.001 
(ANOVA). 
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Figure 3.6: Adipocyte DUHDǋP2) of perirenal adipocytes of lean female (LF; n=7), 
obese female (OF; n=8), lean male (LM; n=10) and obese male (OM; n=9) sheep. 
Values are mean ± SEM. Statistical difference is denoted by *** = p<0.001 (ANOVA). 
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Correlation of PAT size (g) against perirenal adipocyte area (ʅm2) identified a 
positive correlation, with a p value of <0.0001 and r2 of 0.85, see Figure 3.7. 
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Figure 3.7: Relationship between PAT mass (g) and perirenal adipocyte area (ǋm2) of 
total sheep (n=34). Correlation analysis showed a statistical significance where 
p<0.0001 and r2  3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQW 
 
As adipocyte area measurements were mean average values for total 
adipocyte number, analysis of individual adipocyte frequencies were 
performed to elucidate if adipocyte size was affected by gender or its 
exposure to obesity. Using an F-test to compare the variance in a population, 
comparison between adipocyte area distributions identified a significant 
difference in lean females and lean males, (p=0.0002).  
 
As shown in Figure 3.8 (p115), lean female PAT appears to consist of larger 
adipocytes in comparison to lean males despite overall mean adipocyte area 
showing no difference between groups, Figure 3.6 (p113). Performing the 
same variance test between obese females and obese males showed no 
significant difference, see Figure 3.9, p115. 
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Figure 3.8: Frequency distribution (%) of perirenal adipocyte area for lean female (LF; 
n=311) and lean male (LM; n=465) sheep. Variance of distribution between groups by 
F-test showed significance, where p=0.0002. 
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Figure 3.9: Frequency distribution (%) of perirenal adipocyte area for obese female 
(OF; n=242) and obese male (OM; n=301) sheep. Variance of distribution between 
groups showed no statistical significance. 
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3.4.2 The effect of increased adiposity on plasma hormones and 
metabolites 
GTT insulin baseline analysis measured following an overnight fast identified 
elevated plasma insulin levels in obese males compared to lean males, a 
result not observed in females (Figure 3.10). Although appearing to exhibit a 
trend of elevated GTT insulin baseline levels compared to lean females, obese 
females were not statistically significant.  
 
No GTT insulin baseline data was recorded for two animals in the obese 
female and obese male group, and one animal in the lean male group. This 
was possibly due to catheter malfunction resulting in a failure to collect 
plasma from the affected animals. Additionally one obese female displayed 
abnormally high readings of plasma insulin (§15 fold greater) and was 
omitted from subsequent insulin results. As previously postulated, these 
omissions may have reduced the power of the applied statistical test and thus 
reduced any potential statistical significance from the subsequent analysis.  
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Figure 3.10: GTT plasma insulin baseline (ng/ml) of lean female (LF; n=7), obese 
female (OF; n=6), lean male (LM; n=10) and obese male (OM; n=7) sheep. Values 
are mean ± SEM. Statistical difference is denoted by ** = p<0.005 (Kruskal-Wallis). 
Following intravenous glucose administration, time course measurement 
ng/ml (Figure 3.11, p117 and Figure 3.12, p118) and subsequent GTT insulin 
area under the curve (AUC) (Figure 3.13, p118) analysis displayed the same 
trend as the GTT insulin baseline measurements.  
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Obese males again exhibited elevated plasma insulin after glucose 
administration at all time points yet these data were not statistically 
significant. However, obese males did display greater total insulin AUC 
compared to lean males, shown in Figure 3.13.  
Obese females displayed a trend of elevated plasma insulin following glucose 
administration, which were statistically significant between the lean and 
obese groups at 10 and 20 minutes after glucose infusion (Figure 3.11). 
Plasma insulin level converged after 120 minutes. Obese female sample 
numbers were reduced by three, as per the GTT insulin baseline omissions.  
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Figure 3.11: GTT plasma insulin time course measurements of lean female (LF; n=7) 
and obese female (OF; n=6) sheep. Values are mean ± SEM. Statistical difference is 
denoted by ** = p<0.005 between LF and OF at time point 20m; *** = p<0.001 
between LF and OF at time point 10m (Two-way ANOVA with repeated measures). 
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Figure 3.12: GTT plasma insulin time course measurements of lean male (LM; n=10) 
and obese male (OM; n=7) sheep. Values are mean ± SEM.  
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Figure 3.13: GTT plasma insulin AUC (ng/ml) of lean female (LF; n=7), obese female 
(OF; n=6), lean male (LM; n=10) and obese male (OM; n=7) sheep. Values are mean 
± SEM. Statistical difference is denoted by * = p<0.05 (Kruskal-Wallis). 
 
A SRVLWLYH FRUUHODWLRQ ZDV GHWHUPLQHG E\ 3HDUVRQ¶V FRUUHODWLRQ FRHIILFLHQW   
(r2 =0.46, p=0.003) in correlation analysis of total fat mass and GTT plasma 
insulin AUC in males only (Figure 3.15, p119), where females did not display 
this trend (Figure 3.14, p119). 
119 | P a g e  
 
0 2000 4000 6000 8000 10000
0
20
40
60
80
100
p=0.16
r2 = 0.21
Females
Total fat mass (g)
G
T
T
 p
la
s
m
a
 i
n
s
u
li
n
 A
U
C
 (
n
g
/m
l)
 
Figure 3.14: Relationship between total fat mass (g) and plasma insulin AUC (ng/ml) 
of female (n=12) sheep. Correlation analysis showed no statistical significance where 
p=0.16 and r2 = 0.21 3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQW 
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Figure 3.15: Relationship between total fat mass (g) and plasma insulin AUC (ng/ml) 
of male (n=17) sheep. Correlation analysis showed statistical significance where 
p=0.003 and r2 = 0.46 3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQW 
Baseline plasma leptin measurements (ng/ml) (Figure 3.16, p120) showed no 
statistical significance in gender or obesity groups. Obesity groups exhibited a 
trend, where comparison of lean females to obese females gave a p value of 
0.112 and lean males to obese males gave a p value of 0.081.  
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Figure 3.16: Baseline plasma leptin (ng/ml) of lean female (LF; n=7), obese female 
(OF; n=9), lean male (LM; n=11) and obese male (OM; n=9) sheep. Values are mean 
± SEM. 
Following feeding, plasma samples were collected at various time points to 
determine circulatory levels of leptin. Time course measurements and 
subsequent AUC analysis identified a statistically significant elevation in 
plasma leptin between lean and obese groups, shown in Figures 3.17, 3.18  
and 3.19 (p121-122). Gender appeared to have no effect on plasma leptin. 
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Figure 3.17: Plasma leptin time course measurements after feeding for lean female 
(LF; n=7) and obese female (OF; n=9) sheep. Values are mean ± SEM. Statistical 
differences are denoted by * = p<0.05 between LF-OF at time point 8h; *** = 
p<0.001 between LF-OF at time point 24h (Two-way ANOVA with repeated measures). 
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Figure 3.18: Plasma leptin time course measurements after feeding for lean male (LM; 
n=11) and obese male (OM; n=9) sheep. Values are mean ± SEM. Statistical 
differences are denoted by ** = p<0.01 between LM-OM at time point 4h, *** = 
p<0.001 between LM-OM at time point 8h and 24h (Two-way ANOVA with repeated 
measures). 
 
122 | P a g e  
 
LF OF LM OF
0
50
100
150
200
** ***
P
la
s
m
a
 l
e
p
ti
n
 A
U
C
 (
n
g
/m
l)
 
Figure 3.19: Plasma leptin AUC (ng/ml) of lean female (LF; n=7), obese female (OF; 
n=9), lean male (LM; n=11) and obese male (OM; n=9) sheep. Values are mean ± 
SEM. Statistical differences are denoted by ** = p<0.005; *** = p<0.001 (ANOVA). 
Correlation analysis of total fat mass (g) against plasma leptin AUC (ng/ml) 
identified a positive correlation with a p value of <0.0001 and r2 of 0.64, see 
Figure 3.20. 
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Figure 3.20: Relationship between total fat mass (g) and plasma leptin AUC (ng/ml) 
of total sheep (n=36). Correlation analysis showed a statistical significance where 
p<0.0001 and r2 = 0.64 3HDUVRQ¶Vcorrelation coefficient). 
No statistical significance was observed in correlation analysis between GTT 
plasma insulin AUC and plasma leptin AUC shown in Figure 3.21, p123. 
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Figure 3.21: Relationship between GTT plasma insulin AUC (ng/ml) and plasma leptin 
AUC (ng/ml) of total sheep (n=30). Correlation analysis showed no significant 
difference where p=0.02 and r2 = 0.18 3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQW 
Baseline plasma cortisol (nmol/l) measurements (Figure 3.22) showed a 
significant elevation between obese females compared to obese males, a 
result not displayed between the lean groups. The effect of obesity in the 
female group exhibited a trend towards elevated baseline plasma cortisol 
(p=0.058) although this result was not statistically significant. Obesity in 
males had no effect in comparison to their lean counterparts. 
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Figure 3.22: Baseline plasma cortisol (nmol/l) of lean female (LF; n=7), obese 
female (OF; n=9), lean male (LM; n=11) and obese male (OM; n=9) sheep. Values 
are mean ± SEM. Statistical difference is denoted by ** = p<0.005 (ANOVA).  
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Similarly to baseline plasma cortisol levels, following feeding, plasma cortisol 
time course measurements (Figures 3.23-3.24, p125) and AUC (Figure 3.25, 
p125) analysis identified elevated levels in the obese female group only. 
Obese females displayed significantly increased plasma cortisol levels in 
comparison to both lean females and obese males, where p<0.005. Again 
obesity in males appeared to have no effect in comparison to lean males.  
 
 
 
Figure 3.23: Plasma cortisol time course measurements after feeding for lean female 
(LF; n=7) and obese female (OF; n=9) sheep. Values are mean ± SEM. Statistical 
differences are denoted by * = p<0.05 between LF-OF at time point 0h, 8h and 24h; 
** = p<0.01 between LF-OF at time point 0h and 4h (Two-way ANOVA with repeated 
measures). 
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Figure 3.24: Plasma cortisol time course measurements after feeding for lean male 
(LF; n=11) and obese male (OF; n=9) sheep. Values are mean ± SEM.  
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Figure 3.25: Plasma cortisol AUC (nmol/l) of lean female (LF; n=7), obese female 
(OF; n=9), lean male (LM; n=11) and obese male (OM; n=9) sheep. Values are mean 
± SEM. Statistical difference is denoted by ** = p<0.005 (ANOVA).  
Correlation analysis between plasma cortisol AUC (nmol/l) and omental and 
PAT depots identified D SRVLWLYH FRUUHODWLRQ LQ IHPDOHV ZKHUH 3HDUVRQ¶V
correlation coefficient showed p=0.0003 and r2=0.63 shown in Figure 3.26, 
p126. This relationship was not demonstrated in analysis of the males, see 
Figure 3.27, p126. 
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Figure 3.26: Relationship between omental + PAT mass (g) and plasma cortisol AUC 
(nmol/l) of female sheep (n=16). Correlation analysis showed a statistical significance 
where p=0.0003 and r2 = 0.63 3HDUVRQ¶VFRUUHlation coefficient). 
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Figure 3.27: Relationship between omental + PAT mass (g) and plasma cortisol AUC 
(nmol/l) of male sheep (n=20). Correlation analysis showed no statistical significance 
where p=0.25 and r2 = 0.07 3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQW 
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To further assess circulatory metabolic status, additional plasma metabolite 
concentration analyses of glucose, NEFAs and triglycerides were performed. 
These measurements identified no significant differences related to either 
gender or obesity shown in Table 3.4.  
Group LF (n=7) OF (n=9) LM (n=11) OM (n=9) Gender Obesity 
Glucose 
(mmol/l) 
3.04±0.18 3.08±0.14 2.94±0.10 3.03±0.11 NS NS 
NEFAs 
(mmol/l) 
0.43±0.06 0.49±0.06 0.40±0.03 0.50±0.06 NS NS 
Triglycerides 
(mmol/l) 
0.35±0.06 0.31±0.03 0.40±0.05 0.38±0.07 NS NS 
Table 3.4: Plasma metabolite measurements for glucose, non-esterified fatty acids 
(NEFAs) and triglycerides (mmol/l) of lean female (LF), obese female (OF), lean male 
(LM) and obese male (OM) sheep. NS = no significant difference (ANOVA). Plasma 
glucose analysis treated with Kruskal-Wallis statistical test. 
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3.4.2.1 The effect of increased adiposity on triglyceride accumulation 
in muscle 
In determination of triglyceride accumulation (mg per g LD muscle tissue), 
analysis of LD muscle samples identified a significant increase (p<0.05) in 
obese males compared to lean males, a result not seen in females. Statistical 
analysis of muscle triglyceride accumulation of lean to obese females 
provided a p value of p=0.112. Gender analysis of the lean and obesogenic 
groups identified no significant differences, shown in Figure 3.28. 
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Figure 3.28: Triglyceride deposition in mg per g longissimus dorsi (LD) muscle of lean 
female (LF; n=7), obese female (OF; n=9), lean male (LM; n=11) and obese male 
(OM; n=9) sheep. Values are mean ± SEM. Statistical difference is denoted by * = 
p<0.05 (Kruskal-Wallis).  
3HDUVRQ¶V FRUUHODWLRQ FRHIILFLHQW DQDO\VLV RIPXVFOH WUiglycerides and plasma 
insulin (Figure 3.29, p129) displayed no statistical correlation, p=0.20 and 
r2=0.06. 
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Figure 3.29: Relationship between GTT plasma insulin AUC (ng/ml) and muscle 
triglycerides (mg/g) of total sheep (n=30). Correlation analysis showed no statistical 
significance where p=0.20 and r2 = 0.06 3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQW 
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3.5 Discussion 
3.5.1 An obesogenic environment and obesity development 
In my study, the exposure to an obesogenic environment, i.e. an area of 
higher stocking rates of sheep (6 sheep per 19m2 compared to 6 sheep per 
1125m2) led to a reduction in physical activity, with no alteration to the 
amount of relative energy consumed. This reduction in physical activity and 
subsequent imbalanced ratio of energy intake to physical activity contributed 
to increased body weights beWZHHQ WKH µOHDQ¶ DQG µREHVH¶ HQYLURQPHQW
animals. However, the lean female sheep were slightly less active than their 
male counterparts and although not statistically significant, nevertheless 
showed a resulting smaller energy intake ratio imbalance in comparison to 
males. From human behavioural studies, in general, females usually display 
reduced physical activity in comparison to their male counterparts; this is 
attributed to a number of lifestyle and psychological factors285. Shown by the 
obesogenic model used in this study, it is unknown as to why the lean female 
animals exhibited a slight, albeit non-significant reduction in physical activity 
to the lean males, although this subtle difference was removed between the 
obese animals. In contrast, many rodent models of physical activity induced 
obesity have demonstrated a gender dimorphic response where females 
display on average a 20-50% higher activity rate than males286. It is 
proposed that sex hormones may be mediating this gender dimorphic activity 
response observed in rodents. Gorzek at al reported that ovariectomy in 
female mice led to reduced physical activity, a trend which was reversed by 
WKHDGPLQLVWUDWLRQRIǃ-oestradiol287. Yet in the human population, activity 
levels in postmenopausal females negatively correlate with elevated serum 
oestradiol concentrations288 suggesting in humans that sex hormones may 
have the reverse effect on physical activity compared to rodents. It is 
therefore possible that in sheep that sex hormones influence physical activity 
similarly to that observed in humans rather than rodent models. 
Despite the fact only males showed a significant reduction in physical activity 
with obesity, both females and males exhibited increased body weights of 25% 
and 50% respectively after exposure to an obesogenic environment, albeit 
with males showing a much greater response.  
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In the obese males, this observed body weight increase was attributed to an 
increase in both fat mass and lean mass offering an explanation for the 
increased energy balance. In a human MRI scan study, males displayed 
higher muscle and skeletal mass compared to females289. The study also 
demonstrated that the resting metabolic rate of skeletal muscle tissue was 
54.4 kJ/kg and adipose tissue 18.8 kJ/kg289 and hence a higher proportion of 
muscle mass would require higher amounts of energy. One hypothesis during 
the experimental analysis of these morphometric body measurements was 
that the increase in lean mass observed in the obese male sheep, may have 
been due to increased triglyceride and lipid accumulation in the muscle tissue. 
It is widely established that the presence of obesity contributes to increased 
triglyceride accumulation in skeletal muscle tissue290, a finding supported in 
this study where obese males showed elevated muscle triglycerides compared 
to their lean counterparts. However, obese males did not show elevated 
muscle triglycerides in comparison to the obese females, suggesting that the 
obese male lean mass increase was not due to increased muscle triglycerides, 
and a more probable explanation for the observed difference was an increase 
in skeletal muscle mass. In obese females the body weight increase was 
completely attributable to raised fat mass.  
Both genders showed a significant increase in total fat mass after exposure to 
an obesogenic environment. However as expected, lean and obese female 
animals were relatively fatter than the males, results which are in agreement 
with human epidemiological data11,12. Relative total fat mass percentage 
identified a two-fold increase with obesity. In obese humans, it is estimated 
that total body fat mass percentage is approximately >32% and >25% for 
females and males respectively291. Yet in this sheep study despite the two-
fold increase in body fat percentage, obese females had only §15% and 
obese males §13% of relative fat mass. In comparison to another sheep 
obesity study, exposure of animals to an obesogenic environment of both 
increased food intake and restricted physical activity, resulted in body fat 
percentages to increase from §15% to §30%234. However the animals in the 
comparative study were reared for a shorter period (13 months) and 
consumed increased amounts of food.  
The relative fat mass results for this particular study model of obesity through 
restricted physical activity only, implies the development of a moderate obese 
condition in the sheep exposed to an obesogenic environment.  
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3.5.2 Changes in adipose tissue deposition, location and physiology 
A more detailed analysis of the adipose tissue location and deposition 
indicated both genders exposed to such an environment exhibited increased 
adipose tissue mass in subcutaneous and central depots (PAT and omental). 
Obese males possessed more omental and subcutaneous adipose tissue mass 
compared to obese females. Human epidemiological data tends to suggest 
that in obesity, males develop increased central adipose tissue and females 
develop more peripheral adipose depots, i.e. gluteal and subcutaneous 
adipose depots11,12.  
It appeared not to be the case in this sheep study, although the males may 
have exhibited higher increases of omental and subcutaneous adipose tissue 
due to a higher energy ratio imbalance and more a pronounced reduction in 
physical activity. Furthermore, development of adipose tissue in females 
occurs during critical physiological periods, and can be affected by changes in 
sexual maturity, parity and at menopause292. Taking this into consideration, 
the female sheep in my study were relatively young and allowing for a longer 
rearing period of these animals may alter the observed results in adipose 
depot locations. 
Alternatively a reason for these discrepancies may be the higher inaccuracies 
of indirect methods used in some human body fat measurements, such as 
skin-fold thickness against a more direct and accurate DXA scanning method. 
In analysis of relative adipose deposition, in response to an obesogenic 
environment, relative subcutaneous depot percentage was reduced due to an 
overriding increase in central adipose tissue deposition. This was the case for 
both genders, and obese females even showed higher relative PAT and 
omental adipose tissue percentage in comparison to obese males, a finding 
which reinforces the notion that females in general have a higher body fat 
percentage composition293. 
Microscopic analysis of perirenal adipocytes identified adipocyte enlargement 
between the obese and lean sheep. Subsequent quantitative analysis 
identified a three-fold difference in mean adipocyte area in the obese 
compared to lean animals, where gender showed no effect. 
In human adipocyte studies, obese individuals, both males and females, were 
shown to have increased ectopic and intra-abdominal adipose tissue depot 
mass, results which were due to parallel adipocyte enlargement hypertrophy 
rather than adipocyte hyperplasia294,295.  
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In my study, the strong correlation (r2=0.85) between adipocyte area and 
PAT mass would suggest that adipocyte hypertrophy is largely responsible for 
the increase in PAT mass size. Although experimental attempts were made to 
determine possible adipocyte hyperplasia of each PAT mass sample via 
individual adipocyte cell counting, no validated counting method could be 
produced to translate two dimensional samples to a three dimensional tissue 
depot. Therefore it was not possible to determine any potential effect of 
obesity on increased perirenal adipocyte number. Population distribution 
analysis of perirenal adipocytes identified that lean males tended to have 
smaller adipocytes than lean females, but after exposure to an obesogenic 
environment and resulting adipocyte enlargement, this difference was 
removed. These results may reflect the fact that females generally have a 
higher body fat percentage, and thus require a higher storage capacity for 
triglycerides and lipids. Alternatively this may reflect a difference in the male 
PAT depot capabilities, and male central adipocytes may have a larger storage 
capacity for triglycerides and lipids, potentially encouraging the increased 
central deposition observed in male obesity. It is possible that with a longer 
exposure to obesity, the male animals could display a greater increase in 
perirenal adipocyte enlargement than the female animals. In human studies, 
subcutaneous adipocytes were demonstrated to be larger and have an 
increased triglyceride storage capacity than intra-abdominal adipocytes in 
females or males. Additionally these subcutaneous depots were shown to be 
more active, and thus play a greater role in the metabolic profile of females38.   
Several human studies suggest that in adipose tissue mass enlargement, the 
non-fat cell fraction of adipose tissue increases. This includes elevated 
immune cell and macrophage infiltration, preadipocyte infiltration and 
endothelial cell deposition65,66,67 which can result in changes to adipose tissue 
physiology and signs of tissue damage, for example the increased 
development of crown-like structures296. In general observations of the 
analysed microscopic samples, no increased cellular bodies or any crown-like 
structures were observed. Again, this may be due to analysing two-
dimensional samples in relation to a three-dimensional tissue depot, and thus 
any effect of these parameters was therefore not detected.  
Also the magnification capabilities of the equipment were limited to 40x, a 
magnification power which did not allow for identification of the individual 
nucleated cell bodies present.  
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Alternatively, Sharkey et al reported the increased occurrence of PAT crown-
like structures and adipocyte cell death in the presence of severe obesity in 
sheep. These findings were conjoined by elevated mRNA expression in cluster 
of differentiation 68 (CD68), a marker of macrophage infiltration227. Perhaps 
then, the moderate nature of the developed obese condition, age of the 
animals and length of exposure period in these sheep may give explanation to 
the general observations made 
3.5.3 Metabolic adaptations with obesity and gender 
My study also analysed a number of circulatory hormones and metabolites 
which human studies been shown to increase in the presence of an obese 
condition. In response to moderate obesity, the main finding in this chapter 
identified an increase of baseline plasma cortisol in obese females compared 
to obese males which persisted after feeding, but without effect between any 
other groups. Plasma cortisol AUC measurements further reinforced the 
baseline plasma cortisol results, as obese females showed elevated plasma 
cortisol compared to both lean females and obese males. Elevation of plasma 
glucocorticoids is an established measure of the level of physiological, social 
or psychological stress297, these results therefore suggest that the 
development of a moderate obese condition in females results in a higher 
stress response in sheep. Different species have shown varying results in 
regards to gender and stress response, for example rat studies have 
demonstrated a higher stress response in females298, but in adult humans, 
aged matched males are reported to show increased plasma cortisol in 
varying stress responses in comparison to females299. It is likely that the 
variations displayed in the referenced studies are attributable to the type and 
age of the species studied, and also the type of stress imposed on the test 
subjects 
Research into the relationship between fat mass and cortisol has 
demonstrated that hypercortisolism is a feature in human obesity, both 
systemically and intracellularly136. It is generally understood that with obesity, 
cortisol production is enhanced but cortisol clearance is also raised, and thus 
circulating plasma concentration is not affected137. A human gender-obesity 
study identified a positive correlation between raised cortisol clearance rate 
and increased total body fat in females only, which suggested that female 
adipose tissue contained a functioning binding mechanism for cortisol i.e. GR 
which was not shown in males300.  
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Although no cortisol clearance rates were determined in these sheep, the 
correlation in PAT mass and plasma cortisol shown by the females suggests a 
gender disparity in obesity with cortisol and possible glucocorticoid function, a 
finding further discussed in Chapter 4 and 5. Generally it is thought chronic 
exposure to raised plasma cortisol and repeated activation of the HPA 
contributes to the pathogenesis and development of abdominal obesity301. 
This mechanism may have aided in the central fat deposition observed in the 
female sheep, which was contrary to the surveyed human data in relation to 
gender adiposity dimorphism37,38. Additionally, amplified plasma and tissue 
cortisol levels are believed to suppress inflammation via immune cell function 
inhibition143, and as a consequence may provide protection against the 
chronic low-grade inflammation often exhibited by obese subjects71. 
The sex differences observed in HPA axis activation and resulting stress 
response is thought to be partly due to the circulating gonadal sex steroid 
hormone milieu. Through cognate central nervous system (CNS) receptor 
binding, it is believed oestrogen can amplify HPA function, whereas 
testosterone via the same mechanism has the opposite effect and suppresses 
HPA function302. Again, unfortunately no circulatory sex hormone levels were 
determined for the study animals, but Austin et al reported elevated serum 
oestrone and oestradiol in adult females in response to obesity303. It is 
possible then, that the development of moderate obesity exhibited in this 
study consequently elevates oestrogen HPA enhancement action in the obese 
females, potentially mediated by central or ectopic adipose depots. This 
results in increased plasma cortisol, an outcome not observed in the obese 
males which conversely may be due to the HPA suppressive functionality of 
testosterone.  
Fasting insulin concentrations are known to be elevated in obese subjects in 
comparison to lean counterparts, a relationship often associated with 
development of central obesity51. In my study, plasma insulin did not appear 
to be affected by intravenous administration of glucose. Although obese 
males exhibited initial raised baseline plasma insulin levels, during the GTT 
only lean and obese females displayed time course differences, which were 
observed immediately after glucose infusion, and during the remaining GTT 
time points, insulin levels were not significantly different. This may be due to 
the relative insulin insensitivity and reduced glucose utilization observed in 
sheep304.  
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Overall only obese males presented elevated plasma insulin at baseline and 
AUC levels, a metabolic alteration not displayed by females with obesity. This 
suggests that perhaps the male sheep are more sensitive to developing 
hyperinsulinaemia in the presence of moderate obesity. Chronic exposure of 
hyperinsulinaemia, otherwise termed insulin resistance, is believed to be a 
precursor of diabetes mellitus type II. Insulin resistance can also result in 
additional weight gain and obesity development, hypertension and 
dyslipidaemia. Epidemiological data suggests that the prevalence of diabetes 
mellitus type II and abnormalities in glucose metabolism is higher in males 
compared to females, and females also exhibit a decreased susceptibility to 
NEFA induced peripheral insulin resistance305.  
These gender differences in insulin sensitivity are often attributed to the 
actions of sex hormones. Differences which are especially evident during the 
period of menopause where a reduction in oestrogen and increase in 
testosterone levels contributes to a loss of peripheral adipose tissue and 
increase in visceral fat mass in females leading to an increase in insulin 
resistance13. The exact mechanism behind this sex hormone mediated 
reduction in development of insulin resistance observed in females is 
currently unknown.  
As expected, this study demonstrated that moderate obesity results in 
hyperleptinaemia, but gender had no effect on this outcome. Baseline levels 
of plasma leptin showed a slight trend towards increased concentration in 
both genders. These levels were then shown to be significant with obesity 
directly after feeding and with AUC analysis. Elevated plasma leptin is linked 
to adiposity and central nervous system regulation of appetite reduction and 
enhanced energy expenditure306. Additional studies have demonstrated 
positive correlations between hyperleptinaemia and hyperlipidaemia, insulin 
resistance and hypertension independent of total adiposity306.  
In vitro administration of insulin and glucocorticoids were also shown to 
contribute to elevated plasma leptin in sheep307, results that suggested that 
insulin and glucocorticoids may play a role in regulation of white adipocyte 
leptin mRNA expression. This may explain the possible mechanisms mediating 
the hyperleptinaemic conditions observed in the obesogenic animals within 
the present study. This study showed no positive correlations between plasma 
leptin and insulin but a positive correlation between total fat mass and plasma 
leptin.  
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It is possible that the moderate nature of the obese condition displayed in 
these sheep has contributed to onset hyperleptinaemia in an attempt to 
control appetite, energy expenditure and further weight gain. Prolonged 
exposure to this hyperleptinaemic condition and a more severe obesity 
challenge could amplify the detrimental effects often linked with elevated 
plasma leptin.  
In analysis of circulating glucose, NEFAs and triglycerides in this study, no 
differences were observed in any group and thus neither gender nor obesity 
had any effect. This may be due to the moderate nature of obesity 
development; alternatively these results may be because of the altered 
utilization and synthesis of these metabolites in sheep304,308. In human 
epidemiological studies, obesity is often associated with the development of 
hyperglycaemia and dyslipidaemia121,309,310. 
3.5.4 Lipid deposition, peroxidation and lipotoxicity with gender and 
obesity 
Despite there being no effect of gender or obesity in circulatory plasma NEFAs 
and triglycerides in this study, analysis of lipid accumulation in muscle tissue 
identified an increase in lipid deposition in obese males compared to their 
lean counterparts. This trend was also reflected in the female group. Muscle 
triglyceride accumulation has been suggested to contribute to the 
pathogenesis of insulin resistance290, a pathway especially enhanced in the 
presence of obesity and diabetes mellitus type II. The postulated mechanism 
behind this relationship is a functional impairment of mitochondria in obesity 
resulting in fatty acid metabolism dysfunction, a defect which leads to 
diminished usage of NEFAs and an increased esterification and storage of 
lipids within skeletal muscle tissue311. This fatty acid metabolic impairment is 
thought to be related to the development of reduced insulin sensitivity and 
impairment of glucose metabolism associated with insulin resistance124,125,311. 
Although in this study, plasma insulin and muscle triglyceride composition 
measurements do not correlate directly in individuals, obese males exhibited 
both elevated plasma insulin and increased muscle triglyceride deposition. A 
result which suggests that even in moderate exposure to obesity, the male 
sheep are prone to a greater risk of insulin resistance; possibly through a 
raised capacity to store triglycerides in lean mass, which was increased with 
obesity in the males.
138 | P a g e  
 
3.5.5 Conclusion and summary 
In conclusion, this study has demonstrated that sheep exposed to a post-
natal obesogenic environment through a reduction in physical activity develop 
a moderate obese condition. In general the obesogenic animals exhibited 
increased body weights and higher adipose tissue deposition, of which 
adipose tissue accumulation occurred in central fat depots. In more detailed 
analysis, the treated animals also displayed differing systemic, physiological 
and phenotypic characteristics in relation to gender. Obese males appeared to 
exhibit a more pronounced response to moderate obesity compared to obese 
females, as summarised in Figure 3.30, p139. These findings may in part help 
to elucidate some of the mechanisms involved in the gender disparity 
observed in human epidemiological obesity studies, particularly the 
anatomical distribution of adipose tissue and its associated risk with metabolic 
syndrome development demonstrated by obese males. In addition to these 
findings it is postulated that sex hormones significantly contribute to these 
gender dimorphic mechanisms, a potential target for future studies302.  
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Figure 3.30: Summary of findings in effect of gender and obesity on systemic 
metabolism and adipose tissue physiology. HPA ± Hypothalamic pituitary adrenal axis. 
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Chapter 4 ± The effects of gender and 
obesity on the perirenal adipose tissue 
inflammatory genotype  
4.1 Introduction and aims 
My thesis has already discussed the effect of exposure to an obesogenic 
environment on adipose tissue deposition, physiology and systemic 
metabolism, and how gender impacts on these outcomes (see Chapter 3). 
Evidence in the scientific literature suggests that the alterations so far 
observed in this study in development of central obesity and resulting 
metabolic adaptations50, are biological contributors to the chronic low-grade 
inflammation often exhibited by obese subjects63,64. Therefore the focus for 
this chapter was investigating the presence of moderate obesity and resulting 
metabolic and adipose tissue phenotype adaptations resulted in an amplified 
inflammatory genotype, specifically in perirenal adipose tissue. It was also 
postulated that due to the gender dimorphism that existed in the present 
study, that gender may play a role in the inflammatory genotype and status 
of perirenal adipose tissue.  
4.1.1 Hypothesis 
The hypothesis for Chapter 4 was that the metabolic and physiological 
adaptations mediated by moderate obesity and gender contribute to an 
elevated inflammatory state in PAT.  
 
To elucidate any potential mechanism behind this, mRNA transcription 
analysis of the PAT depot was performed on genes involved in metabolic, 
glucocorticoid and inflammatory pathways which may display adaptive 
regulation in exposure to moderate obesity and its resulting effects.  
4.2 Materials and methods 
A complete description of all the methods used in this chapter can be located 
in Chapter 2. Development and optimisation of the mRNA primers was 
performed by Dr S.Sebert, Dr L.Chan, Dr M.Hyatt and myself. Normalisation 
and expression values for the mRNA gene results were calculated with 
GeNorm software against two reference genes (RPO and RPL19). Where 
appropriate, any sample or analytical omissions are explained in the relevant 
results section. In addition, description of statistical tests utilised are provided 
in this results chapter or can be found in Chapter 2.  
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4.3 Results 
4.3.1 The effect of moderate obesity and gender on the metabolic 
genotype in perirenal adipose tissue 
Metabolite analysis identified elevated plasma leptin in response to moderate 
obesity in both genders. In analysis of leptin and leptin receptor mRNA in PAT, 
no significant differences were exhibited in response to either gender or 
obesity in either leptin or its receptor, shown in Table 4.1. During the 
experimental analysis, one obese male PAT sample could not be located in the 
-80°C storage freezer, thus this sample was omitted from all the mRNA PAT 
analysis performed. 
Group LF (n=7) OF (n=9) LM (n=11) OM (n=8) Gender Obesity 
Leptin  0.14±0.06 0.27±0.06 0.18±0.10 0.25±0.04 NS NS 
Leptin 
Receptor  
0.22±0.02 0.27±0.06 0.24±0.07 0.18±0.05 NS NS 
Table 4.1: Leptin and leptin receptor GeNorm mRNA gene expression values of lean 
female (LF), obese female (OF), lean male (LM) and obese male (OM) sheep in PAT. 
Values are mean ± SEM. NS = no significant difference (Kruskal-Wallis). 
In contrast, PAT mRNA analysis of adiponectin identified a significant up-
regulation of mRNA expression between the obese males and obese females. 
No further statistical significance was demonstrated in comparison of the 
remaining gender and obesogenic groups, although statistical analysis did 
identify a subtle up-regulation trend in comparison of lean males to obese 
males where p=0.09, see Table 4.2, p142. Similarly, PAT mRNA expression 
analysis of adiponectin receptor exhibited no significant differences in 
response to either gender or obesity, although comparison of lean females to 
obese females exhibited a subtle trend of up-regulation where p=0.06 and 
lean males to obese males did display a down-regulation trend where p=0.09. 
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Group LF (n=7) OF (n=9) LM (n=11) OM (n=8) Gender Obesity 
Adiponectin 0.10±0.02 0.09±0.03
a
 0.26±0.14 0.46±0.09
b
 S NS 
Adiponectin 
Receptor 
0.27±0.05 0.50±0.07 0.41±0.05 0.36±0.06 NS NS 
Table 4.2: Adiponectin and adiponectin receptor GeNorm mRNA gene expression 
values of lean female (LF), obese female (OF), lean male (LM) and obese male (OM) 
sheep in PAT. Values are mean ± SEM. NS = no significant difference, S = significance 
where only one of two comparable groups display significance; statistical difference is 
denoted by ab = p<0.005 (Kruskal-Wallis). 
4.3.2 The effect of moderate obesity and gender on the glucocorticoid 
genotype in perirenal adipose tissue 
The differences in plasma cortisol response observed between the study 
groups led to an investigative focus on the glucocorticoid pathway and the 
adipose tissue gene transcription response. GR PAT mRNA expression analysis 
identified a significant up-regulation of expression between the lean female 
and obese female groups, a difference not exhibited in comparison of the 
male groups. Additionally, obese females also displayed up-regulated GR 
expression in comparison to obese males, shown in Figure 4.1, a result which 
was not demonstrated by the lean groups.  
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Figure 4.1: Glucocorticoid receptor (GR) GeNorm mRNA expression values of lean 
female (LF; n=7), obese female (OF; n=9), lean male (LM; n=11) and obese male 
(OM; n=8) sheep in PAT. Values are mean ± SEM. Statistical difference is denoted by 
* = p<0.05 (ANOVA). 
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Analysis of PAT ǃHSD1 mRNA expression demonstrated a significant down-
regulation in expression between obese males and obese females. No other 
significant differences were exhibited in comparison of obesity and gender, 
shown in Figure 4.2. 
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Figure 4.2: ǃ-hydroxysteroid dehydrogenase type 1 ǃ+6'GeNorm mRNA 
expression values of lean female (LF; n=7), obese female (OF; n=9), lean male (LM; 
n=11) and obese male (OM; n=8) sheep in PAT. Values are mean ± SEM. Statistical 
difference is denoted by * = p<0.05 (Kruskal-Wallis). 
3$7P51$H[SUHVVLRQDQDO\VLVRIWKHǃ+6'HQ]\PHLVRIRUPGLVSOD\HGDQ
RSSRVLWH WUHQG WR ǃ+6' ZKHUH OHDQ PDOHV VKRZHG D VLJQLILFDnt up-
regulation of mRNA expression in comparison to lean females, shown in 
Figure 4.3, p144. Again, no other significant differences were exhibited in 
comparison of the remaining obesity and gender groups. 
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Figure 4.3: ǃ-K\GUR[\VWHURLGGHK\GURJHQDVHW\SHǃ+6'GeNorm mRNA 
expression values of lean female (LF; n=7), obese female (OF; n=9), lean male (LM; 
n=11) and obese male (OM; n=8) sheep in PAT. Values are mean ± SEM. Statistical 
difference is denoted by * = p<0.05 (Kruskal-Wallis). 
4.3.3 The effect of moderate obesity and gender on the inflammatory 
genotype in perirenal adipose tissue 
To determine the effects of moderate obesity and gender on PAT mediated 
inflammation, mRNA transcription analysis was performed on certain key 
genes involved in obesity linked inflammatory conditions. PAT mRNA 
expression analysis of IL-6 identified a significant down-regulation in lean 
females of IL-6 expression in comparison to lean males, shown in Figure 4.4, 
p145. No additional differences were observed in analysis of the remaining 
comparable gender and obesogenic groups. 
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Figure 4.4: Interleukin-6 (IL-6) GeNorm mRNA expression values of lean female (LF; 
n=7), obese female (OF; n=9), lean male (LM; n=11) and obese male (OM; n=8) 
sheep in PAT. Values are mean ± SEM. Statistical difference is denoted by * = p<0.05 
(Kruskal-Wallis). 
Analysis of PAT mRNA expression of MCP-1 identified a significant up-
regulation of expression in obese males compared to lean males, and 
although this trend was also exhibited in comparison of the female groups, 
this result was not statistically significant, shown in Figure 4.5. Additionally, 
comparison of gender groups showed no significant differences. 
LF OF LM OM
0.0
0.1
0.2
0.3
0.4
0.5
*
M
C
P
-
1
 G
e
N
o
rm
 e
x
p
re
s
s
io
n
 
Figure 4.5: Monocyte chemoattractant protein-1 (MCP-1) GeNorm mRNA expression 
values of lean female (LF; n=7), obese female (OF; n=9), lean male (LM; n=11) and 
obese male (OM; n=8) sheep in PAT. Values are mean ± SEM. Statistical difference is 
denoted by * = p<0.05 (Kruskal-Wallis). 
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This pattern of significantly elevated mRNA expression exhibited by the obese 
in comparison to lean males was also reflected in analysis of PAT mRNA TLR4 
expression, shown in Figure 4.6. Obese females indicated a subtle increased 
response in mRNA TLR4 expression in comparison to lean, but again this was 
result was not statistically significant. No further significant differences were 
demonstrated in comparison of the gender groups.  
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Figure 4.6: Toll-like receptor 4 (TLR4) GeNorm mRNA expression values of lean 
female (LF; n=7), obese female (OF; n=9), lean male (LM; n=11) and obese male 
(OM; n=8) sheep in PAT. Values are mean ± SEM. Statistical difference is denoted by 
* = p<0.05 (ANOVA). 
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4.4 Discussion 
4.4.1 Metabolic gene expression of PAT in response to moderate 
obesity 
Prior to tissue sampling the study animals demonstrated plasma 
hyperleptinaemia (Chapter 3, Figures 3.16-3.18, p121-122), a condition 
linked to total fat mass168. It was therefore hypothesised that perhaps, leptin 
adipose tissue mRNA expression may be up-regulated in the obesogenic 
animals, providing a mechanistic source for the plasma leptin elevation 
observed in the obese animals. In response to the elevated plasma leptin, it 
was also hypothesised that mRNA leptin receptor expression may be down-
regulated, and thus providing a mechanism of leptin resistance often 
observed in obese subjects169. However, leptin mRNA expression results in 
PAT identified that transcription was not affected, a result also observed in 
leptin receptor. Leptin transcription and subsequent protein synthesis are 
demonstrably affected by energy intake, a pathway that is decreased with 
fasting and increased with feeding312. An additional rodent study has 
demonstrated a reduction in leptin expression from white adipose tissue after 
exogenous intravenous leptin administration313. It is possible the leptin and 
leptin receptor mRNA results reflect these mechanisms. The animals were 
euthanised after an overnight fasting period, so potentially the mRNA 
transcript instance at the time of tissue harvest was during a period of 
reduced energy intake and thus PAT leptin expression was consequently 
down-regulated. Alternatively, as the obese males and females displayed 
hyperleptinaemia, leptin mRNA transcript may have been down-regulated as 
a compensatory mechanism towards the increased systemic plasma elevation. 
Human and primate studies in leptin expression have identified adipose depot 
and gender specific differences, where leptin mRNA expression levels were 
demonstrated as higher in subcutaneous in comparison to omental fat depots, 
an effect heightened in females314. A ruminant based study further reinforced 
these findings as sheep and goat leptin mRNA was again demonstrated as 
higher in subcutaneous adipose depots compared to visceral tissues307. As no 
study to date has focused on PAT in comparative adipose depot genotypes, 
potentially the PAT transcription profile may differ in comparison to other 
adipose tissue depots.  Perhaps different adipose depots contribute to certain 
signaling pathways more than others, a possible explanation for the observed 
leptin mRNA expression results.  
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Conversely, the leptin and leptin receptor mRNA transcription levels may be 
reflective of the moderate obese condition present in the test subjects, and 
perhaps a more severe or prolonged exposure to obesity would regulate  
chronic leptin and leptin receptor mRNA up and down-regulation respectively, 
as associated with obesity mediated leptin resistance169. 
No plasma adiponectin analysis was performed for this study as no 
commercially reliable plasma adiponectin kit was available for sheep. 
However adiponectin mRNA expression did show an up-regulation in obese 
males compared to obese females, although no differences were observed 
between the lean groups or as a direct effect of obesity. Adiponectin receptor 
mRNA expression demonstrated no differences in expression from either 
gender or obesity. Human adiponectin studies have demonstrated a strong 
positive correlation between plasma adiponectin and adiponectin mRNA 
expression in white adipose tissue, this correlation was weakened in the 
presence of obesity, as adiponectin expression was down-regulated in obese 
subjects315. Gender was also shown to have an effect in the human study, 
despite females possessing higher relative body fat which is linked to reduced 
plasma adiponectin163, females actually exhibited increased plasma 
adiponectin compared to males315. As the current study demonstrated reverse 
trends, it is possible that plasma hyperinsulinaemia may be the mediating 
factor behind this elevation in adiponectin mRNA observed in the obese males. 
Several studies have identified that adiponectin plays a role in insulin 
mediated glucose uptake, and perhaps the elevation in plasma insulin and 
potential increased risk of insulin resistance development displayed by the 
obese males, results in a compensatory up-regulation in adiponectin mRNA to 
increase insulin sensitization. However, in vivo and in vitro studies of insulin 
action has demonstrated the direct effect of down-regulating adiponectin in 
white adipose tissue, and therefore perhaps the over-expression of 
adiponectin exhibited in the present study is being mediated by an unknown 
insulin-sensitising agent316. It is possible this mechanism is being mediated by 
testosterone, as one study reported a strong correlation between low serum 
testosterone concentration and promotion of insulin resistance via impaired 
mitochondrial function in males317. Additionally enhancement of insulin-
sensitivity via adiponectin action is postulated to occur via direct action on 
insulin receptor substrate and IL-6 molecule pathways through activation of 
an unidentified adiponectin receptor318, a potential explanation as to why no 
differences in mRNA adiponectin receptor expression were observed in the 
current study.  
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Unfortunately without plasma adiponectin measurements for the current 
study subjects, it is impossible to confirm the proposed hypothesis. 
 
Over-expression of adiponectin in white adipose tissue has been linked with 
promotion of an anti-inflammatory condition, reduction in adiposity and 
attenuated oxidative DNA damage319. In the current study, perhaps the 
pronounced morphometric and metabolic response exhibited in the male 
sheep has also resulted in a more pronounced genotype response in the 
ectopic adipose depots, especially the inflammatory network and associated 
glucocorticoid genes which is discussed in the following sub-chapter. 
4.4.2 Glucocorticoid and inflammatory gene expression of PAT in 
response to moderate obesity 
One of the key findings in Chapter 3 was raised plasma cortisol in females in 
response to obesity. My study has also demonstrated an increase in GR mRNA 
expression in PAT in obese females. Obesity is recognised to affect 
glucocorticoid metabolism in humans and rodents, which has been shown by 
an up-regulation in GR DQG ǃ+6' JHQH H[SUHVVLRQ LQ visceral adipose 
tissue, and by enhanced glucocorticoid signaling through increased cortisol 
secretion320. A human study conducted by Veilleux et al, reported an elevation 
RIǃ+6'P51$H[SUHVVion in omental compared to subcutaneous adipose 
tissue in females3217KHVHILQGLQJVZHUHLQFRQMXQFWLRQZLWKUDLVHGǃ+6'
protein abundance and increased plasma cortisol levels, which were positively 
correlated to visceral obesity321. ǃ+6'KDVEHHQVKRZQWRFRQYHUWLQDFWLYH
cortisone to cortisol in mature adipocytes, an effect amplifying local 
glucocorticoid action in obese rodents and humans322. Over-expression of 
ǃ+6' LV also associated with an over-expression of GR-Į LQ PXULQH
adipose tissue323 :DNH HW DO GHPRQVWUDWHG WKDW H[SUHVVLRQ RI ǃ+6'
P51$FRUUHODWHGZLWKǃ+6'Hnzyme activity in human adipose tissue324. 
As discussed in Chapter 3, human females have shown increased oestrogen 
concentration with obesity303, and rodent models of elevated circulating 
oestrogen in females were shown to mediate an enhanced HPA function302.  
Taking these findings into account, the elevation in PAT GR mRNA expression 
displayed in the obese females only, may be a compensatory response in 
central fat to raised plasma cortisol mediated via elevated circulatory 
oestrogens. ǃ-oestradiol concentrations have been reported to augment 
both basal and stimulated ACTH secretion in rodent and ovine animal 
models325, and such a mechanism could be responsible for the observed raise 
in plasma cortisol. 
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Consequently increased GR gene expression leads to an up-regulation in 
ǃ+6' P51$ H[SUHVVLRQ322, and aPSOLILHG DFWLYLW\ RI WKH ǃ+6' JHQH 
may further contribute to an increase in both circulatory and intra-adipose 
tissue cortisol.  
ǃ+6'JHQHH[SUHVVLRQ LQhuman and ovine adipose tissue is a relatively 
recent discovery and its precise role in adipose tissue physiology is 
unknown326. /HYHOVRIDGLSRVHWLVVXHǃ+6'P51$Hxpression were shown 
to correlate with BMI, however this was only in subcutaneous adipose depots 
of male rodents327. $V WKH IXQFWLRQ RI WKH ǃ+6' HQ]\PH LV WR convert 
inactive cortisol to cortisone, the higher levels of gene expression observed in 
male PAT are predicted to increase ǃ+6' DFWLYLW\ 7KLV PD\ DOORZ for 
greater amounts of cortisol to be deactivated and stored in male PAT as 
cortisone, which limits available systemic and intracellular cortisol compared 
to females. 7RGDWHQRVWXG\KDVEHHQSHUIRUPHGRQǃ+6'DFWLYLW\ and 
cortisone storage capacity in PAT with respect to gender. 
Intracellular glucocorticoid binding to GR is a pathway involved in the 
inhibition of cytokine transcription and production129, as this pathway 
appeared to be increased in the obese females, my hypothesis was that PAT 
inflammatory gene expression would be down-regulated in the females 
compared to males with obesity. Both MCP-1 and TLR4 mRNA expression in 
PAT showed a similar pattern whereby obese males demonstrated an up-
regulation in these inflammatory genes compared to their lean counterparts. 
Although the obese females exhibited a trend in elevated gene expression, 
the results were not significant. This suggests that perhaps the potential 
increased activation of GR through raised circulatory cortisol and amplified GR 
expression observed in the obese females may be responsible for a modest 
inhibition of MCP-1 and TLR4 expression in PAT of obese females. Over-
expression of MCP-1 in murine adipose tissue is linked to raised plasma MCP-
1, increased adipose tissue macrophage infiltration and development of 
insulin resistance64. Elevated TLR4 gene expression in adipose tissue 
contributes to adipocyte hypertrophy, insulin resistance and increased 
macrophage infiltration328. MCP-1 and TLR4 are both linked to development of 
insulin resistance. Thus the mRNA expression levels of these genes displayed 
by the obese males may explain their more pronounced hyperinsulinaemic 
condition.  
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As discussed in Chapter 3, no evidence of macrophage infiltration was 
observed in PAT from the obese subjects. However the displayed over-
expression in PAT inflammatory genes in the obese males may be an early 
onset marker for this infiltration process. 
Glucocorticoids have also been shown to down-regulate adiponectin329, a 
molecule demonstrated to possess anti-inflammatory properties166. 
Adiponectin mRNA expression in PAT of my study showed an analogous 
response as the pro-inflammatory molecules, so perhaps the glucocorticoid-
GR binding displayed in the obese females is suppressing both anti- and pro-
inflammatory gene expression in PAT. 
Atypical of this genotype pattern was expression levels for IL-6, which only 
displayed a difference in expression between the lean groups. As no effect 
was observed with obesity, it is unlikely that increased cortisol-GR binding 
altered PAT IL-6 expression. IL-6 gene and protein levels have however been 
shown to correlate to both total fat mass and exercise330. Perhaps the 
reduced levels of PAT IL-6 mRNA expression exhibited by the lean females 
are reflective of the subtle decrease in activity displayed by these animals 
which is offset with obesity. 
4.4.3 Conclusion and summary 
Following on from the conclusion in Chapter 3, in response to moderate 
obesity the males appear to show a more pronounced inflammatory genotype 
in PAT, which may be responsible for a greater risk in metabolic dysfunction, 
i.e. the development of hyperinsulinaemia and insulin resistance reported in 
the last chapter. Obesity in females may be inhibiting this same response by 
the glucocorticoid and GR binding pathway, supported by raised plasma 
cortisol, and up-regulation of GR and ǃ+SD1 gene expression in PAT. The 
key findings in Chapter 4 are summarised in Figure 4.7, p152. The findings 
reported in this chapter can help in understanding the dimorphic gender 
response in clinical morbidity trends, particularly in relation to obesity and its 
comorbidities13. Again there is a strong suggestion that sex hormones are key 
mediators behind these observed sex differences, further strengthening the 
case for future investigations in the role of sex hormones in obesity mediated 
inflammation.  
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Figure 4.7: Summary of findings in effect of gender and obesity on perirenal adipose 
tissue (PAT) inflammatory genotype. ǃ+6'/2 ± 11beta hydroxysteroid 
dehydrogenase type-1/2; GR-Į± Glucocorticoid receptor-ĮHPA ± Hypothalamic 
pituitary adrenal axis. 
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Chapter 5 ± The effects of gender and 
obesity on renal physiology, function and 
inflammation 
 
5.1 Introduction and aims 
The previous results sections have discussed how development of moderate 
obesity leads to the development of adaptations in metabolism, adipose 
tissue and PAT inflammation. However, these responses have displayed a 
sexual dimorphism which suggested that females showed a reduced 
inflammatory status compared to males. In the introduction section, obesity 
was identified as a risk factor for both structural and functional impairment of 
renal tissue via obesity associated metabolic dysfunction, elevated adipose 
tissue inflammation and impairment of haemodynamic parameters62,102. The 
investigative focus for this chapter was that the presence of moderate obesity 
and resulting metabolic and adipose tissue inflammatory status would lead to 
haemodynamic alterations contributing to structural impairment, dysfunction 
and possible early signs of renal injury in the test sheep. Additionally the 
observed gender differences in PAT inflammation and metabolism could also 
manifest themselves in determination of renal response to moderate obesity.  
5.1.1 Hypothesis 
Chapter 5 investigates the hypothesis that moderate obesity and the reported 
adipose tissue inflammation and metabolic adaptations observed with gender 
so far, impacts on renal morphology, physiology and function. Analysis of 
renal mRNA transcription of inflammatory and metabolic genes was 
undertaken to elucidate the genotype of the kidney. Histological, lipotoxicity 
and protein analysis was also performed to understand the renal phenotype in 
these animals.  
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5.2 Materials and methods 
A complete description of all the methods used in this chapter can be located 
in Chapter 2. Development and optimisation of the mRNA primers was 
performed by Dr S.Sebert, Dr D.Sharkey, Mr M.Pope and myself. 
Normalisation and expression values for the mRNA gene results were 
calculated using the 2-¨ct method and normalised against one reference gene 
(r18s). Where appropriate, any sample or analytical omissions are explained 
in the relevant results section. In addition, description of statistical tests 
utilised are provided in this results chapter or can be found in Chapter 2.  
5.3 Results 
5.3.1 The effect of moderate obesity and gender on renal morphology, 
physiology and function. 
Analysis of total kidney weight (g) in the study animals identified an increase 
in kidney weight in obese males compared to lean males, a result not 
observed between the female groups, shown in Table 5.1. Obese males also 
showed a significant difference in kidney weight in comparison to their obese 
female counterparts (Table 5.1). Additionally relative kidney (g kidney per kg 
body weight) only identified a significant difference in comparison of lean to 
obese males, where lean males had higher relative kidney weights. 
Group LF (n=7) OF (n=9) LM (n=11) OM (n=9) Gender Obesity 
Kidney 
weight 
(g) 
117.8±9.38 116.5±5.04
a
 110.7±5.05** 144.3±4.80
b
** S S 
Relative 
Kidney 
weight 
(g/kg) 
2.39±0.24 1.89±0.06 1.98±0.07* 1.72±0.04* NS S 
Table 5.1: Kidney weight (g) and relative kidney weight (g/kg body weight) of lean 
female (LF), obese female (OF), lean male (LM) and obese male (OM) sheep. Values 
are mean ± SEM. NS = no significant difference, S = significance where only one of 
two comparable groups display significance; statistical differences are denoted by ab,* 
= p<0.05; ** = p<0.005 (ANOVA). Relative kidney weight analysis treated with 
Kruskal-Wallis statistical test. 
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5.3.1.1 Glomerular physiology 
To determine the impact of moderate obesity on renal morphology, an 
investigation on glomerular area (ʅm2) and glomerular nucleated cell number 
was performed. This analysis showed a statistically significant increase in 
glomerular size and cell number between lean and obese males, a difference 
which was also displayed in comparison of obese males to females (Figures 
5.2-5.3, p156-157). Correlation analysis between glomerular area and 
glomerular nucleated cell number showed a very strong correlation using 
3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQWZKHUHSDQGU2=0.82 (see Figure 5.4, 
p157) 
 
Two lean male kidney samples had not been loaded into a paraffin histology 
cassette at time of dissection, and thus were omitted from all relevant renal 
histology analysis. Representative kidney sections used in glomerular analysis 
are shown in Figure 5.1, p156. 
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Figure 5.1: Representative haematoxylin & eosin (H&E) 5µm stained microscopic 
sections at 20x magnification; A ± lean female, B ± obese female, C ± lean male and D 
± obese male sheep. The pink coloured stain represents connective tissue, red blood 
cells and non-nucleated cellular material shown by arrow E. Blue/black staining 
represents cellular nuclei (arrow F). The circular structures are the glomeruli (arrow G). 
In area and cell count analysis §40 glomeruli were analysed for each animal. 
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Figure 5.2: Glomerular area mean average (ʅm2) of lean female (LF; n=7), obese 
female (OF; n=9), lean male (LM; n=9) and obese male (OM; n=9) sheep. Values are 
mean ± SEM. Statistical difference is denoted by ** = p<0.005 (ANOVA). 
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Figure 5.3: Glomerular nucleated cell number mean average of lean female (LF; n=7), 
obese female (OF; n=9), lean male (LM; n=9) and obese male (OM; n=9) sheep. 
Values are mean ± SEM. Statistical difference is denoted by * = p<0.05; ** = 
p<0.005 (Kruskal-Wallis). 
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Figure 5.4: Relationship between glomerular area (ʅm2) and glomerular nucleated 
cell number of total sheep (n=34). Correlation analysis showed a statistical 
significance where p<0.0001 and r2 = 0.82 3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQW 
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5.3.1.2 Haemodynamic parameters 
To elucidate either the mechanism or resulting effect by this increase of 
glomerular size and accompanying increase of glomerular nucleated cell 
infiltration, haemodynamic parameters were investigated. Table 5.2 shows 
results for heart rate, systolic, diastolic and mean blood pressure 
measurements. No data was collected for one lean male due to equipment 
failure and was omitted from the data analysis. Statistical analysis of all 
haemodynamic parameters showed no differences in comparison of either 
gender or obesity.  
 
Group LF (n=7) OF (n=9) LM (n=10) OM (n=9) Gender Obesity 
Heart rate 
(bpm) 
86.22±11.5 81.01±5.02 62.07±3.78 81.58±6.18 NS NS 
Systolic 
blood 
pressure 
(mmHg) 
126.9±8.91 134.1±4.88 132.3±4.36 138.2±4.60 NS NS 
Diastolic 
blood 
pressure 
(mmHg) 
86.79±5.43 91.92±4.44 86.75±4.08 88.72±3.30 NS NS 
Mean 
blood 
pressure 
(mmHg) 
106.8±7.09 113.0±4.55 109.5±4.09 113.5±3.58 NS NS 
Table 5.2: Heart rate (bpm), systolic, diastolic and mean blood pressure (mmHg) 
measurements for lean female (LF), obese female (OF), lean male (LM) and obese 
male (OM) sheep. Values are mean ± SEM. NS = no significant difference (ANOVA).  
5.3.1.3 Glomerular cellular proliferation and apoptosis 
As glomerular nucleated cell number increased with glomerular area, cellular 
turnover was analysed. Protein expression of markers involved in proliferation 
and apoptosis were measured using IHC; representative slides of caspase-3 
and PCNA immunostaining are shown by images A-D in Figure 5.5-5.6, p159-
160. In general histological observation of caspase-3 IHC, cells contained 
within the glomerulus appeared to show a reduced amount of positive 
staining compared to the rest of the microscopic section, a trend which was 
reversed in PCNA staining. Thus separate positive staining analysis was 
performed on total and glomerular regions.  
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Figure 5.5: Representative capase-3 (1:50 primary antibody dilution) 
immunohistochemistry 5µm stained microscopic sections at 10x magnification; A ± 
lean female, B ± obese female, C ± lean male and D ± obese male sheep. The brown 
coloured stain represents positively stained nuclei shown by arrow E. Blue staining 
represents negatively stained nuclei (arrow F). 
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Figure 5.6: Representative proliferating cell nuclear antigen (PCNA, 1:4000 primary 
antibody dilution) immunohistochemistry 5µm stained microscopic sections at 10x 
magnification; A ± lean female, B ± obese female, C ± lean male and D ± obese male 
sheep. The brown coloured stain represents positively stained nuclei shown by arrow E. 
Blue staining represents negatively stained nuclei (arrow F). 
Total caspase-3 positive staining displayed no significant differences with 
either gender or obesity, but in glomerular caspase-3 stain abundance, lean 
males showed an up-regulation in protein expression compared to their obese 
counterparts which was not observed in the females (Table 5.3, p161). 
Neither total nor glomerular PCNA protein abundance was affected with 
gender or obesity, shown in Table 5.3. 
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Group LF (n=7) OF (n=9) LM (n=9) OM (n=9) Gender Obesity 
Total  
caspase-
3 % 
44.99±3.10 33.78±3.03 46.61±3.21 43.82±2.88 NS NS 
Glomerular 
caspase-
3 % 
9.07±1.64 8.55±3.06 18.21±3.82* 5.72±1.58* NS S  
Total 
PCNA % 
13.87±0.39 11.72±0.74 10.84±0.68 11.25±0.79 NS NS 
Glomerular 
PCNA % 
20.21±2.96 14.21±1.86 16.41±2.34 17.23±2.41 NS NS 
Table 5.3: Total and glomerular staining % of caspase-3 and proliferating cell nuclear 
antigen (PCNA) of lean female (LF), obese female (OF), lean male (LM) and obese 
male (OM) sheep. Values are mean ± SEM. NS = no significant difference, S = 
significance where only one of two comparable groups display significance; statistical 
difference is denoted by * = p<0.05 (ANOVA).  
 
5.3.1.4 Renal triglyceride accumulation and oxidative stress 
In contrast to LD muscle tissue, triglyceride accumulation analysis (mg per g 
kidney tissue) in renal tissue identified a significant increase (p<0.005) of 
renal triglycerides in obese females compared to obese males. Comparison of 
all other comparative groups in renal triglyceride levels displayed no 
statistical significant differences, shown in Figure 5.7. One lean male kidney 
sample could not be located during -80°C freezer storage and was therefore 
omitted from renal lipotoxicity and oxidative stress analysis.  
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Figure 5.7: Triglyceride deposition in mg per g kidney of lean female (LF; n=7), 
obese female (OF; n=9), lean male (LM; n=10) and obese male (OM; n=9) sheep. 
Values are mean ± SEM. Statistical difference is denoted by ** = p<0.005 (ANOVA). 
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To determine the lipid peroxidation status of renal tissue, TBARS (MDA 
ǋM/total protein ǋg/ǋl) analysis was performed. TBARS results showed no 
significant differences influenced by gender or in exposure to an obesogenic 
environment, see Figure 5.8. 
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Figure 5.8: Renal thiobarbituric acid reactive substance (TBARS) measurements of 
lean female (LF; n=7), obese female (OF; n=9), lean male (LM; n=10) and obese 
male (OM; n=9) sheep. Values are mean ± SEM. 
5.3.1.5 Renal collagen deposition 
Using Masson trichrome histological staining, collagen deposition was 
analysed using an adapted semi-quantitative grading system, see 2.5.3.1, 
p85. No signs of increased collagen deposition were observed in the samples 
(representative microscopic slides are shown in images A-D, Figure 5.9, 
p163), and no signs of increased collagen development was observed in the 
glomeruli in comparison between the study groups. Statistical analysis of the 
collagen deposition data identified no significant differences with either 
gender or obesity, shown in Table 5.4, p163. However, Masson trichrome 
staining did appear to be affected by the histological and sectional tissue 
processing. It is possible that xylene, alcohol and paraffin wax processing led 
to greater dehydration of some samples compared to others which resulted in 
increased stain binding as shown in images E-F, Figure 5.9, p163. Despite 
this discrepancy between samples, over-staining did not appear to lead to an 
over- or under-estimation in the final collagen index grading results.  
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Figure 5.9: Representative Masson trichrome staining for collagen 5µm stained 
microscopic sections at 5x magnification; A ± lean female, B ± obese female, C ± lean 
male and D ± obese male sheep. The red coloured stain represents keratin and 
connective tissue (arrow G), green colour represents staining of collagen peptides 
(arrow H) and blue/black staining represents cellular nuclei (arrow J). Images E and F 
represent over-stained samples, possibly due to increased dehydration during tissue 
processing. 
 
Group LF (n=7) OF (n=9) LM (n=9) OM (n=9) Gender Obesity 
Collagen 
index 
2.98±0.26 2.61±0.25 2.92±0.19 2.45±0.13 NS NS 
Table 5.4: Collagen index (arbitrary units) for lean female (LF), obese female (OF), 
lean male (LM) and obese male (OM) sheep. Values are mean ± SEM. NS = no 
significant difference (Kruskal-Wallis). 
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5.3.1.6 Plasma creatinine and renal function 
To determine renal function, plasma creatinine (nmol/ʅl) was measured 
(Figure 5.10). Unfortunately no additional urine creatinine measurements 
were collected and no eGFR for sheep currently exists. Therefore as creatinine 
is a metabolite of creatine phosphate in muscle84,85, plasma creatinine levels 
were corrected for lean muscle mass (nmol/ʅl per g of lean mass) shown in 
Figure 5.11, p165, to estimate potential creatinine clearance and subsequent 
renal function.  
Statistical analysis of plasma creatinine identified a significant increase in lean 
males compared to lean females, a gender effect not observed in the obese 
animals, Figure 5.10. Additionally, obesity had no effect on plasma creatinine 
levels. 
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Figure 5.10: Plasma creatinine (nmol/ǋl) of lean female (LF; n=7), obese female (OF; 
n=9), lean male (LM; n=11) and obese male (OM; n=9) sheep. Values are mean ± 
SEM. Statistical difference is denoted by ** = p<0.005 (ANOVA). 
After correcting plasma creatinine levels for lean mass, statistical analysis 
showed a significant decrease in the obese compared to lean males, a 
response not displayed by the females (Figure 5.11, p165). Linear regression 
analysis identified a negative correlation between lean mass and plasma 
creatinine where p=0.004 and r2=0.51 (Figure 5.12, p166), a relationship 
which was not exhibited in females (Figure 5.13, p166). No further gender or 
obesity differences were observed.  
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Figure 5.11: Plasma creatinine FRUUHFWHGIRUOHDQPDVVQPROǋOkg) of lean female 
(LF; n=7), obese female (OF; n=9), lean male (LM; n=11) and obese male (OM; n=9) 
sheep. Values are mean ± SEM. Statistical difference is denoted by * = p<0.05 
(ANOVA). 
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Figure 5.12: Relationship between lean mass (kg) and plasma creatinine corrected 
for lean mass (nmol/ʅl/kg) of female sheep (n=15). Correlation analysis showed no 
statistical significance where p=0.82 and r2 = 0.004 3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQW 
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Figure 5.13: Relationship between lean mass (kg) and plasma creatinine corrected 
for lean mass (nmol/ʅl/kg) of male sheep (n=15). Correlation analysis showed a 
statistical significance where p=0.0004 and r2 = 0.51 3HDUVRQ¶VFRUUHODWLRQ
coefficient). 
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5.3.2 The effect of moderate obesity and gender on the renal 
inflammatory genotype. 
To determine the renal inflammatory genotype, gene expression analysis was 
performed on a number of key genes involved in obesity mediated renal 
inflammation as discussed in the introduction chapter. One lean male tissue 
sample could not be located in the -80°C storage freezer and thus is omitted 
from all renal gene expression analysis.  
5.3.2.1 Glucocorticoid renal gene expression 
Glucocorticoid analysis showed a statistically significant up-regulation in 
ǃ+6'UHQDOJHQHH[SUHVVLRQRIREHVHPDOHVFRPSDUed to both lean males 
and obese females, shown in Figure 5.14. 
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Figure 5.14: ǃ-K\GUR[\VWHURLGGHK\GURJHQDVHW\SHǃ+6'2^-(¨Ct) mRNA 
expression values of lean female (LF; n=7), obese female (OF; n=9), lean male (LM; 
n=10) and obese male (OM; n=9) sheep in renal tissue. Values are mean ± SEM. 
Statistical difference is denoted by * = p<0.05; ** = p<0.005 (Kruskal-Wallis). 
 
GR analysis showed the same significant trend where obese males showed 
over-expression in obese males in comparison to lean males and obese 
females, Figure 5.15, p168. No additional statistical differences were 
REVHUYHGLQHLWKHUǃ+6'RU*5DQDO\VLV 
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Figure 5.15: Glucocorticoid receptor (GR) 2^-(¨Ct) mRNA expression values of lean 
female (LF; n=7), obese female (OF; n=9), lean male (LM; n=10) and obese male 
(OM; n=9) sheep in renal tissue. Values are mean ± SEM. Statistical difference is 
denoted by *** = p<0.001 (ANOVA). 
 
5.3.2.2 Pro-inflammatory renal cytokine expression 
Gene expression analysis of pro-inflammatory cytokines identified no 
significant differences in renal IL-18 expression with gender of obesity (Table 
5.5). However, renal IL-6 expression displayed an up-regulation in lean 
females compared to lean males, shown in Table 5.5. 
Group LF (n=7) OF (n=9) LM (n=10) OM (n=9) Gender Obesity 
IL-6      
(2^-¨&W) 
2.07x10-5 
±0.37x10-5
a
 
1.98x10-5 
±0.23x10-5 
1.07x105    
±0.14x10-5
b
 
1.13x10-5 
±0.14x10-5 
S NS 
IL-18   
(2^-¨&W) 
1.60x10-5 
±0.44x10-5 
1.12x10-5 
±0.20x10-5 
1.02x10-5 
±0.04x10-5 
1.20x10-5 
±0.24x10-5 
NS NS 
Table 5.5: Interleukin-6 (IL-6) and interleukin-18 (IL-18) 2^-(¨Ct) mRNA gene 
expression values of lean female (LF), obese female (OF), lean male (LM) and obese 
male (OM) sheep in renal tissue. Values are mean ± SEM. NS = no significant 
difference, S = significance where only one of two comparable groups display 
significance; statistical difference is denoted by ab = p<0.05 (ANOVA). IL-18 analysis 
treated with Kruskal-Wallis statistical test. 
In response to gender and obesity, renal MCP-1 expression was not altered 
and no statistical differences were observed between any of the groups (Table 
5.6, p169). Yet MCP-1 receptor (CCR2) showed mRNA over-expression with 
gender (p<0.005) in both lean and obese groups and also in response to 
obesity in the male animals (p<0.001), shown in Table 5.6, p169.  
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Group LF (n=7) OF (n=9) LM (n=10) OM (n=9) Gender Obesity 
CCR2     
(2^-¨&W) 
0.78x10-5 
±0.09x10-5 
1.11x10-5    
±0.17x10-5 
3.98x10-5 
±0.59x10-5*** 
7.42x10-5       
±0.82x10-5*** 
** S 
MCP-1      
(2^-¨&W) 
2.53x10-5 
±0.54x10-5 
1.98x10-5 
±0.23x10-5 
1.81x10-5            
±0.17x10-5 
2.77x10-5       
±0.31x10-5 
NS NS 
Table 5.6: Chemokine C-C motif receptor 2 (CCR2) and monocyte chemoattractant 
protein-1 (MCP-1) 2^-(¨Ct) mRNA gene expression values of lean female (LF), obese 
female (OF), lean male (LM) and obese male (OM) sheep in renal tissue. Values are 
mean ± SEM. NS = no significant difference, S = significance where only one of two 
comparable groups display significance; statistical differences are denoted by ** = 
p<0.005; *** = p<0.001 (ANOVA). MCP-1 analysis treated with Kruskal-Wallis 
statistical test. 
Figure 5.16 shows statistical analysis of renal IFN-ǄH[SUHVVLRQZKHUHREHVH
males exhibited elevated gene expression compared to obese females. Lean 
males displayed a trend of up-regulation compared to lean females where 
p=0.11, but this result was not statistically significant. No differences were 
observed in response to obesity. 
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Figure 5.16: Interferon-Ǆ,)1-Ǆ2^-(¨Ct) mRNA expression values of lean female (LF; 
n=7), obese female (OF; n=9), lean male (LM; n=10) and obese male (OM; n=9) 
sheep in renal tissue. Values are mean ± SEM. Statistical difference is denoted by ** 
= p<0.005 (ANOVA). 
 
Similarly, TNF-Į UHQDO JHQH H[SUHVVLRQ DOVR showed up-regulation in the 
obese males compared to obese females (Figure 5.17, p170). No additional 
significant differences or trends were exhibited in response to gender or 
obesity. 
170 | P a g e  
 
LF OF LM OM
0
1e-005
2e-005
3e-005 *
T
N
F
-D
 2
^
-(
'C
t)
 
Figure 5.17: Tumour necrosis factor-Į71)-Į2^-(¨Ct) mRNA expression values of 
lean female (LF; n=7), obese female (OF; n=9), lean male (LM; n=10) and obese 
male (OM; n=9) sheep in renal tissue. Values are mean ± SEM. Statistical difference is 
denoted by * = p<0.05 (Kruskal-Wallis). 
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5.3.2.3 Anti-inflammatory renal gene expression 
In response to gender and obesity, anti-inflammatory gene expression was 
up-regulated in obese males compared to obese females. This expression 
pattern was shown by all three of the anti-inflammatory genes analysed; IL-
10, iNOS and PPAR-ǄDVVKRZQLQTable 5.7. 
Group LF (n=7) OF (n=9) LM (n=10) OM (n=9) Gender Obesity 
IL-10   
(2^-¨&W) 
0.85x10-6 
±0.25x10-6 
0.86x10-6 
±0.02x10-6
a
 
2.71x10-6 
±0.06x10-6
 
3.07x10-6 
±0.04x10-6
b
 
S NS 
iNOS     
(2^-¨&W) 
0.08x10-5 
±0.02x10-5 
0.09x10-5 
±0.02x10-5
a
 
0.16x10-5 
±0.03x10-5 
0.23x10-5 
±0.03x10-5
b
 
S NS 
PPAR-Ǆ
(2^-¨&W) 
0.16x10-5 
±0.04x10-5 
0.16x10-5 
±0.20x10-5
a
 
0.29x10-5 
±0.02x10-5 
0.37x10-5   
±0.08x10-5
b
 
S NS 
Table 5.7: Interleukin-10 (IL-10), inducible nitric oxide synthase (iNOS) and 
peroxisome proliferator activated receptor-Ǆ33$5-Ǆ^-(¨Ct) mRNA gene expression 
values of lean female (LF), obese female (OF), lean male (LM) and obese male (OM) 
sheep in renal tissue. Values are mean ± SEM. NS = no significant difference, S = 
significance where only one of two comparable groups display significance; statistical 
difference is denoted by ab = p<0.05. iNOS analysis treated with ANOVA statistical test. 
 
5.3.2.4 Lipid sensing receptor renal gene expression 
As displayed by the anti-inflammatory molecules, renal gene expression of 
the lipid sensing receptors involved in the inflammation pathway showed a 
similar trend. Both CD14 and TLR4 exhibited increased gene expression in 
obese males compared to obese females (Figure 5.18-5.19 p172). In addition, 
TLR4 also showed up-regulation in mRNA expression in males with obesity, 
where conversely females did not show an equivalent response (Figure 5.19, 
p172).  
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Figure 5.18: Cluster of differentiation 14 (CD14) 2^-(¨Ct) mRNA expression values of 
lean female (LF; n=7), obese female (OF; n=9), lean male (LM; n=10) and obese 
male (OM; n=9) sheep in renal tissue. Values are mean ± SEM. Statistical difference is 
denoted by ** = p<0.005 (ANOVA). 
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Figure 5.19: Toll-like receptor 4 (TLR4) 2^-(¨Ct) mRNA expression values of lean 
female (LF; n=7), obese female (OF; n=9), lean male (LM; n=10) and obese male 
(OM; n=9) sheep in renal tissue. Values are mean ± SEM. Statistical difference is 
denoted by ** = p<0.005; *** = p<0.001 (ANOVA). 
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5.3.2.5 Cell adhesion molecule renal gene expression 
Again renal gene expression of the cell adhesion molecules ICAM-1 and 
VCAM-1 exhibited an up-regulation between the obese males and obese 
females (Table 5.8). VCAM-1 also showed increased expression in the males 
with obesity, see Table 5.8.  
 
Group LF (n=7) OF (n=9) LM (n=10) OM (n=9) Gender Obesity 
ICAM-1 
(2^-¨&W) 
1.69x10-5 
±0.60x10-5 
1.23x10-5 
±0.15x10-5
a 
2.56x10-5 
±0.34x10-5 
4.20x10-5 
±0.72 x105
b
 
S NS 
VCAM-1 
(2^-¨&W) 
0.10x10-5 
±0.04x10-5 
0.11x10-5 
±0.02x10-5
a
 
0.20x10-5 
±0.02x10-5** 
0.35x10-5 
±0.05x10-5
b
** 
S S 
Table 5.8: Intracellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule (VCAM-1) 2^-¨&W mRNA gene expression values of lean female (LF), obese 
female (OF), lean male (LM) and obese male (OM) sheep in renal tissue. Values are 
mean ± SEM. NS = no significant difference, S = significance where only one of two 
comparable groups display significance; statistical differences are denoted by ab,** = 
p<0.005 (ANOVA). 
 
5.3.2.6 Renal molecule gene expression 
Analysis of EPOR identified this repeated expression pattern where obese 
males display an up-regulation compared to obese females, and once again 
males also showed increased expression in response to obesity (Table 5.9). 
However, renin gene expression analysis showed no statistical differences 
with either gender or obesity (Table 5.9). 
 
Group LF (n=7) OF (n=9) LM (n=10) OM (n=9) Gender Obesity 
EPOR   
(2^-¨&W) 
0.31x10-5 
±0.09x10-5 
0.43x10-5 
±0.08x10-5
a
 
0.54x10-5 
±0.10x10-5** 
1.09x10-5 
±0.13x10-5b** 
S S 
Renin  
(2^-¨&W) 
0.39x10-5 
±0.19x10-5 
0.26x10-5 
±0.03x10-5 
0.29x10-5 
±0.05x10-5 
0.40x10-5 
±0.10x10-5 
NS NS 
Table 5.9: EPOR (erythropoietin receptor) and renin 2^-(¨Ct) mRNA expression values 
of lean female (LF; n=7), obese female (OF; n=9), lean male (LM; n=10) and obese 
male (OM; n=9) sheep in renal tissue. Values are mean ± SEM. Statistical differences 
are denoted by ** = p<0.005; ab = p<0.001 (ANOVA). Renin analysis treated with 
Kruskal-Wallis statistical test. 
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5.3.3 The effect of moderate obesity and gender on inflammatory 
protein expression 
To compliment the collated renal gene expression data, protein expression 
analysis was performed on TLR4 protein using Western blotting and IHC in 
kidney tissue. Additionally, to determine how renal gene expression impacts 
on systemic circulatory inflammation, IL-6 and TNF-ĮSODVPDFRQFHQWUDWLRQV
were analysed using an ELISA technique. These methods are described in 
Chapter 2. 
5.3.3.1 Renal TLR4 protein expression 
Figure 5.20 shows a Western blotting trial on random protein samples using a 
TLR4 primary antibody; a faint protein band was displayed at the expected 
protein size location (§100 kDa). To ensure the visible bands were not due to 
non-specific binding, a negative control blot was performed using non-
immune mouse serum in place of the TLR4 primary antibody, shown in Figure 
5.21, p174. Unfortunately the same protein bands appeared in the blot; 
therefore it was likely that the protein bands were non-specific products 
binding to the secondary antibody.  
 
Figure 5.20: Representative Western blot image for toll-like receptor 4 (TLR4) a 
100kDa protein; 1:500 TLR4 mouse primary antibody dilution; 1:2000 rabbit anti-
mouse secondary antibody dilution on 20µg random protein samples. Arrow A 
identifies the faint protein band at approximately 100kDa, referenced against protein 
standard lane identified by arrow B. The main protein band (§50kDa) identified by 
arrow C is unknown.  
B 
A 
C 
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Figure 5.21: Representative Western blot image for toll-like receptor 4 (TLR4) 
negative control; 1:1000 non-immune mouse serum dilution; 1:2000 rabbit anti-
mouse  secondary antibody dilution on 20µg random protein samples. Faint 100kDa 
band is still present in negative control identified by arrow A. Protein standard lane 
identified by arrow B. 
In an attempt to resolve this problem, an alternative secondary antibody was 
used (Protein G). However, using this secondary antibody produced no 
protein bands and the blot was blank. Due to time constraints, no additional 
secondary antibodies could be purchased and trialled.  
IHC analysis using the same TLR4 primary again displayed non-specific 
binding highlighted in image A Figure 5.22. All background tissue stained 
brown in comparison to a negative control (image B Figure 5.22), rather than 
the expected target areas (i.e. cellular membranes). 
   
Figure 5.22: Representative toll-like receptor 4 (TLR4) immunohistochemistry 5µm 
stained microscopic sections at 10x magnification; A ± 1:100 primary antibody dilution, 
B ± negative control. The brown coloured stain represents positively stained area 
which appeared to be due to non-specific binding shown by arrow D. Blue staining 
represents negatively stained nuclei (arrow E). 
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5.3.3.2 Systemic IL-6 and TNF-ĮSURWHLQconcentrations 
After spectroscopic analysis, sample plasma measurements for IL-6 and TNF-
ĮVKRZHGsimilar concentration as the negative control (blocking buffer only). 
This result may be for a number of reasons and one possibility may be 
because of cytokine half-life. Rabbit models of LPS induced inflammation have 
demonstrated that IL-6 and TNF-ĮSODVPDFOHDUDQFHDIWHUV\QWKHVLVLVDURXQG
6-7 minutes331. Although the plasma samples were stored at -80°C after 
collection, it is possible that any cytokine molecules have degenerated in the 
short time period after collection. Alternatively the target cytokine molecules 
may have degraded during the freeze/thaw process which occurred prior to 
analysis. It is probable that plasma cytokine analysis must be performed 
immediately after collection or by in vivo techniques. 
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5.4 Discussion 
5.4.1 Alterations in renal and glomerular physiology and function 
with moderate obesity 
Renal size has been shown to increase with early stage obesity in dogs, this 
adaptation was coupled with increased glomerular area, hypertension, 
enlargement and thickening of the mesangial matrix, and raised glomerular 
nucleated cell number attributed to elevated PCNA protein expression260. This 
study however did not investigate gender. In my study, the development of 
moderate obesity has led to increased kidney size in the males only. 
Alongside this change, the obese males also showed enlarged glomerular area 
and increased glomerular nucleated cell number, alterations which were not 
observed in obese females. Additionally glomerular caspase 3 protein 
expression was also decreased with obesity in the males, a possible sign of 
reduced apoptosis which has been linked to the development of glomerular 
proliferative nephritis in humans215. Despite this observed response with 
obesity in males, no changes were seen in the haemodynamic parameters 
and these animals were not hypertensive. However these measurements were 
made whilst the animals were sedated and at only one time point; 
anaesthesia in sheep can result in hypotension and bradycardia332, which may 
have influenced the haemodynamic measurements recorded. Alternatively, 
the absences of hypertension may have been due to the onset and moderate 
nature of the developed obese condition, and perhaps the observed renal 
adaptations in these animals are precursors which contribute towards obesity 
associated hypertension. It is possible that males are at an increased risk to 
obesity associated renal adaptations responsible for increases in blood 
pressure, and prolonged exposure to an obesogenic environment may reflect 
this hypothesis.   
Several studies have shown that glomerular hypertrophy and increased 
glomerular volume is a factor of pathogenesis in FSGS and glomerular 
scarring75. Yet collagen deposition analysis in my study showed no differences 
with obesity or gender. Hyperinsulinaemia has also been linked with 
glomerular hypertrophy and sclerotic damage, a condition exhibited in the 
obese male animals333. This suggests again that the alterations observed with 
obesity in the males are early markers of renal adaptations which may be 
enhanced and more progressive with a prolonged period of exposure to 
obesity.  
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Although glomerular hypertrophy is often linked with increased capillary 
pressures and subsequent hypertension75, the absence of elevated blood 
pressures in this model shows that development of glomerular hypertrophy 
can be independent from changes in blood pressure. The exact mechanism 
behind the displayed glomerular hypertrophy is unknown, but glomerular 
expansion could occur through increased glomerular cell infiltration. 
Conversely this glomerular hypercellularity may be an effect of the glomerular 
hypertrophy, a mechanism attributed to development of human proliferative 
glomerulonephritis334. Jennette et al proposed that glomerular hypertrophy 
without hypertension is a compensatory mechanism driven by a reduction in 
functioning nephrons75. Additionally, compensatory glomerular hypertrophy is 
associated with higher numbers of endothelial and mesangial cells 
demonstrated in early glomerular alterations of prehypertensive rats335. 
Within this study however, nephron number analysis was not performed as no 
validated and accurately reproducible method of nephron counting was 
available, but this postulated mechanism may be mediating the glomerular 
hypertrophy observed with obesity in the male sheep. 
The accompanying glomerular hypercellularity in the obese males, was shown 
to strongly correlate (r2 = 0.82), to glomerular area. This suggests that 
during glomerular enlargement, cellular hyperplasia occurs rather than 
cellular hypertrophy, another indication of proliferative glomerulonephritis. 
Unfortunately due to limitations in microscopic power, identification of the 
increased nucleated cells present was not achievable but increased infiltration 
happened throughout the entire glomerular diameter including the outer 
capillary tufts and mesangial matrix. Distinction of these cells may be 
accomplished through flow cytometry analysis or more precise histological 
techniques which could be a target for future studies. 
With regards to renal function, the increased plasma creatinine concentrations 
displayed by the lean males was attributed to the increased lean mass 
observed in these animals. However, obese males had higher lean mass 
measurements compared to the lean males and obese females, yet this 
elevation in plasma creatinine was not observed after statistical analysis was 
performed. It was therefore hypothesised that plasma creatinine clearance 
may be increased in males in response to obesity, indicating a functional 
adaptation in the kidney and possible contributory pathway involved in the 
observed glomerular alterations.  
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The estimated plasma creatinine clearance measurements showed that 
obesity in males resulted in reduced plasma creatinine despite having 
increased lean mass. This finding was reinforced by the negative correlation 
where males with increased lean mass showed an elevation in estimated 
plasma creatinine clearance, a relationship not displayed by the females. GFR 
has been shown to be raised with obesity in the human population336 but after 
normalization of GFR measurements with lean instead of total fat mass, this 
increase in GFR is removed336. My study however shows that the 
normalization of plasma creatinine concentrations with lean mass in obese 
males demonstrates an increase in plasma creatinine clearance, a finding 
which may indicate glomerular hyperfiltration in males with obesity. It is 
possible raised synthesis of creatinine from increased muscle development 
and subsequent elevation in plasma creatinine concentration prompts 
adaptive hyperfiltration by enlargement of the glomeruli and accompanying 
glomerular hypercellularity. Bak et al demonstrated that renal enlargement 
and glomerular hypertrophy precede hyperfiltration in a diabetic rat model337, 
structural and functional adaptations that have long been associated with an 
increased risk in the development of glomerulosclerosis and eventual ESRD102. 
As with compensatory glomerular hypertrophy, renal hyperfiltration is 
postulated to occur as a compensatory mechanism from a reduction in 
nephron number338. Decreased nephron number is thought to occur via the 
actions of maladaptive metabolic, haemodynamic and nephropathic 
abnormalities attributed to the presence of obesity339. These include increased 
capillary pressure, glomerular scarring and nephritis which drive tissue injury, 
damage and eventual glomerular loss339.   
 
Although in my study no sign of actual kidney damage or haemodynamic 
impairment was apparent, this may imply that if nephron reduction has 
occurred that an alternate mechanism may be responsible. One proposal is 
that these renal adaptations observed in obesity are not maladaptive but 
represent coordinated and regulated alterations which are proportionate to 
the metabolic and excretory needs of obese individuals339. This may explain 
the absence of hypertension displayed by the obese males in my study. 
However, as a huge body of evidence suggests that obesity contributes to 
hypertension91,92, it is probable that prolonged exposure to obesity and the 
associated renal modifications will lead to hypertension and related kidney 
injury.  
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Such a hypothesis would suggest that males therefore show an increased risk 
to the development of obesity mediated kidney disease, a finding in 
agreement with human epidemiological data110. As discussed in the 
introduction chapter, the gender disparity observed in the progression of 
human renal disease has to date been attributed to differences in diet, 
glomerular haemodynamics, kidney and glomerular size110. It is also believed 
that oestrogens and oestrogen receptors in renal tissue may slow the 
progression rate of kidney disease110.  
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5.4.2 Changes in renal inflammatory gene transcription 
In contrast to glucocorticoid gene expression in PAT, renal mRNA expression 
demonstrated an opposite trend where males showed an up-regulation in 
response to obesity. Females showed no effect of obesity with regards to 
UHQDO*5RUǃ+6'2 expression. This is surprising taking into consideration 
the plasma cortisol concentrations discussed in Chapter 3 which were raised 
with obesity in females. Perhaps the elevated plasma cortisol levels in the 
REHVH IHPDOHV FRQWULEXWH WR QR FKDQJHV LQ EDVDO *5 DQG ǃ+6' P51$
expression in renal tissue in response to obesity. It maybe that the increased 
renal glucocorticoid mRNA levels expressed in the obese males is a 
compensatory mechanism to redress the reduction in plasma cortisol in 
comparison to the obese females. Rat studies have shown raised renal 
ǃ+6' H[SUHVVLRQ DQG DFWLYLW\ is responsible for increased conversion of 
cortisol to cortisone and subsequent impairment in mineralocorticoid-like 
effects in the kidney340 ,W LV SRVVLEOH WKH HOHYDWHG UHQDO ǃ+6' JHQH
expression exhibited by the obese males is converting plasma cortisol to 
cortisone similarly to that hypothesised in PAT tissue (see Chapter 4), 
resulting in lower plasma cortisol concentrations. This mechanism may result 
in a compensatory increase in renal GR mRNA expression to maintain cortisol 
and GR binding in the kidney. Alternatively the glucocorticoid expression 
pattern displayed in the obese male renal tissue may reflect a dysregulation 
LQ*5Į*5ǃ UDWLR DQG WKXVPDOHV LQ UHVSRQVH WRREHVLW\ VKRZDQ LQFUHDVHG
insensitivity to glucocorticoid action161, which may explain the reduction in 
plasma cortisol also demonstrated.  
One of the functions of glucocorticoid binding is an immunosuppressive action 
on chemokine/cytokine transcription and expression144. Further expression 
analysis of renal genes involved in both pro- and anti-inflammation 
demonstrated this familiar pattern where males demonstrated an up-
regulation in transcription of these genes in comparison to females with 
response to obesity. If glucocorticoid binding in males was up-regulated with 
obesity and thus hypothesising that increased GR expression leads to 
elevated GR function, one would expect to see immunosuppressive action on 
the additional inflammatory network genes analysed. However, this was not 
the case, and it was obese females that displayed a possible down-regulation 
in renal pro- and anti-inflammatory gene transcription. This implied 
immunosuppression observed in the females with obesity may be mediated 
by increased plasma cortisol via GR binding in kidney, but also potentially 
directed by the glucocorticoid expression adaptations exhibited by PAT.  
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With the exception of a few inflammatory renal genes analysed (i.e. IL-6, IL-
18 and MCP-1) the obese males consistently displayed an over-expression 
compared to their female counterparts. A regular trend of increased 
expression was also displayed in the males in response to obesity. As this 
expression pattern appears in a variety of molecules involved in a broad 
range of the inflammatory processes. It appears that in males, the presence 
of obesity leads to a potential elevation in basal mRNA levels in kidney in the 
majority of the inflammatory network cascade. Such a genetic response and 
widespread alteration in mRNA transcription is likely to be mediated via a 
transcription control mechanism, and it may be that kidney tissue with 
obesity in males undergoes epigenetic changes.  DNA methylation and histone 
modification can be responsible for adaptations in mRNA expression341. An 
epigenetic obesity study by Wang et al, demonstrated that methylation 
patterns in two inflammatory genes synthesised by leukocytes from lean and 
obese adolescents were differentially methylated, a result that was postulated 
to impact on immune function and subsequent pathogenesis of obesity342. 
Alternatively perhaps the consistent down-regulation in obese female renal 
inflammatory gene expression is due to epigenetic programming which leads 
to gene silencing341. Although epigenetic research with regards to obesity is 
relatively innovative, further investigation into epigenetic alterations in my 
study may help elucidate the mechanisms involved in the extensive dimorphic 
inflammatory gene response shown by males and females with obesity.  
An alternative hypothesis for the exhibited consistent up-regulation of renal 
inflammatory gene expression in obese males was that perhaps due to the 
nature of the cytokine network, i.e. pleiotropic molecules involved in inter-
linked cross-talk synthesis, that up-regulation of one inflammatory mediator 
leads to the up-regulation of the entire pro- and anti-inflammatory gene 
positive feedback network. This increased expression maybe controlled via 
one molecule, for example the transcription factor NF-ǉ% ZKLFK KDV EHHQ
postulated as the master regulator in inflammation and innate immunity343. 
However, to pinpoint the initiating molecule behind this cross-talk up-
regulation would be difficult, but may be elucidated via genome wide 
association analysis.  
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Again it appears that the obese males show a more pronounced response to 
moderate obesity. Perhaps this observed elevated basal inflammatory mRNA 
state is a primed transcriptional condition which may contribute to the gender 
disparity clinically manifested in progression rates of renal disease110. 
Additionally this primed inflammatory state may also be instrumental to the 
adaptations in renal morphology in obese males demonstrated in this chapter. 
For instance increased renal expression of IFN-Ǆ DXJPHQWV PDFURSKDJH
activation and recruitment, leading to tissue inflammation and glomerular 
hypertrophy.  So it is possible that the elevated mRNA expression could be 
driving the observed renal alterations in obese males. However, without 
corroborating protein expression data, it is impossible to determine if the 
elevations in renal gene transcription is coupled with the appropriate protein 
response. In addition, the displayed glomerular hypercellularity in males with 
obesity may involve increased immune cell infiltration, another potential 
mechanism behind the amplified inflammatory gene expression. Although to 
confirm this, mRNA expression analysis would need to be performed on entire 
glomeruli of these animals.  
Gene expression analysis of renin showed no differences in response to 
gender or obesity, which may reflect the absence of any change in 
haemodynamic measurements. This result may also suggest that the RAAS is 
not over-stimulated in a moderate obese condition, although as males have 
shown a more pronounced response to obesity, perhaps a longer exposure 
period alongside the discussed developed conditions may consequently 
produce obesity induced RAAS stimulation and associated glomerulopathy108.  
The exception to the renal gene expression pattern displayed with gender was 
the mRNA expression of IL-6. Lean females expressed higher levels of renal 
IL-6 than lean males, the only cytokine expression result where a difference 
was displayed with gender between the lean groups. It is unknown why this 
difference in renal IL-6 expression was demonstrated, although this disparity 
was removed with obesity.  
  
184 | P a g e  
 
5.4.3 Development of renal lipid deposition 
Renal triglyceride analysis identified increased accumulation in obese females 
compared to obese males. In comparison to lean females, no increased renal 
triglyceride accumulation was observed, suggesting that perhaps obese males 
have reduced renal triglyceride accumulation compared to obese females. 
Renal triglyceride accumulation is attributed to hyperlipidaemia, where excess 
plasma triglycerides and NEFAs filtered by the kidney are deposited in the 
renal tubules leading to lipotoxicity. During this study, one hypothesis for this 
apparent decrease in renal triglyceride deposition exhibited by the obese 
males was that renal lipid peroxidation in obese males was increased thus 
reducing the amount of renal triglyceride deposition. Yet in analysis of renal 
lipid peroxidation, these results showed no differences with effect of gender 
or obesity.  
Perhaps the moderate nature and relative short exposure time to the 
obesogenic environment was not severe enough to lead to renal lipotoxicity 
as expected in the observed obese groups. As discussed in Chapter 3, the 
obese males exhibited a higher lean mass, it is therefore possible that obese 
males have a higher storage capacity of triglycerides from greater skeletal 
muscle mass and larger perirenal adipocyte expansion capacity, thus reducing 
the mechanism of lipid deposition in other organ systems and tissues. 
Alternatively a possible explanation for the absence of any significant increase 
of renal triglyceride deposition in both obese groups may be due to the 
absence of elevated circulatory plasma NEFAs and triglycerides, demonstrated 
in this sheep model of moderate obesity. 
The TBARS assay measures thiobarbituric acid reactive substances, and 
although the gold standard analytical techniques to determine lipid 
peroxidation in obesity mediated oxidative stress279, the technique itself often 
overestimates MDA levels due to unselective binding276. Consequently if a 
more selective analytical technique of oxidative stress i.e. determination of 
OONO- levels was utilised, significantly different results may have been 
observed.  
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5.4.4 Conclusions and summary 
Similar to the conclusions reached in the previous two results chapters, 
obesity in males has resulted in an exaggerated response. Expression of 
inflammatory genes in kidney tissue was up-regulated in the majority of 
analysed molecules. As discussed, this entire inflammatory network over-
expression implicates a potential alteration in transcription control mechanism, 
with a focus on epigenetic changes. This heightened inflammatory 
transcription observed in obese males is another indication of the increased 
risk toward obesity mediated inflammation. Exposure to moderate obesity has 
also led to renal morphological adaptations and functional impairment 
associated with nephropathy in obese males. Although no signs of actual 
tissue damage were apparent, these onset markers are a further suggestion 
that males are at an increased risk of obesity associated renal disease. 
Conversely females appear to show a dampened inflammatory renal response 
and no changes in renal morphology with obesity, which may imply a 
protective immunosuppression via cortisol and glucocorticoid binding in obese 
females. The findings of Chapter 5 are summarised in Figure 5.23, p186. 
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Figure 5.23: Summary diagram of male response to obesity and its effect on renal 
morphology and inflammatory gene expression. None of these renal adaptations were 
displayed by females in response to obesity. ESRD ± End stage renal disease.  
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Chapter 6 ± Conclusion 
6.1 General aims 
My study aimed to investigate the effects of obesity and gender on adipose 
tissue mediated inflammation and its contribution to renal disease. This was 
achieved by assessing the metabolic status, morphology and physiology of 
kidney and adipose tissue depots of male and female sheep exposed to a lean 
or obesogenic environment. Furthermore, this study had a particular focus on 
inflammatory gene expression in PAT and renal tissue. Chapter 6 summarises 
the key findings ascertained during this thesis.  
6.1.1 Development of moderate obesity 
Surveying the scientific literature identified a sexual dimorphism especially 
with regards to adipose tissue deposition in development of obesity. Males 
were often linked with increased central and intra-abdominal fat with 
obesity37, whereas females displayed a greater peripheral accumulation of 
adipose tissue, mainly in the gluteal region38. After exposure to an obesogenic 
environment both genders demonstrated increased body weights and in 
addition, males also showed enlarged lean mass. 
Restriction of physical activity lead to both males and females exhibiting 
increased central and subcutaneous fat mass which in PAT was shown to be 
largely due to adipocyte hypertrophy. This development of adipose tissue 
observed in my study was a moderate increase in comparison to other ovine 
obesity studies234, yet regardless of this and in agreement with 
epidemiological data, females were still relatively fatter than males38. 
Although in contrast to human epidemiological evidence, these animals did 
not display differences in adipose tissue location with gender.  
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6.1.2 Gender disparity in obesity mediated inflammation 
Despite the morphological homogeneity displayed by males and females in 
adipose tissue development in this obesity model, there were inconsistencies 
between gender with respect to metabolic and inflammatory status. With 
obesity, both genders displayed metabolic impairments where males showed 
hyperinsulinaemia and females displayed hypercortisolism. Both these 
systemic conditions may in part contribute to the renal and PAT inflammatory 
gene expression exhibited by the obese animals. Insulin resistance has long 
been established to contribute to the chronic low grade inflammation often 
associated with obesity100. In contrast, cortisol is known to suppress the 
immune system142, a pathway potentially accountable for the reduced renal 
and PAT inflammatory gene expression observed in the obese females. 
Although it is widely accepted that the gender differences observed in 
susceptibility to complex diseases are likely to be endocrinological344, it is 
possible sex hormones may mediate epigenetic modifications in DNA and 
histones which can regulate the risk of disease development344.  
6.1.3 Summary 
Figure 6.1, p189 shows the activated metabolic, renal and PAT gene 
expression pathways of females exposed to an obesogenic environment 
identified in my study. In comparison to males, the female pathway network 
shows a greatly reduced activation and resulting adaptations in renal 
physiology and function. Obese males (Figure 6.2, p190), however, displayed 
a comprehensive augmented renal and PAT inflammatory gene response with 
an indication of renal hyperfiltration, glomerular hypertrophy and glomerular 
hypercellularity, conditions which could lead to eventual renal damage and 
failure337. 
In summary, females appear to show an increased protective response to 
obesity mediated inflammation and associated renal disease compared to 
males.   
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Figure 6.1: Obesity induced inflammatory gene expression and metabolic pathways in PAT and renal tissue exhibited by females in my study. 
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Figure 6.2: Obesity induced inflammatory gene expression and metabolic pathways in PAT and renal tissue exhibited by males in my study. 
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6.2 Study limitations 
6.2.1 Sheep model of obesity 
Using an ovine model of obesity in translational research poses its own 
limitations. As discussed, ruminants possess different dietary requirements to 
that of humans. In particular, sheep show reduced glucose utilization and 
insulin sensitivity, two important metabolic molecules involved in the 
pathogenesis of obesity and diabetic nephropathy. This obesity model 
however, was an investigation into how reduced activity rather than dietary 
manipulation induces increased fat deposition during the post-natal period. As 
demonstrated in Chapter 3, exposure to this reduced physical activity 
HQYLURQPHQWOHGWRLQFUHDVHGIDWPDVVLQWKHµREHVRJHQLF¶DQLPDOVIn addition, 
the alterations in adipose tissue physiology, morphology, metabolism and 
inflammation observed indicate that impaired glucose utilization exhibited by 
ruminants has not undermined the experimental model of obesity used 
throughout this thesis.  
6.2.2 Maternal nutritional intervention  
Part of my study aimed to investigate the effect of maternal foetal 
programming through nutritional intervention and post-natal reduced physical 
activity on obesity and renal inflammation with gender. Unfortunately a 
gender imbalance occurred within the proposed study groups during the 
prenatal period. Moreover, four female animals died prematurely, and these 
events decreased the statistical power to investigate the intended groups. 
Throughout analysis, it was quickly identified that obesity and gender were 
the overriding factors in determination of any statistical differences, and 
whilst the nutritional intervention may have affected the results, no significant 
differences were observed in comparison of these groups. As described in 
Chapter 2, power calculations performed on the maternal nutrition groups 
suggested that sample numbers of §100 per group would be required to 
determine the effects of this intervention.  
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6.2.3 Histological analysis 
Due to a lack of histological expertise it is possible that during analysis of the 
microscopic sections that some markers of renal or adipose tissue damage 
were overlooked in observational scrutiny. For example initial signs of 
glomerular scarring which indicates glomerulosclerosis, can be extremely 
difficult to determine, likewise CLS in adipose tissue. Certain microscopic 
sections appeared to display increased stain intensity in comparison with 
simultaneously processed samples. Other sections displayed artifacts that 
were not features of the sample. One explanation for this is the difference in 
response to histological treatment and processing, which appeared to 
dehydrate some samples more than others. Drier samples when stained 
developed a greater intensity of stain which may have impaired any statistical 
analysis. However, statistical differences were only observed with glomerular 
and adipocyte area, which were not affected by histological staining 
inconsistencies.  
6.2.4 Gene expression 
To date the sheep genome is not recorded in its entirety. This resulted in a 
limitation of which genes could be analysed in determination of mRNA 
expression. For example, NF-ǉ% LV EHOLHYHG WR EH D PDVWHU WUDQVFULSWLRQ
control in the inflammatory network343, yet attempts to design primers to 
analyse its gene expression were unsuccessful because of the incomplete 
sheep genome information available. This restriction affected the examination 
of several other genes of interest, in particular angiotensin II and lipid binding 
protein which were also not successfully analysed. 
6.2.5 Protein expression 
The inflammatory protein expression work performed in my study provided no 
satisfactory data. Commercially available ovine antibodies for markers of 
inflammation are relatively novel in comparison to the antibodies available for 
rodents and humans. Although the purchased TLR4 antibody was anticipated 
to work in sheep tissue, the experimental analysis was ineffectual. It was 
likely that the failed protein expression analysis was due to problems with the 
secondary antibody as discussed in Chapter 5. With a greater time allowance 
it may have been possible to optimise the TLR4 protein expression in both the 
Western blot and IHC analysis by trialing different secondary antibodies. 
Additionally, as commercially existing sheep antibodies are limited and 
untested, perhaps it would be necessary to produce the required antibodies 
during operation of the experimental animal model. 
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6.3 Future work and perspectives 
In order to elucidate the findings in this thesis, it would be necessary to 
complete further investigations using both the applied model of ovine 
moderate obesity and modified versions of this. Several suggestions are 
discussed in the following sub-chapters. 
6.3.1 Physiology and inflammatory profile of other adipose depots 
As demonstrated in Chapter 3, all adipose tissue depots showed increased 
mass with development of moderate obesity. However, only PAT was 
investigated with regards to inflammatory gene profile and tissue physiology. 
Summary Table 1.3 (p18) identifies the different inflammatory responses 
shown with gender and adipose tissue location. To determine if the 
inflammatory response is homogeneous between the different adipose tissue 
depots, and if the PAT observed sexual dimorphic inflammation also exists in 
these depots, it would be necessary to perform similar analyses on both 
central and subcutaneous fat tissue. Histological analysis of these different 
depots could also highlight any development of obesity mediated 
inflammatory pathology that was not observed in PAT.  
6.3.2 Epigenetic factors 
It was proposed in my study that the elevation in basal renal inflammatory 
gene expression exhibited by the obese males may have been due to 
epigenetic changes in gene transcription. To further understand these 
mechanisms, DNA methylation and histone modification analysis could be 
completed on renal DNA samples from the study sheep to determine the role 
of epigenetic alterations in the inflammatory gene profile of kidney tissue with 
obesity.   
6.3.3 Sex hormone analysis 
The disparity in response with gender observed throughout my thesis was 
mainly attributed to differences in sex hormones. To confirm this, future work 
would target endogenous concentrations of oestrogens and androgens in a 
comparable study of moderate obesity. Further analysis could investigate how 
exogenous administration of these hormones affects adipose tissue deposition, 
glucocorticoid response and renal inflammatory gene expression. Additionally 
gonadectomy experiment models could be utilised to determine the absence 
of these hormones on the displayed outcomes addressed in my work. 
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6.3.4 Original project proposal 
Initially my study aimed to investigate inflammation and end-organ damage 
with obesity and sepsis. The aim was to study obesity mediated inflammation 
on the kidney using the EARNEST ovine model and following these analyses to 
replicate this experimental obesity model but induce a septic condition in the 
study animals. This hoped to identify if obesity mediated an inflammatory 
state and subsequent renal pathogenesis which may be attenuated by the 
introduction of a known inflammatory condition, i.e. sepsis. However during 
my research it was quickly realised that replication of the ovine obesity model 
would be impossible within my study period. Additionally the gender disparity 
observed throughout my initial experimental analysis warranted a more 
detailed examination. Therefore further investigation is required to determine 
if this sexual dimorphic renal inflammation observed in moderate obesity 
exists in the presence of a septic condition, with particular interest in the 
glucocorticoid network response. 
6.4 Final remarks 
This study has demonstrated how development in moderate obesity 
contributes to adaptations in adipose tissue physiology, metabolic status and 
modifications in renal and PAT inflammatory gene expression. Additionally, 
gender has been shown to impact on these responses. The findings in this 
study could in part help clarify the mechanisms involved in the reported 
differences between males and females in the human population. Particularly 
with regards to the progression of renal nephropathies often associated with 
the presence of obesity110.  
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Appendices 
 
Appendix A ± Abstracts, original presentation and conferences 
attended 
 
Gender differences of inflammatory cytokine expression in kidney 
using an ovine model of obesity 
Ian Bloor, David Gardner, Ravi Mahajan, Sylvain Sebert and Michael Symonds, 
Department of Academic Child Health School of Clinical Sciences, The 
University of Nottingham, UK.  
Oral presentation by Ian Bloor - Anaesthesia Research Society winter meeting,  
The Royal College of Anaesthetists, London, UK, December 2009. British 
Journal of Anaesthesia 104 (4): 517-31P (2010) 
Obesity has long been linked to a low level pro-inflammatory state which may 
contribute to numerous clinical manifestations1. This study aims to investigate 
expression of two key regulators in the inflammatory apoptosis pathway2 
MCP-1 (monocyte chemo-attractant protein 1) and its receptor CCR2 in 
kidney tissue to investigate inflammation within a localised organ system 
using a sheep model of obesity. At the post-weaning stage of development, 
male (n=19) and female (n=16) sheep were separated into two experimental 
groups of physical activity and raised in either an obesogenic (O) or lean (L) 
environment. Renal tissue RNA was extracted from these sheep and 
expression of MCP-1 and MCP-1 receptor (CCR2) was analysed using 
quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and 
expression quantified using the 2-¨ct method. Expression of MCP-1 showed a 2 
mean fold increase in obese males (n=9) when compared to lean males 
(n=10) (p<0.05) but not in females (n=9). CCR2 expression showed a 2.5 
mean fold increase between lean and obese male sheep (p<0.005) and an 8 
mean fold increase in obese males when compared to obese females 
(p<0.0005).With regards to inflammation in kidney tissue of obese sheep, 
this study shows that expression of MCP-1 and CCR2 are increased in 
comparison to lean sheep in males. However this elevation is not seen in the 
female sheep, suggesting a possible protective effect in obese females which 
future work in the study aims to investigate further. 
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Impact of gender on glomerular responses and inflammatory gene 
expression following juvenile onset obesity in sheep 
Ian Bloor, Sylvain P Sebert, Ravi Mahajan and Michael E Symonds 
Department of Academic Child Health, School of Clinical Sciences, The 
University of Nottingham, United Kingdom. 
Oral presentation by Ian Bloor ± The Physiological Society main summer 
meeting, The University of Manchester, Manchester, UK, June 2010. 
Proceedings of the Physiological Society, 19, C140 
 
Clinical and experimental evidence suggests that obesity mediated low grade 
inflammation may contribute towards organ damage and other adverse 
clinical effects1 that may be gender dependent. The present study aims to 
investigate whether obesity modifies kidney glomeruli physiology and gene 
expression of key regulators involved in activation of the inflammatory 
immune response, such as cluster of differentiation 14 (CD14)2, a 
lipopolysaccharide binding protein.  In addition, we examined the impact of 
gender on these outcomes. Three months after birth, male (n=12) and 
female (n=10) sheep were randomly separated into two experimental groups, 
comprising of restricted and unrestricted activity and thus raised in either a 
lean (L) or obesogenic (O) environment. At § 17 months of age all animals 
were humanely euthanised and all major organs and tissues sampled. Gene 
expression was determined using quantitative reverse transcriptase 
polymerase chain reaction (RT-PCR) and expression quantified using the 2-¨ct 
method. Histological staining was performed using haematoxylin and eosin on 
paraffin-HPEHGGHG UHQDO WLVVXH VHFWLRQHG DW ǋP *ORPHUXODU DUHD DQG
nucleated cell count were quantified using image analysis software Volocity.  
Kidney weight was increased (p<0.05) with obesity in males (Obese - 
140.1±5.044, (n=7); Lean 120.2±7.276g, (n=5)), but not females, as was 
mean glomerular area (Obese - 19790±1094: lean -  ǋm2 
(p<0.05)). This adaptation was accompanied by raised mRNA abundance of 
CD14 with obesity in males only (Obese - 3.214±0.913: Lean - 0.992±0.168 
2-¨ct (p<0.01)). Our study suggests that males are much more sensitive to the 
adverse effects of obesity on both glomeruli physiology and inflammatory 
responses. The mechanisms by which females may be protected from these 
effects are currently being explored.  
This study was funded by the British Journal of Anaesthesia and the Royal 
College of Anaesthetists. 
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Influence of gender on the inflammatory response to the kidney 
following juvenile onset obesity 
Ian Bloor, Sylvain P Sebert, Ravi Mahajan and Michael E Symonds 
Department of Academic Child Health, School of Clinical Sciences, The 
University of Nottingham, United Kingdom. 
Oral presentation by Michael Symonds ± Federation of American Societies for 
Experimental Biology (FASEB) Renal Haemodynamics 2010, Vermont 
Academy, Vermont, USA. 
Extensive studies in small animals indicate that gender has a major influence 
on a majority of the long term cardiovascular and metabolic outcomes in the 
offspring following a change in either the amount or composition of the 
PRWKHU¶VGLHWWKURXJKSUHJQDQFy and/or lactation. These differential 
responses may be mediated by either changes in growth rate and body 
composition between genders in conjunction with different effects of sex 
steroids. In large mammals and humans differences in growth through 
pregnancy, lactation and juvenile life are much more subtle which may 
explain why the effects of gender on cardiovascular control and kidney 
function are not so prominent. These effects in large mammals, such as sheep, 
may also not be dependent on sex steroids as the increased fat mass in 
females is present from the neonatal period and is accompanied by raised 
plasma leptin. We have also shown, in the sheep, that maternal nutrient 
restriction targeted at the stage of early kidney development has little, if any, 
effect on blood pressure of the resulting offspring when they are maintained 
with a free-living natural environment. When these offspring are then 
exposed to a low activity obesogenic environment then all offspring become 
equally hypertensive although the adverse effects in the kidney in terms of 
inflammatory and angiogenic adaptations appear to be blunted.  
We therefore examined the impact of gender on the kidneys response to 
obesity as we found that male sheep appear to be much more sensitive to the 
hypertensive effects of obesity than females. This is despite the fact that they 
possess approximately one-third less perirenal adipose tissue, one potential 
risk factor for kidney dysfunction following obesity. In lean animals there is 
very little difference in kidney structure or gene expression of inflammatory 
and related markers of apoptosis and macrophage function between males 
and females.  
 
221 | P a g e  
 
Following obesity however, we only find structural damage in the kidney of 
males that is accompanied by a pronounced increase in gene expression of 
key gene regulators in the inflammatory apoptosis pathway such as monocyte 
chemoattractant protein 1, its receptor CCR2 and the lipopolysaccharide 
receptor involved in the inflammatory response, toll-like receptor 4. Obesity, 
therefore, results in a pronounced increase in the inflammatory response in 
the kidney in males but not females, suggesting possible protection in 
females. The extent to which this response may be seen in other tissues and 
the mechanisms by which females may be protected from some of the 
adverse effects of obesity is currently under investigation. 
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Sex differences in adiposity and inflammatory gene expression in 
kidney following juvenile onset obesity in sheep 
 
Ian Bloor, Sylvain P Sebert, Ravi Mahajan and Michael E Symonds 
Department of Academic Child Health, School of Clinical Sciences, The 
University of Nottingham, United Kingdom. 
Poster presentation by Ian Bloor ± Federation of American Societies for 
Experimental Biology (FASEB) 2011, Walter E Washington Convention Center, 
Washington DC, USA, April 2011. The FASEB Journal, 2011; 25: 835.1 
 
The study aimed to investigate whether obesity affects inflammatory gene 
expression in kidney using a sheep model of obesity. In addition, we also 
explored the impact of gender on these outcomes.  
Three months after birth, male (n=19) and female (n=16) sheep were 
randomly separated into two experimental groups, comprising of restricted 
and unrestricted activity, thus raised in either a lean (L) or obesogenic (O) 
environment. Gene expression was determined using quantitative reverse 
transcriptase PCR and expression quantified using the 2-¨ct method. Perirenal 
adipose tissue per g/kg of body weight was increased (p<0.05) with obesity 
in females compared to males (Obese females ± 17.05±1.84, (n=9); Obese 
Males 11.41±1.29g, (n=9)), as was renal triglyceride deposition mg/g 
(Females ± 0.219±0.016: males ± 0.140±0.019mg (p<0.05)). mRNA 
abundance of Toll like receptor 4 was elevated with obesity only in males 
(Obese - 33.11±5.89: Lean ± 17.24±2.27, (n=10) 2-¨ct (p<0.01)). Our study 
suggests that despite increased renal adiposity and triglyceride deposition in 
females, only males appear to respond to obesity through elevated 
inflammatory gene expression, thus possibly displaying increased sensitivity 
to obesity. The mechanisms by which females may be protected from these 
effects are currently being explored.  
This study was funded by the British Journal of Anaesthesia and the Royal 
College of Anaesthetists.  
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Appendix B ± Details of suppliers 
Abcam®, 330 Cambridge Science Park, Cambridge, CB4 0FL, UK; 
www.abcam.com  
Abgene Ltd, Abgene House, Blenheim Road, Epsom, KT19 9AP, UK; 
www.abgene.com  
$FWLJUDSK, 15 W Mainstreet, Pensacola, Florida (FL), 32502, USA; 
www.theactigraph.com  
Alpha Laboratories Ltd, 40 Parnham Drive, Eastleigh, Hampshire, SO50 
4NU, UK; www.alphalabs.co.uk  
Anglia Scientific Ltd, 94 Fordham Road, Soham, Ely, Cambridgeshire, CB7 
5AJ, UK; http://www.angliainst.co.uk/  
Antec International Ltd, Windham Road, Chilton Industrial Estate, Sudbury, 
Suffolk, CO10 2XD, UK; www.ahs.dupont.com 
Applied Biosystems, 5791 Van Allen Way, PO Box 6482, Carlsbad, 
California (CA), USA; www.appliedbiosystems.com  
Bibby Scientific Ltd, Beacon Road, Stone, Staffordshire, ST15 0SA, UK; 
www.techne.com  
Biotek UK, 6 Bull Street, Potton, Befordshire, SG19 2NR, UK; 
www.biotek.com  
Bio-Rad Laboratories Ltd, Bio-Rad House, Maxted Road, Hemel Hempstead, 
Hertfordshire, HP2 7DX, UK; www.bio-rad.com  
Bioron, Rheingoenheimer Str. 36, D-67065, Ludwigshafen, Germany; 
www.bioron.net  
Cell Biolabs Inc., 7758 Arjons Drive, San Diego, California (CA), 92126, USA; 
www.cellbiolabs.com   
Diagnostic Products Corporation, Llanberis, Glyn Rhonwy, Caernarfon, 
Gwynedd, LL55 4EL, UK; www.pharmaceutical-int.com  
Ecolabs®, 370 Wabasha St N, Saint Paul, Minnesota (MN), 55102, USA; 
www.ecolab.com  
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Fisher Scientific UK Ltd, Bishop Meadow Road, Loughborough, 
Leicestershire, LE11 5RG, UK; www.fisher.co.uk  
GE Healthcare Ltd, Amersham Place, Little Chalfont, Buckinghamshire, HP7 
9NA, UK; www.gehealthcare.com  
Genetex Inc., 2456 Alton Parkway, Irvine, California (CA), 92606, USA; 
www.genetex.com  
GraphPad Software Inc., 2236 Avenida de la Playa, La Jolla, California (CA), 
92037, USA; www.graphpad.com  
Grenier Bio-One Ltd, Brunel Way, Stroudwater Business Park, Stonehouse, 
GL10 3SX, UK; www.greinerbioone.com  
Hoefer® Inc., 84 October Hill Road, Holliston, Massachusetts (MA), 01746, 
USA; www.hoeferinc.com  
IBM UK Ltd, PO Box 41, North Harbour, Portsmouth, Hampshire, PO6 3AU, 
UK; www.spss.com  
Invitrogen Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, 
UK; www.invitrogen.com     
Leica Microsystems (UK) Ltd, Davy Avenue Knowlhill, Milton Keynes, 
Buckinghamshire, MK5 8LB, UK; www.leica-microsystems.com  
Linton Instrumentation, 1 Forge Business Centre, Upper Rose Lane, 
Palgrave, Diss, Norfolk, IP22 1AP, UK; www.lintoninst.co.uk  
Manor Farm Feeds Ltd, Owston, Oakham, Rutland, LE15 8DH, UK; 
www.manorfarmfeeds.co.uk  
Mercodia, Sylveniusgatan 8A, SE-754 50, Uppsala, Sweden; 
www.mercodia.se  
Menzel-Gläser Inc., Glasbearbeitungswerk GmbH & Co., Saarbrückener Str. 
248, D-38116, Braunschweig, Germany; www.menzel.de  
Microsoft Corporation, One Microsoft Way, Redmond, Washington (WA), 
98052, USA; www.microsoft.com  
Millipore, 290 Concord Road, Billerica, Massachusetts (MA), 01821, USA; 
www.millipore.com  
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Minitab Ltd, Brandon Court, Unit E1-E2, Progess Way, Coventry, CV3 2TE, 
UK; www.minitab.com  
PerkinElmer, Saxon Way Bar Hill, Cambridge, Cambridgeshire, CB23 8SL, 
UK; www.perkinelmer.co.uk  
Premier Biosoft International, 3786 Corina Way, Palo Alto, California (CA), 
94303, USA; www.premierbiosoft.com  
Primer Design Ltd, Millbrook Technology Campus, Second Avenue, 
Southampton, Hampshire, SO15 0DJ, UK; www.primerdesign.co.uk  
Qiagen UK Ltd, Qiagen House, Fleming Way, Crawley, West Sussex, RH10 
9NQ, UK; www.qiagen.com  
Randox Laboratories Ltd, 55 Diamond Road, Crumlin, County Antrim, BT29 
4QY, UK; www.randox.com  
Raytek Corporation, 1201 Shaffer Road, Santa Cruz, California (CA), 95061, 
USA; www.raytek.com  
Roche Diagnostics Ltd, Applied Science, Charles Avenue, Burgess Hill, West 
Sussex, RH15 9RY, UK; www.rocheuk.com  
Scientific Laboratory Supplies (SLS) Ltd, Orchard House, The Square, 
Hessle, East Riding of Yorkshire, HU13 0AE, UK; www.scientificlabs.co.uk  
Severn Biotech Ltd, Unit 2, Park Lane, Kidderminster, Worcestershire, DY11 
6TJ, UK; www.severnbiotech.com  
Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset, BH12 4QH, UK; 
www.sigmaaldrich.com  
Simport Ltd, 2588 Bernard-Pilon, Beloeil, Quebec (QC) J3G 4S5, Canada; 
www.simport.com  
VWR International, Hunter Boulevard, Magna Park, Lutterworth, 
Leicestershire, LE17 4XN, UK; www.vwr.com  
Wolf Laboratories Ltd, Colenso House, 1 Deans Lane, Pocklington, York, 
YO42 2PX, UK; www.wolflabs.co.uk  
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